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Abstract: 
 Gene therapy involves the introduction of exogenous nucleic acids into target cells to regulate gene 
expression. The recent discovery of the CRISPR/Cas9 gene editing system provides a powerful tool for site-
specific editing of the host cell genome, further expanding the therapeutic potential of genetic medicine. 
Because of their high molecular weight and overall hydrophilicity, nucleic acids and proteins are inherently 
cell membrane impermeable. The efficacy of these biomacromolecules thus depends heavily on their ability to 
reach intracellular sites of action. Chemical gene delivery systems have been studied as promising vectors for 
gene therapy, and the recent development of lipid nanoparticle-based mRNA COVID-19 vaccines have 
demonstrated their efficacy and scalability. But more work still needs to be done to characterize and optimize 
non-viral nanoparticles for gene therapy applications. To this end, the work in this thesis sought to rationally 
engineer materials for delivery of different biomacromolecule cargos and validate their efficacy in vitro and in 
vivo.  
 Chapter one outlines the guiding aims of the thesis. Chapter two contains background information 
on intracellular delivery. Chapter three describes a collaborative work with Dr. John Laterra’s lab using bio-
reducible poly(beta-amino ester) (PBAE) nanoparticles to deliver cancer-inhibitory miRNAs to treat 
glioblastoma. Chapter four describes a study using plasmid DNA-containing nanoparticles to enable HSVtk 
suicide gene therapy to treat murine models of pediatric brain cancer. Chapter five details my work using 
PBAE nanoparticles to deliver DNA plasmids to enable CRISPR gene editing in mammalian cells. Chapter 
six further studies non-viral delivery of CRISPR gene editing tools using a series of bio-reducible, branched 
PBAE polymers to deliver Cas9 plasmid DNA and sgRNA in short RNA form. Chapter seven is an 
interesting study using carboxylated PBAE structures for intracellular delivery of proteins and also 
demonstrates the feasibility of non-viral CRISPR delivery in ribonucleoprotein form. Chapter eight explores 
the combined use of high-throughput imaging and a genetically-encoded galectin 8 endosomal disruption 
sensor to characterize intracellular gene delivery barriers in vitro as well as validate top structures for mRNA 
delivery in vivo. Chapter nine discusses my perspectives on exciting recent advances and future directions for 
the field of non-viral delivery. 
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 1 
Chapter 1. Introduction to the Thesis 
1.1 Objectives 
 The primary objective of this thesis was to develop biomaterials for non-viral delivery of genes and 
proteins and demonstrate their utility for cancer gene therapy in proof-of-concept animal studies. This work 
was accomplished broadly following the following aims: 
1. Evaluate the efficacy of polymeric nanoparticles as nucleic acid delivery vehicles for cancer gene 
therapy. 
a. Identify nanoparticle formulations to deliver plasmid DNA to human brain cancer cells and 
validate their in vivo efficacy using HSVtk suicide gene therapy in mice. 
b. Engineer bio-reducible PBAEs for the delivery of small RNAs to treat glioblastoma. 
2. Rational design and validation of polymers that enable CRISPR gene editing through delivery of 
different nucleic acid and protein cargos. 
a. Develop materials to enable CRISPR gene editing through combinatorial nucleic acid 
delivery. 
b. Design and validation of protein delivery materials to enable CRISPR editing in vivo. 
3. Apply polymeric nanoparticle formulations to deliver mRNA in vivo. 
a. Develop high-throughput methods for polymer library synthesis and high content imaging-
based in vitro screening. 
b. Investigate mRNA transfection after intravenous or intramuscular nanoparticle 
administration. 
  
1.2 Summary of Contributions 
Chapter 2: A background in non-viral delivery of biomacromolecules 
• Review article – Kozielski K*, Rui Y*, Green JJ. Non-viral nucleic acid containing nanoparticles as 
cancer therapeutics. Expert Opinion on Drug Delivery, 13 (10) pp 1475-1487. (2016). *These authors 
contributed equally. 
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• Review article – Rui Y*, Wilson DR*, Green JJ. Non-viral delivery to enable genome editing. Trends 
in Biotechnology, 37 (3), pp 281-293. (2018). *These authors contributed equally. 
Chapter 3: Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell-
regulating miRNAs inhibit Glioblastoma Growth and Prolong Survival 
• Research article – Lopez-Bertoni H*, Kozielski KL*, Rui Y*, Lal B, Vaughan H, Wilson DR, 
Mihelson N, Eberhart CG, Laterra J, Green JJ. Bioreducible polymeric nanoparticles containing 
multiplexed cancer stem cell-regulating miRNAs inhibit glioblastoma growth and prolong survival. 
Nano Letters. 18 (7), pp 4086–4094 (2018). *These authors contributed equally.  
• Research talk – Rui Y, Lopez-Bertoni H, Kozielski KL, Lal B, Wilson DR, Laterra J, Green JJ. 
Environmentally-responsive polymeric nanoparticles for brain cancer gene therapy. Johns Hopkins 
Institute for Nanobiotechnology Student Research Forum. Baltimore, MD. 2019. 
Chapter 4: Nonviral Polymeric Nanoparticles for Gene Therapy in Pediatric CNS Malignancies 
• Research article – Choi J*, Rui Y*, Kim J*, Gorelick N, Wilson DR, Kozielski K, Mangraviti A, 
Sankey E, Brem H, Tyler B, Green JJ, Jackson EM. Nonviral polymeric nanoparticles for gene 
therapy in pediatric CNS malignancies. Nanomedicine: Nanotechnology, Biology and Medicine. 23 (2020). 
*These authors contributed equally. 
Chapter 5: Poly(beta-amino ester) nanoparticles enable non-viral delivery of CRISPR/Cas9 plasmids 
for gene knockout and gene deletion 
• Research article – Rui Y, Varanasi M, Mendes S, Yamagata HM, Wilson DR, Green JJ. Poly(beta-
amino ester) nanoparticles enable non-viral delivery of CRISPR/Cas9 plasmids for gene knockout 
and gene deletion. Molecular Therapy: Nucleic Acids. 20, pp 661-672 (2020). 
• Research talk – Rui Y, Wilson DR, Green JJ. Poly(beta-amino ester) nanoparticles for the delivery of 
CRISPR/Cas9 achieves efficient genome editing. Mid-Atlantic Biomaterials Day. Baltimore, MD. 
2018. 
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• Research poster – Rui Y, Kozielski K, Wilson DR, Green JJ. Poly(β-amino ester) nanoparticles for 
delivery of CRISPR/Cas9 to primary human brain cancer cells. International Nanomedicine & Drug 
Delivery Symposium. Baltimore, MD. 2016 
Chapter 6: Reducible Branched Ester-Amine Quadpolymers (rBEAQs) Co-delivering Plasmid DNA 
and RNA Oligonucleotides Enable CRISPR/Cas9 Genome Editing 
• Research article – Rui Y, Wilson DR, Sanders K, Green JJ. Reducible branched ester amine 
quadpolymers (rBEAQs) co-delivering plasmid DNA and RNA oligonucleotides enable 
CRISPR/Cas9 genome editing. ACS Applied Materials & Interfaces. 11 (11), pp 10472-10480 (2019). 
• Research talk – Rui Y, Wilson DR, Sanders K, Green JJ. Hyperbranched bioreducible poly(beta-
amino ester)s for efficient delivery of siRNA. Biomedical Engineering Society National conference. 
Phoenix, AZ. 2017. 
• Research poster – Rui Y, Wilson DR, Green JJ. Hyperbranched bioreducible poly(beta-amino ester)s 
for efficient delivery of siRNA. Johns Hopkins Women in STEM Symposium. Baltimore, MD. 2018. 
Chapter 7: Carboxylated branched poly(beta-amino ester) nanoparticles enable robust cytosolic 
protein delivery and CRISPR/Cas9 gene editing 
• Research article – Rui Y, Wilson DR, Choi J, Varanasi M, Sanders K, Karlsson J, Lim M, Green JJ. 
Carboxylated branched poly (B-amino ester) nanoparticles enable robust cytosolic protein delivery 
and CRISPR-Cas9 gene editing. Science Advances. 5 (12) (2019). 
• Research talk – Rui Y, Wilson DR, Sanders K, Green JJ. Carboxylated branched poly(B-amino ester) 
nanoparticles enable robust intracellular protein delivery and CRISPR/Cas9 gene editing. Society for 
Biomaterials National Conference. Seattle, WA. 2019 
• Research talk – Rui Y, Wilson DR, Sanders K, Green JJ. Carboxylated branched poly(B-amino ester) 
nanoparticles enable robust intracellular protein delivery and CRISPR/Cas9 gene editing. Wilmer Eye 
Institute Research Discussion (W.E.I.R.D.) Seminar Series. Baltimore, MD. 2019. 
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• Research poster – Rui Y, Wilson DR, Choi J, Varanasi M, Sanders K, Karlsson J, Lim M, Green JJ. 
Carboxylated branched poly(β-amino ester) nanoparticles enable robust intracellular protein delivery 
and CRISPR/Cas9 gene editing. US-Japan Symposium on Drug Delivery Systems. Maui, HI. 2019. 
• Research poster – Rui Y, Wilson DR, Sanders K, Green JJ. Carboxylated branched poly(beta-amino 
ester) nanoparticles enable non-viral CRISPR/Cas9 gene editing via intracellular ribonucleoprotein 
delivery. American Society of Gene & Cell Therapy Annual Meeting. Washington D.C. 2019. 
Chapter 8: Poly(beta-amino ester) Quadpolymer Structure Tunes Endosomal Escape, Cellular 
Uptake, and In Vivo Delivery of mRNA Nanoparticles 
• Research article – Rui Y, Wilson DR, Tzeng SY, Yamagata HM, Sudhakar D, Conge M, Berlinicke 
CA, Zack DJ, Tuesca A, Green JJ. Poly(beta-amino ester) quadpolymer structure tunes endosomal 
escape, cellular uptake, and in vivo delivery of mRNA nanoparticles. (2021). Submitted.  
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Abstract 
Introduction: The delivery of nucleic acids such as DNA and short interfering RNA (siRNA) is promising 
for the treatment of many diseases, including cancer, by enabling novel biological mechanisms of action. 
Non-viral nanoparticles are a promising class of nucleic acid carriers that can be designed to be safer and 
more versatile than traditional viral vectors.  
Areas covered: In this review, recent advances in the intracellular delivery of DNA and siRNA are described 
with a focus on non-viral nanoparticle-based delivery methods. Material properties that have enabled 
successful delivery are discussed as well as applications that have directly been applied to cancer therapy. 
Strategies to co-deliver different nucleic acids are highlighted, as are novel targets for nucleic acid co-delivery.  
Expert opinion: The treatment of complex genetically-based diseases such as cancer can be enabled by safe 
and effective intracellular nucleic acid delivery of multiple nucleic acids. Non-viral nanoparticles can be 
fabricated to deliver multiple nucleic acids to the same cell simultaneously to prevent tumor cells from easily 
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compensating for the knockdown or overexpression of one genetic target. The continued innovation of new 
therapeutic modalities and non-viral nanotechnologies to provide target-specific and personalized forms of 
gene therapy hold promise for genetic medicine to treat diseases like cancer in the clinic. 
Keywords: cancer, DNA, gene delivery, gene therapy, nanoparticle, polymer, siRNA  
Article highlights: 
• Obstacles to intracellular nucleic acid delivery include rapid clearance from circulation, tissue and 
tumor targeting, cellular internalization, endosomal escape, and intracellular release. 
• Lipid-based and inorganic materials protect nucleic acids from degradation and condense them into 
nanoparticles for improved cellular uptake. 
• Cationic polymers self-assemble into polyplexes with nucleic acids via electrostatic interactions and 
possess functional groups to aid in improved cellular uptake, endosomal escape through endosomal 
buffering, and intracellular cargo release via biodegradable linkages. 
• Nanoparticle formulations optimized for the co-delivery of multiple DNA or siRNA cargos can be 
used to reach novel synergistic cancer therapy targets. 
• Therapeutic modalities such as DNA, siRNA, and CRISPR/Cas technology may benefit from non-
viral nanoparticle delivery platforms for the treatment of complex genetically-based diseases. 
 
1. Introduction 
 The discovery that exogenous DNA introduced into isolated nuclei can be transcribed into mRNA 
[1] and lead to protein expression [2, 3] created the promise of gene therapy as a modality capable of treating 
myriad diseases. siRNA is a more recently discovered therapeutic modality and can be used to knock down 
gene expression through the RNA interference (RNAi) pathway. RNAi was initially discovered in C. elegans as 
a gene silencing pathway used as a natural mechanism for viral defense [4]. A strand of long, double-stranded 
RNA (dsRNA) is cleaved by the Dicer protein into 21-25 bp siRNAs [5]. siRNA is then incorporated into the 
RNA-induced silencing complex (RISC) where the sense strand is removed. The antisense strand is then used 
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as a template for complementary mRNA. mRNA that pairs with siRNA-RISC is cleaved, thus preventing 
translation and thereby gene expression. (For review, see Hannon [6].)  
Early delivery methods of these nucleic acids often involved introducing nucleic acids by mechanical 
disruption of the cell membrane or direct injection [7, 8]. However, these methods are laborious and not 
clinically translatable. Viral methods of DNA and siRNA delivery are effective [9], yet often induce 
immunogenicity or tumorigenicity and are therefore limited for clinical translation [10]. Non-viral nucleic acid 
delivery has traditionally been considered less effective [11], but can be designed to avoid tumorigenesis and 
immune stimulation. Recent advances in nanoparticle vectors for nucleic acid delivery have continued to 
improve delivery efficacy while minimizing toxicity, but several obstacles remain that make successful delivery 
an ongoing challenge.  
 
1.1 Obstacles to intracellular delivery 
 Due to their size and negative charge, nucleic acids cannot readily pass through the cell membrane to 
their intracellular sites of action (Figure 2-1). Nanocarriers can encapsulate nucleic acids to not only promote 
successful delivery into cells, but also to protect them from degradation by extracellular nucleases. 
Nanocarriers for nucleic acid delivery include liposomes that hold DNA and siRNA within their aqueous 
interiors [12-14], cationic polymers that bind anionic nucleic acids to form polyplexes [15, 16], and solid 
nanoparticles that can carry nucleic acids via covalent linkages [17]. For nanocarriers that electrostatically bind 
to nucleic acids, special considerations must be taken for short oligonucleotides like siRNA, which are much 
shorter and stiffer than plasmid DNA, and are therefore often harder to complex into nanoparticles [18, 19]. 
To prevent unwanted non-specific interactions between nanoparticles and biomolecules and cells, 
nanoparticles are frequently coated with hydrophilic polymers, such as polyethylene glycol (PEG) [20].  
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Figure 2-1. Overview of nanoparticle codelivery of DNA and siRNA. (A) Nanoparticles carrying DNA and 
siRNA cargoes separately yield little codelivery, while nanoparticles carrying both nucleic acids optimize 
coexpression. (B) There are multiple classes of non-viral nanoparticles for gene delivery. Each class with its 
own representative chemical structure (top), nanoparticle structure (center), and method of carrying nucleic 
acid (bottom). (C) There are multiple steps for successful intracellular delivery of DNA and siRNA. 
For intracellular delivery, cells must take up the nucleic acid carrying nanoparticles. To enable cellular 
uptake, cell-penetrating peptides can be used to promote internalization directly through the cell membrane 
[21-23], or cationic nanoparticles can nonspecifically interact with the negatively charged cell surface to 
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promote endosomal uptake [24-27]. If internalized via endosomes, the nanoparticle must escape the 
endosome to prevent degradation in lysosomes, prevent recycling out of the cell, and to promote cytosolic 
delivery. This can be achieved with hydrophobic or amphiphilic biomaterials that can destabilize the 
endosomal membrane [28, 29]. Endosomal escape can also be achieved using the proton sponge mechanism, 
in which a nanomaterial may act as a buffer against endosomal acidification and eventually result in 
endosomal lysis. Although this mechanism has been challenged [30], it is the most widely accepted hypothesis 
to explain successful transfection when utilizing nanomaterials with titratable amines [31, 32].   
For siRNA delivery, the nanocarrier must release its contents at the site of RNAi in the cytosol [33]. 
Several polymeric materials degrade hydrolytically and can thereby release siRNA as the polymer degrades 
[34, 35]. As the cytosol is approximately 1000 times more reducing than the extracellular space [36], 
nanomaterials may also employ bioreducible disulfide bonds to promote release targeted specifically to the 
cytosol. (For review, see Son et al.[37]) Nanocarriers delivering DNA may need to remain intact longer, as 
naked DNA is slow to diffuse in the cytosol and may be degraded by cytosolic nucleases on its way to the 
nucleus [38, 39]. Nuclear penetration is an additional major bottleneck to gene delivery. It has been shown 
that actively dividing cells are easier to transfect [40], and this can be an avenue to increase transfection in 
cancer cells compared to non-cancerous slower growing cells. In non-mitotic cells, attaching a nuclear 
localization signal peptide sequence to DNA is a strategy that improves nuclear penetration by using the cell’s 
own nuclear import machinery [41]. Complexing DNA within a polymeric nanocarrier has been shown to 
increase nuclear association and permeability [42]. For all of these steps, nanomaterial properties are key in 
order to achieve intracellular nanoparticle-based DNA and siRNA delivery (Table 2-1).  Table 1 also 
illustrates the evolution of nanomaterials used for non-viral gene delivery from readily available off-the-shelf 











Co-precipitate nucleic acids 
with calcium phosphate to 
form nanocrystals 
1973[171] Melanoma and breast 
cancer[172]; nasopharyngeal 
carcinoma[173] 
Liposomes Encapsulate nucleic acid 
cargo in aqueous interior 
1980[174] Colorectal cancer and breast 
cancer[175]; pancreatic islet 
cell tumors[176]; Lewis lung 
carcinoma[48] 
PLL Cationic polypeptide for 
nucleic acid binding 
1987[16] Lung cancer[177]; bladder 
cancer[178] 
Gold Chemically inert, easily 
functionalized; can be used 
for theranostic purposes 
1990[179] Breast cancer[180, 181] 
Dendrimers Highly branched polymers 
with greater shape control 
and end group density 
1993 (PAA)[182]; 1999 
(PPI)[183] 




PEI Titratable amines facilitate 
endosomal escape 
1995[16, 99] Neuroblatoma[149]; glioma 
and medulloblastoma[187]; 
glioma and hepatoma[150] 
PLGA Encapsulates nucleic acids 
through double emulsion 
process 
1997[182, 183, 188] Lung cancer[92]; prostate 
cancer[184-186, 189] 
Cyclodextrin Water-soluble polysaccharides 
that can complex with nucleic 
acids 
1999[190] Hepatoma[114]; 




Solid material with porous 
structure allowing cargo 
adsorption on the outer 
surface and inside pores 
2000[83] Lung cancer[89]; ovarian 
cancer[87]; breast cancer[192] 
PBAE Contains hydrolizable ester 
bonds for greater 
biocompatability 
2000[122] Glioblastoma[125, 126, 170]; 




Table 2-1. Key nanomaterials listed in chronological order of their initial investigation to illustrate the 
evolution of nanomaterials used for non-viral gene delivery. Representative cancer types that have been 
investigated using each material for therapeutic gene delivery are also listed. 
2. Nanoparticles for DNA and siRNA delivery 
2.1 Liposomes and lipid-based materials 
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 Lipid-based nanoparticles are the most commonly used non-viral chemical method of intracellular 
nucleic acid delivery. Several commercially available transfection reagents including Lipofectamine® 2000 
[43], 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) [44], RNAifect [44], TransIT-TKO and TransIT-
siQuest [45] are all lipid-based. For DNA delivery, the molecular structure of the cationic lipid is an important 
factor in transfection efficacy as it determines how the liposome interacts with the cell membrane [46, 47]. 
These liposomes can be modified by conjugating targeting ligands on the surface [48] or adding cholesterol to 
improve cell binding and uptake [49]. In liposomes delivering siRNA, cholesterol is often added to 
formulations to increase membrane fluidity and thereby increase cell membrane fusion and cellular uptake 
[50, 51]. Other lipid-based approaches utilize modified structures of individual lipids to make it energetically 
easier for the liposome to leave the lamellar phase and disrupt the endosome, thus releasing nucleic acid cargo 
into the cytoplasm and preventing lysosomal degradation [24, 52, 53]. Liposomally delivered siRNA cargo 
simultaneously escapes the endosome and is released from its carrier into the cytosol, its site of action. Lipid 
hydrocarbon tail properties such as chain length and saturation have been shown to play a role in cell 
membrane fusogenicity and can be optimized to promote cellular uptake [54].  
 Factors other than efficacy must be considered when designing nanoparticle systems. For example, 
DOTAP forms stable nanoparticles that protect DNA from degradation [55] but has been shown to promote 
strong interferon responses in mice [44]. Chono et al. modified DOTAP with hyaluronic acid and were able to 
demonstrate reduced immunotoxicity as measured by inflammatory cytokine expression [56]. Functionalizing 
liposomes with a hydrophilic polymer poly(ethylene glycol) (PEG) has also been shown to reduce immune 
stimulation [57]. Semple et al. were able to show successful intravenous administration of siRNA using 
PEGylated lipids in non-human primates [58]. Interestingly, some groups have been able to take advantage of 
the immunogenic properties of DOTAP. Ott et al. showed that DOTAP nanoparticles in a DNA vaccine 
formulation induced greater antibody response compared to naked DNA [59]. Thus, DOTAP could 
potentially be used as an adjuvant as well as a carrier in DNA vaccines.  
 
2.2 Inorganic nanoparticles 
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 Calcium phosphate (CaP) nanoparticles enable DNA delivery via co-precipitation of CaP and DNA 
into nanoscale crystals [60-62]. Sokolova et al. synthesized nanoparticles with a CaP core and alternating DNA 
and CaP shells that protected DNA from degradation and improved transfection [63]. Methods to optimize 
CaP for siRNA delivery have often employed polymers. Polymethacrylate-PEG (PMA-PEG) block 
copolymers were coated onto the surface of CaP/siRNA nanoparticles and assisted in endosomal escape [64]. 
To improve loading of siRNA into CaP, Zhang et al. covalently functionalized siRNA with PEG and then co-
precipitated siRNA and CaP [65]. 
 Gold nanoparticles are advantageous for several types of gene delivery because they are safe, easy to 
chemically functionalize, and have the potential for diagnostic as well as therapeutic use [66, 67]. The particle 
surface can be modified by cationic groups such as quaternary ammonium salts to increase DNA binding 
[68]. Alternatively, anti-sense DNA oligonucleotides have been covalently linked to the surface of 
nanoparticles to induce gene knockdown [69]. Spherical nucleic acids, oligonucleotides arranged in a dense, 
oriented, and spherical configuration, have shown promise for intracellular delivery in multiple applications 
and are often designed by conjugation to an inorganic nanoparticle core, such as thiolated nucleic acids 
conjugated to gold nanoparticles [70, 71]. The covalent linker can also be modified to allow greater control of 
DNA release. Han et al. used a photoactive o-nitrobenzyl ester linker to control the spatial and temporal 
release of DNA by applying a near-UV light [72]. Alternative approaches to deliver siRNA using inorganic 
nanoparticles include combination with polymers. siRNA can be non-covalently layered onto gold 
nanoparticles by alternating layers of siRNA with the cationic polymer poly(ethylene imine) (PEI) [73]. A 
combinatorial approach was designed by Lee et al. in which siRNA was covalently linked to gold nanoparticles 
via disulfide bonds and then electrostatically coated with PBAEs in order to promote cell uptake and 
endosomal buffering [74]. 
 Quantum dots such as CdSe/ZnS nanoparticles can be used as fluorophores as well as nucleic acid 
delivery vehicles [75-77]. DNA can be covalently conjugated onto the quantum dot using a peptide nucleic 
acid linker [78], or through non-covalent association with cationic polymers that are capped on the quantum 
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dot surface [79]. Methods for siRNA delivery commonly employ covalently linking siRNA to the quantum 
dot surface, often with a polymeric spacer [80, 81]. 
 Mesoporous silicas are solid materials that have a honeycomb-like porous structure with empty 
channels (mesopores) that can encapsulate bioactive molecules.[82] This unique porous structure provides an 
inner and an outer surface onto which cargo can adsorb. Silica has been shown to have high affinity for the 
head groups of phospholipids that promotes its association with the cell membrane, enhancing cellular uptake 
through physical concentration of mesoporous silica nanoparticles (MSNs) on the cell surface [83, 84]. MSNs 
for DNA delivery require surface modification with cationic groups for DNA binding [85]. Similarly, MSNs 
have been coated with cationic polymers such as PEI [86] and PAA [87] to facilitate siRNA binding. In 
addition to nucleic acid binding on the outside, the internal surfaces of MSN mesopores  have been used to 
encapsulate fluorescent dyes for intracellular tracking [88] or anticancer drugs for multimodal therapies [87]. 
Li et al. designed an MSN modified with PEI and the fusogenic peptide KALA encapsulating siRNA targeting 
vascular endothelial growth factor receptor [89]. When these particles were injected intratumorally into mice 
that had been subcutaneously inoculated with human lung cancer cells, they significantly inhibited tumor 
growth through the suppression of tumor neovascularization. These results demonstrate the potential of 
MSNs delivering nucleic acids as powerful anti-cancer therapies. 
 
2.3 Polymeric nanoparticles 
 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are advantageous for several types of drug delivery 
due to their biodegradability and safety, and PLGA as a biomaterial has already been used in a number of 
FDA-approved devices. PLGA particles are typically synthesized via a simple emulsion-solvent evaporation 
process [90] and have a readily functionalizable surface chemistry that allows easy attachment of molecules to 
promote delivery functions like tissue homing and cellular uptake [91].  DNA can be encapsulated within 
PLGA particles through a double emulsion process or adsorbed onto the particle surface after surface 
treatment with bioadhesive agents such as Carbopol, a polyacrylic acid-based polymer [92]. Cationic polymers 
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such as chitosan or spermidine can be blended into PLGA particles, the latter of which was used by 
Woodrow et al. for intravaginal siRNA delivery [93].  
  More commonly employed polymers for polymeric gene delivery nanoparticles are often cationic and 
electrostatically interact with nucleic acids to form polyplexes. Early gene delivery strategies often employed 
poly(L-lysine) (PLL) due to its cationic nature [15, 16]. PLL particles delivering DNA have been modified by 
adding PEG groups to prevent particle aggregation in serum [94] and Kim et al. created a terplex system with 
stearyl-PLL, low density lipoprotein, and DNA that increased particle compactness and improved DNA 
binding [95]. PEG-PLL block copolymers have also been used for siRNA delivery [96], but were often so 
stable that the siRNA cargo could not be released. Miyata et al. enabled PEG-PLL nanoparticles to undergo 
cytoplasmic siRNA release by crosslinking PLL end chains with bioreducible disulfides [97]. A similar delivery 
system was later modified with the RGD integrin recognition peptide to promote in vivo tissue targeting [98].  
 PLL nanoparticles often are unable to escape the endosome. This realization led to the exploration of 
other cationic polymers such as PEI, a polymer that contains primary, secondary, and tertiary amines to 
enable both nucleic acid binding and more efficient endosomal escape [99]. Godbey et al. used extensive 
confocal microscopy experiments to elucidate the intracellular fate of PEI-DNA nanoparticles. They found 
that PEI particles aggregate in discrete patches on the cell surface before being internalized through endocytic 
vesicles; some particles then escape through lysed endosomes and localize to the nucleus [100]. The polymer 
structure can be tuned to modulate gene delivery as low molecular weight PEI cannot condense DNA as well 
as its high molecular weight counterpart but is less toxic than higher molecular weight PEI [101]. 
Modifications with targeting ligands and PEGylation have also been shown to improve particle stability and in 
vivo transfection [102]. PEI analogs optimized for siRNA delivery frequently employ lower molecular weight 
linear PEIs linked with disulfide bonds to enable degradation and siRNA release, as PEI itself contains no 
biodegradable moieties [103].  
 Similar polymeric materials such as poly(amido amine)s (PAAs) and poly(amido ethyleneimine)s 
(PAEIs) have been designed that have buffering capacities in the endosomal pH range superior to PEI [104]. 
Partial degradation of PAA dendrimers by heat treatment increases the dendrimer flexibility and has been 
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shown to lead to better transfection [105]. PEGylation further increases transfection efficacy and decreases 
toxicity [106]. PAA modifications for siRNA delivery employ disulfides linkages in the polymer backbone, 
and have shown superior siRNA delivery compared to PEI even in cells with comparable nanoparticle uptake 
[107-109]. This is likely due to the enhanced cytoplasmic siRNA release enabled by the inclusion of 
bioreducible disulfides. Modification of disulfide containing PAAs with PEG has shown a reduction in 
hemolysis and particle aggregation in vivo, but with reduced particle stability and decreases in gene knockdown 
[110].   
Cyclodextrin-based nanoparticles are effective and have reached clinical trials. Cycldextrins are a class 
of water-soluble molecules of 6-9 glucose units that form a cone-shaped structure with a hydrophobic interior 
that can complex with various molecules, including nucleic acids [111]. Nanoparticles for DNA delivery can 
be made by conjugating cyclodextrin with polymers including PEI [112] and PAA [113], which condense 
DNA through electrostatic interactions. DNA can also be covalently linked to cyclodextrin via cationic 
adamantyl linkers [114]. For siRNA delivery, self-assembled nanoparticles can be made from cyclodextrin 
polymer, siRNA, and adamantane-PEG conjugates [115, 116]. These nanoparticles were used to deliver 
siRNA targeting the M2 subunit of ribonucleotide reductase in a Phase 1a/1b clinical trial which 
demonstrated siRNA activity in humans [116, 117].   
Dendrimers are polymer structures that consist of a central core molecule from which highly 
branched arms extend out in an ordered and symmetric fashion. The stepwise method of dendrimer synthesis 
lends greater control of polymer size while the branching structure results in a higher density of terminal 
groups, offering unique surface characteristics and additional attachment sites for drugs or targeting moieties 
[118]. Two dendrimers that have been used for gene delivery are the PAAs mentioned above and 
polypropylenimine (PPI). PPI dendrimers with a butylenediamine (DAB) core have been shown to increase 
DNA binding with increasing dendrimer generations, with generation 2 providing the optimal balance 
between nucleic acid binding and toxicity [119]. Arginine has been conjugated to the terminal ends to increase 
membrane permeability and improve nuclear localization [120]. PPI nanoparticles for siRNA delivery have 
been modified with a disulfide crosslinking molecular cage on the surface to increase particle stability [121]. 
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2.4 Poly(beta-amino ester) (PBAE) nanoparticles for DNA and siRNA delivery to cancer 
 PBAEs are a class of polymer that contains tertiary amines and ester bonds along the polymer 
backbone. These chemical moieties provide positive charge for nucleic acid binding, buffering to promote 
endosomal release, and hydrolytic degradability for cargo release [122]. PBAEs have been well studied for 
DNA delivery, and have been designed to deliver DNA more efficiently and with less cytotoxicity than 
commercially available reagents such as PEI and Lipofectamine  2000 in several cell types [123, 124]. By 
changing the chemical properties of the PBAE, it is possible to design nanoparticles that selectively deliver 
DNA to certain cell types, while avoiding delivery to others [124]. PBAEs can also be designed to deliver 
DNA to cancer while avoiding healthy cells, thereby allowing for the delivery of cell-killing genes to tumor 
cells without off-target effects [125-127]. Additionally, PBAE-DNA nanoparticles can be fabricated, dried, 
and stored as a powder for at least two years at -20 C without losing function, highlighting their translational 
potential [125, 127]. 
 Various modifications to the PBAE backbone have been made to allow controlled DNA release 
from PBAE nanoparticles. A light-responsive 2-nitrobenzene moiety was added to the PBAE backbone to 
allow quick and controlled DNA release upon UV radiation (Figure 2-2) [128]. Gu et al. electrostatically 
linked pH-sensitive carboxymethyl poly(L-histidine) groups to PBAE-DNA nanoparticles to neutralize the 
particle’s positive surface charge and increase buffering capacity; this modification decreased erythrocyte 
agglutination and enhanced the particle’s tumor targeting capabilities after intravenous injection [129]. 
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Figure 2-2. Light-responsive PBAE nanoparticles (P1-13700) delivering an EGFP plasmid to Hela cells with 
or without 2 minutes of UV irradiation; Lipofectamine™ 2000 (LPF) was used as a control. PBAE 
transfection efficacy increased with UV treatment, which broke 2-nitrobenzene linkers in the polymer 
backbone and allowed controlled DNA release. Reproduced with permission [128]. 
 
 Due to the physical differences between DNA and siRNA described above, PBAE-based siRNA 
delivery had initially been difficult without the addition of other delivery vectors such as gold nanoparticles 
[74]. Hong et al. took the approach of modifying the siRNA itself. They designed complementary 
DNA/siRNA strands that self-assembled to form a dendrimeric siRNA structure; these siRNA dendrimers 
had higher charge density and structural flexibility, which allowed them to form stable particles with PBAE 
formulations that had been optimized for DNA delivery [130]. Tzeng et al. modified the polymer structure by 
end-capping traditional PBAEs with a disulfide-containing small molecule and showed successful siRNA 
delivery to both cancer cells and mesenchymal stem cells [131, 132]. The addition of the degradable disulfide 
moiety enabled this polymer structure to form polyplexes at a higher polymer:siRNA mass ratio (wt/wt) 




Building on this work, Kozielski et al. designed a novel disulfide containing monomer to form disulfide bonds 
within every repeat unit [133]. This monomer, 2,2’-disulfanediylbis(ethane-2,1-diyl) diacrylate, was referred to 
as “BR6” as it was the reducible form of a well-established PBAE monomer known as “B6,” hexane-1,6-diyl 
diacrylate [134]. PBAE nanoparticles made from BR6 were shown to bind siRNA with the same strength as 
particles made from its non-reducible analog but quickly released its siRNA cargo in a reducing environment, 
unlike the conventional non-bioreducible PBAEs. Furthermore, these particles achieved gene knockdown in 
vitro that was significantly higher than that achieved by Lipofectamine  2000 (Figure 2-3) and was shown to 
preferentially deliver siRNA to brain cancer cells while avoiding delivery to healthy brain cells.  
 
Figure 2-3. Phase contrast (top) and fluorescence (bottom) images of GFP+ GBM cells with bioreducible 
PBAE (R647) nanoparticles delivering either an siRNA targeting GFP (left) or a scrambled control RNA 
(right) [170]. 
 
 The ability to effectively bind and deliver both DNA and siRNA make PBAEs an attractive option 
for gene delivery in cancer therapies. PBAE nanoparticles delivering the p53 tumor suppressor gene inhibited 
tumor growth in a small cell lung cancer mouse model after intratumoral injection [135]. A nanoparticle with 
a PBAE-DNA core and a pullulan-methotrexate shell showed enhanced circulation time and targeted delivery 
to hepatoma cells in vivo, with high levels of particle accumulation and transfection in the tumor [136]. For 
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more controlled long-term release, Segovia et al. encapsulated PBAE-siRNA particles in a PAA-dextran 
aldehyde hydrogel; when implanted in a breast cancer model, they saw a high level of knockdown even after 7 
days [137]. Our group is particularly interested in the use of PBAE nanoparticles for the treatment of 
glioblastoma. Glioblastoma (GBM), a grade IV glioma, is one of the most deadly human cancers with a 
median survival of only 15 months following treatments such as tumor resection, chemotherapy and 
radiotherapy [138-140]. Polymeric nanoparticles for the intracellular delivery of nucleic acids enable new 
modalities of treatment for many cancer cell types, including GBM. By tuning the PBAE polymer structure, 
we were able to form PBAE nanoparticles that preferentially delivered nucleic acids to brain tumor initiating 
cells, a cell population that is believed to be responsible for tumor recurrence [127]. High levels of 
transfection were seen when PBAE particles delivering a GFP reporter gene were injected into an orthotopic 
GBM murine model [125]. In addition, these particles were able to achieve a therapeutic effect. PBAE 
nanoparticles delivering DNA encoding the herpes simplex virus-derived thymidine kinase (HSVtk) were 
injected intracranially in a rat GBM model while the ganciclovir pro-drug was administered systemically [126]. 
The PBAE nanoparticles penetrated through the whole brain tumor volume (a length of approximately 2 
mm) and HSVtk catalyzed the phosphorylation of ganciclovir into its active form to enable killing of brain 
cancer cells, resulting in significant survival benefits [126]. 
 Further modifications of PBAEs such as synthesis of dendrimeric versions of the polymers are 
interesting future directions for enhanced nucleic acid delivery. Cutlar et al. synthesized a highly branched 
PBAE that showed higher transfection efficacy when compared to linear counterparts as they could better 
condense their DNA cargo [141]. Zhou et al. synthesized a dendrimeric ester nanoparticle that successfully 
delivered microRNAs to a liver cancer model and achieved significant survival benefits [142]. The authors 
hypothesized that the increased nucleic acid binding capacity and degradability of these polyester dendrimers 
contributed to successful RNA delivery while maintaining low hepatotoxicity. Indeed, dendrimeric PBAEs 
may produce smaller, more compact nanoparticles that contain more polymer end groups, which could 
increase biomaterial-mediated cell specificity. This may be especially relevant for cancer therapy, including 
brain cancer therapy, where smaller particle sizes can increase particle penetration and transport.  
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2.5 Methods for DNA and RNA co-delivery 
 Despite the physical differences between DNA and RNA that present different challenges for their 
intracellular delivery, several strategies have been developed for co-delivery in order to achieve novel 
therapeutic goals. In designing nanoparticle formulations, it is particularly important to also ensure that each 
of the different nucleic acids to be delivered reaches the target cells at the desired ratios. To enable co-
delivery to the same cell, loading different nucleic acids into the same particles (rather than delivering a 
combination of particles, each with its own cargo) has been show to increase the co-expression of delivered 
nucleic (Figure 2-4) [143]. As polyplexes are formed through self-assembly between cationic polyelectrolytes 
and anionic polyelectrolytes, with larger more multivalent polyelectrolytes leading to enhanced stability, 
carrier DNA can be complexed into the same polyplexes as siRNA as a strategy to stabilize the particle for 
enhanced siRNA delivery [144]. This can be an effective way to achieve gene knockdown and expression in 
the same cell to achieve synergistic therapeutic effects [145, 146]. Another way to complex multiple nucleic 
acids in the same particle is through layer-by-layer (LbL) assembly. Elbakry et al. used LbL to synthesize a 
particle with a gold core, 11-mercaptoundecanoic acid coating, and PEI-siRNA layers to condense siRNA 
into a particle and achieve effective knockdown [73]. Bishop et al. adopted a similar strategy but added DNA, 
siRNA, and PBAE layers [147]. This strategy can be used to deliver multiple nucleic acid cargos as well as 
control their relative release times.  
 
Figure 2-4. (A) Nanoparticles carrying either GFP or DsRed plasmid DNA are blended following 
nanoparticle fabrication, resulting in particles containing only one type of plasmid. Transfection of IMR90 
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human fibroblasts with this nanoparticle combination yields little codelivery, as indicated by few cells 
coexpressing GFP and DsRed (yellow cells). (B) Nanoparticles formed using a blend of GFP and DsRed 
plasmids yield particles containing both plasmids, and coexpression is high. Reproduced with permission 
[143]. 
3. Conclusion 
 Non-viral nanoparticle technologies for DNA and siRNA delivery have advanced rapidly, with many 
complementary biomaterial and particle designs. Several promising delivery platforms involving lipid-based, 
inorganic, and polymeric nanocarriers have been developed with strong in vivo efficacies, some of which have 
entered clinical trials. The interest in these technologies is due to the large potential for gene delivery and 
siRNA-induced gene knockdown to treat diseases caused by aberrant gene expression, such as cancer, and the 
need to obtain safe and effective delivery methods. Non-viral nanoparticles have the potential to fulfill this 
promise. Continuing to investigate the barriers to intracellular delivery as well as to innovate the 
nanotechnologies capable of overcoming these barriers may one day allow genetic medicine to clinically treat 
genetically based diseases such as cancer.  
 
4. Expert Opinion 
 As polymeric nanoparticle-based gene therapy shows increasing promise against cancer in vitro and 
for local administration in vivo, increasing attention is being turned towards strategies to allow the systemic 
delivery of these particles to treat metastatic cancer. A common method employs PEGylation, which shields 
the particles from interacting with serum proteins or off-target cells. For example, PEGylation of PLL, PEI, 
and PAA-based nanoparticles has been shown to enhance their circulation time and reduce hemolysis and 
serum-induced aggregation [110, 148]. Such a strategy could greatly enhance the ability of newer types of non-
viral nanoparticles, such as PBAE-based nanoparticles, to enable them to circulate effectively and diffuse 
through tissue, improving their translational potential for use in cancer applications. 
 PEG can also be used as a linking molecule onto which targeting ligands may be conjugated to 
enable nanoparticle targeting to cellular receptors. Ligands that have successfully been conjugated to 
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PEGylated nanocarriers for cancer targeting include the RGD peptide sequence targeting integrins in tumor 
vasculature [149] as well as folate [150] and transferrin [151], molecules whose receptors are overexpressed in 
many cancer cell types. This strategy takes advantage of PEG’s ability to increase nanocarrier serum stability, 
reduce non-specific uptake, and better enable the display of targeting moieties on the nanoparticle surface, 
resulting in higher particle accumulation in the tumor. However, one potential concern with PEGylated 
electrostatic polyplex nanocarrier systems is that while the charge masking properties of PEG have been 
shown to increase nanoparticle colloidal stability in serum, they may also decrease particle complexation 
stability. Kichler et al. showed that in a PEI polymer covalently endcapped with high molecular weight PEG, 
the resulting nanoparticles could not protect their DNA cargo from nuclease degradation and resulted in 
poor transfection when compared to un-PEGylated PEI [152]. Similarly, Mao et al. showed that in PEI-PEG 
block copolymers, formulations with lower molecular weight PEG at higher substitution levels resulted in 
large, loosely structured particles that could not effectively condense siRNA and resulted in poor knockdown 
[153]. The charge shielding capability of PEG molecules protect cationic polymers from serum aggregation 
but also reduce their ability to electrostatically bind to nucleic acid cargos. To create a PEGylated polymer for 
successful nanoparticle formation, it is crucial to balance these opposing forces, such as through the addition 
of crosslinks or by adding non-PEGylated polymers to the co-complex to increase its stability.  
Another strategy for systemic delivery is coating the particle with peptides to decrease toxicity, 
enhance circulation time, and enable particle targeting to specific organs or tumors [154]. Simberg et al. coated 
a peptide sequence to iron oxide particles that targeted clotted plasma proteins in leaky tumor vasculature 
[155]. These particles in turn induced more clots and amplified the effect. PBAE nanoparticles 
electrostatically coated with poly(glutamic acid) based peptide sequences reduced in vivo toxicity and could 
enable targeting to specific organs based on peptide sequence differences and nanoparticle properties [156]. 
Peptide coating can allow nanoparticles to remain in circulation for longer periods of time and can enhance 
particle targeting and uptake through ligand-mediated endocytosis. An important area for future research in 
the field is the investigation of new types of nanoparticle coatings that enable greater specific intracellular 
delivery to on-target cancer cells (perhaps in a manner specific to the receptors on a patient’s particular 
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tumor), while preventing intracellular delivery to off-target cells. In addition, such next generation coating 
must enable prolonged circulation times, including resistance to clearance by neutralizing antibodies, even 
after multiple previous treatments of the next-generation nanoparticles. 
 The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 
system is a recently discovered genome editing tool with many potential therapeutic applications. The 
CRISPR/Cas9 system derives from a bacterial defense mechanism, where foreign DNA segments are 
transcribed into a dual-RNA complex and used to recognize and silence invading targets through double-
stranded breaks (DSB) induced by the Cas9 endonuclease [157]. A single chimeric sgRNA was recently 
developed that can activate site-specific cleavage by Cas9 [158]. The resulting DSB can be repaired through 
error-prone non-homologous end joining, leading to indels that knock out gene function, or homology-
directed repair upon introduction of a donor repair template [159]. The CRISPR/Cas9 system has been 
successfully used in human cells to introduce permanent changes in the genome [159, 160], making it a 
powerful tool for gene editing to treat diseases like cancer. 
 Only a handful of studies have been done using non-viral methods to deliver the CRISPR/Cas9 
system. Jinek et al. constructed a plasmid encoding Cas9 and the sgRNA and delivered it using commercial 
transfection agents. However, they were only able to achieve editing efficiencies in the range of 6-8% [161]. 
Sun et al. constructed DNA nanoclews by packing sgRNA and the Cas9 protein into DNA strands that are 
partially complementary to the sgRNA and coating the outside with PEI (Figure 2-5); the DNA nanoclew 
system achieved a 36% editing efficiency [162]. The low editing efficiency seen by many groups may be due to 
poor delivery efficacy of the Cas9 plasmid or sgRNA. Co-delivery of the two using non-viral nanoparticles, 
such as biodegradable polymeric nanoparticles, is a potential way to increase expression and gene editing 
efficacy. Strategies such as a layer-by-layer approach can be used to package the Cas9 plasmid and sgRNA 
using polymers that are suitable for each and to control their intracellular temporal release.  
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Figure 2-5. (Top) Assembly schematic of DNA nanoclew (DNA-NC) carrying Cas9 and sgRNA. Cas9 and 
sgRNA were incubated together and complexed with the DNA-NC; a PEI coating was then applied to the 
outside to facilitate endosomal escape . (Bottom) Fluorescence microscopy images of EGFP+ U2OS cells 
with or without treatment with DNA-NC delivering Cas9 and EGFP-specific sgRNA. Cas9-induced DNA 
cleavage resulted in significant EGFP gene knockout. Reproduced with permission [162]. 
 
 Another interesting target for the co-delivery of DNA and siRNA is the TNF-related apoptosis-
inducing ligand (TRAIL) system. TRAIL induces apoptosis in many transformed cell lines by binding to the 
death receptors DR4 and DR5 on the cell surface [163, 164]. Its apoptotic function is selective for 
transformed and tumor cells [165], and exhibits a bystander effect [166]. These properties make TRAIL an 
attractive delivery target for cancer treatment as it can produce a cancer-specific, self-amplifying apoptotic 
effect. However, it has been shown that many cancer cell types resist TRAIL action. One explanation for this 
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phenomenon is the presence of decoy receptors DcR1 and DcR2, which lack functional intracellular death 
domains [167]. Studies have shown that DcR2 is upregulated in some TRAIL-resistant breast and prostate 
cancers [168, 169]. siRNA knockdown of DcR2 in these cells sensitized them to TRAIL-induced apoptosis. 
When TRAIL plasmids were delivered to the same cells, their tumorigenic potential was significantly reduced. 
This suggests that co-delivery of siRNA to knock down decoy receptors and DNA to upregulate TRAIL 
expression can work synergistically to cause cancer cell apoptosis and may be a promising target for polymeric 
nanoparticle delivery. Similarly, other siRNA and DNA co-delivery strategies may enable breakthroughs 
against cancer resistance and are enabled by non-viral nanoparticles. 
 Treatment of genetically-based diseases such as cancer often requires a combinatorial approach, as 
cells can often compensate for the knockdown or overexpression of one genetic target. For the proposed 
treatment strategies suggested herein, co-delivery of DNA and RNA is required to occur within the same 
cells, not simply within the bulk of a tissue or tumor. While the materials optimal for DNA and siRNA often 
vary, a treatment strategy requiring co-delivery would ideally require a material optimized to deliver both. As 
previously demonstrated [143], a blend of nanoparticles containing different cargos is less likely to co-deliver 
both cargos to the same cells. Conversely, particles containing the cargo blended within each nanoparticle 
results in high co-delivery rates. Temporal control of DNA and RNA release [147] is also imperative for 
systems which would require DNA transcription and siRNA-induced knockdown to occur in a non-
simultaneous fashion. Future nanoparticle designs that would have the sophistication and control to 
combinatorially deliver multiple types of nucleic acids against multiple targets have the potential to address 
the heterogeneity and mutational capabilities of genetic diseases such as cancer.  
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Abstract 
Genome editing technologies such as zinc finger nucleases, transcription activator-like effector nucleases, and 
the clustered regularly interspaced short palindromic repeat/CRISPR-associated protein system have 
revolutionized biological research. Each biotechnology consists of a DNA binding protein that can be 
programmed to recognize and initiate double stranded breaks for site-specific gene modification. These 
technologies have the potential to be harnessed to cure diseases caused by aberrant gene expression. In order 
to be successful therapeutically, their functionality depends on their safe and efficient delivery into the cell 
nucleus. This review discusses the challenges in the delivery of genome editing tools and highlights recent 
innovations in non-viral delivery that have potential to overcome these limitations and advance the translation 
of genome editing towards patient care. 
 




ZFN: Zinc Finger Nucleases are FokI based, targeted DNA cleaving proteins that can introduce double 
stranded breaks targeted by triplet DNA bp recognizing zinc finger motifs 
TALEN: Transcription Activator-Like Effector Nucleases are FokI based nucleases that are targeted to 
specific DNA sequences by central repeat domains in which 33-35 amino acids specify a single target DNA 
base 
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats refers to the RNA targeted, DNA 
cleaving system originating in bacteria that has been re-appropriated for RNA guided DNA cleavage in 
mammalian cells 
Cas: CRISPR associated protein, frequently Cas9 from S. aureus or S. pyogenes 
PAM: Protospacer Adjacent Motifs are a short (2-6 bp) region of DNA recognized by the CRISPR 
associated proteins as non-bacterial in origin and are required to mediate CRISPR cleavage at RNA targeted. 
The canonical PAM sequence is 5’-NGG-3’ but other Cas variants with different PAM sequences have been 
discovered or engineered. 
DSB: Double stranded breaks occur when both strands of DNA are cleaved, triggering DNA repair 
pathways 
NHEJ: Non-Homologous End-Joining is the primary, non-specific repair pathway of double-stranded break 
ligation in mammalian cells 
HDR: Homology Directed Repair occurs when a donor template containing a gene insert flanked by 
homology arms that are complementary to DNA sequences flanking the cut site is present after double-
stranded breaks  
HITI: Homology-Independent Target Integration introduces gene inserts via donor templates that do not 
contain homology arms 
RNP: Ribonucleoproteins in the context of CRISPR refers to the assembled complex of gRNA and Cas 
protein that can actively induce DNA cleavage 
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ZFNs, TALENs, and CRISPR/Cas 
Zinc Finger Nucleases (ZFNs) (see Glossary) and Transcription Activator-like Effector Nucleases 
(TALENs) are hybrid restriction enzymes comprised of a DNA binding domain and a DNA cleavage 
domain based on the FokI endonuclease [1]. In contrast to ZFNs and TALENs, both of which use protein 
structures to recognize DNA sequences, the Clustered Regularly Interspaced Short Palindromic 
Repeat/CRISPR-associated system (CRISPR/Cas) enables DNA recognition through RNA-defined 
specificity. This simplifies the design of a target-specific gene editing complex to a short guide RNA (sgRNA) 
with a 20 bp complementarity with the target DNA sequence, as opposed to a new protein array, though the 
target sequence must be upstream of a protospacer adjacent motif (PAM) sequence [2, 3]. Table 2-2 
summarizes the characteristics of each gene editing system. Gene editing technologies continue to advance 
rapidly and recent reviews have provided coverage of many physical and chemical strategies for intracellular 
delivery of macromolecules that can potentially be adopted for gene editing applications as well as strategies 
for specific modification of genome editing proteins [4, 5]. In this review, we provide in-depth discussion of 
the most recent studies on non-viral gene editing, most of which were published in the last year, with an 
emphasis on the utilization of nanoparticle-based delivery vehicles. 












Each zinc finger 
protein recognizes 3 
bp DNA 
Target sequence length 
must be multiple of 3; 
longer target sequence 
requires larger protein 








Each TALE protein 
unit recognizes 1 bp 
DNA 
Cloning of TALE repeat 
arrays can be technically 
challenging; longer target 








20 bp targeting region 




Target sequence must be 
upstream of PAM site 
Table 2-2. Comparison of ZFN, TALEN, and CRISPR/Cas gene editing systems. 
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All three gene editing systems result in sequence-specific DNA cleavage, at which point the cell’s 
own DNA repair machinery can be harnessed to achieve gene modification. In the absence of a donor DNA 
template, double stranded breaks (DSBs) are repaired through error-prone non-homologous end joining 
(NHEJ), which introduces small indels that can shift the reading frame and result in gene knockout. When a 
donor DNA template is present, entire genes can be knocked in at the cut site. This is commonly achieved 
through homology directed repair (HDR) [6, 7], although some studies have shown higher integration rates 
through a process termed homology-independent targeted integration (HITI) [8].  The DNA binding 
capabilities of these genome editing enzymes have been further harnessed to enable site-specific single base 
pair editing [9, 10] and epigenetic [11, 12] or transcriptional [13, 14] modulation of gene expression. 
In order for gene editing complexes to be functionally active, they must first be delivered into the cell 
nucleus, necessitating delivery across both the plasma and nuclear membranes. Historically, the most 
common way to achieve this is through the use of viral vectors, in which nucleic acids coding for the enzyme 
complexes are packaged into viruses and delivered to a target cell. While viral vectors are often highly 
effective, the complexity and challenge associated with scale-up of virus production, potential for insertional 
mutagenesis, and possible immune responses against the viral vector limit their use in a therapeutic capacity 
[15]. Viral vector cargo size limitations additionally limit efficacy particularly in AAV systems, which can 
necessitate editing enzymes and donor templates to be packaged into separate viral particles [16, 17]. Non-
viral delivery methods have emerged as a viable alternative as they can be engineered to largely avoid these 
problems, but they require substantial improvements in order to reach the efficacy of their viral counterparts. 
Challenges to non-viral delivery include protection of nucleic acid or protein cargo from degradation, 
opsonization, and immune avoidance, as well as delivery to specific cell targets and cellular compartments. 
Recent research has further highlighted risks of host humoral and cell mediated immunity to the Cas9 protein 
[18] as well as double-stranded break P53 responses associated with genome editing that risk selection of P53 




Cargo selection: DNA, mRNA, or Protein 
Plasmid DNA 
 Genome editing complexes can be delivered by non-viral vectors in the form of plasmid DNA, a 
format that offers flexibility in design as DNA sequences can be easily incorporated into plasmids using 
simple molecular cloning techniques. However, gene editing efficiency is often limited by the efficiency of 
nuclear delivery and gene expression that is required to generate the final gene editing protein complexes. 
Upon systemic injection, DNA nanoparticles face multiple barriers before successful delivery to target tissues 
(Figure 2-6). Nanoparticles with highly positive surface charges are prone to serum protein adsorption, 
aggregation, premature cargo release [21], and nanoparticle clearance by immune cells [22]. Coating 
nanoparticles with hydrophilic molecules such as poly(ethylene glycol) (PEG) is a common anti-fouling 
strategy that has been shown to reduce immune stimulation and increase circulation time [23], however anti-
PEG responses resulting in accelerated clearance upon repeated administration may limit the applicability of 
PEGylation in the clinic for some applications [24]. Nanoparticle size is another important feature as 
molecules smaller than 5.5 nm in diameter have been shown to experience rapid clearance from the kidneys 
[25]. Complexation into nanoparticles decreases renal clearance of DNA by increasing its size beyond the 
renal filtration limit, and nanoparticles effective for gene delivery have been found to fall in the range of 100-
250 nm in diameter [26]. 
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Figure 2-6. Extracellular and intracellular obstacles for non-viral delivery of gene editing tools. 
Systemically injected nanoparticles carrying gene editing complexes must protect their cargo from 
destabilizing serum components, enzyme degradation, and clearance by immune cells or in the liver and 
kidneys. Upon reaching the target tissue, they face further intracellular delivery barriers. Protein or nucleic 
acid cargo must be (1) encapsulated in nano-carriers for (2) efficient intracellular uptake to occur. Upon 
endocytosis into the cell, nanoparticles need to (3) escape from degradative endo-lysosomal compartments. 
For mRNA delivery, cargo release should occur in the cytosol (4a) to enable mRNA translation at the 
ribosomes (5a). For DNA delivery, plasmid DNA needs to traffic to the nucleus (4b) where DNA can be 
transcribed into mRNA (5b); the mRNA transcript must then enter the cytosol to be translated into protein 
(6b). Protein complexes, whether synthesized in the cell (6a and 7b) or delivered directly by the nanocarrier 
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(4c), must localize to the nucleus for gene editing to occur. Intracellular delivery steps common to all cargo 
formats are shown in black arrows and those specific to mRNA, plasmid DNA, and protein complexes are 
shown in red, green, and blue arrows, respectively. 
Upon arrival at target cells, nanoparticles must first cross the cell membrane. Cellular uptake can be 
enabled by attaching cell-penetrating peptides on nanoparticle surfaces to promote direct internalization [27] 
or through non-specific interactions between cationic nanoparticles and the anionic cell surface [28, 29]. If 
internalized via endocytosis, nanoparticles must also escape from degradative endo-lysosomal compartments. 
Many materials have been proposed to escape the endosome via the debated proton sponge mechanism, 
where nanomaterials containing uncharged amines at neutral pH acquire charge during endosome 
acidification, leading to polymer swelling and membrane destabilization for transient endosomal escape [30]. 
Several recent studies suggest that upon protonation in the acidifying endosome, polycations such as 
polyethylenimine (PEI) cause endosomal deformation and increase the permeability of the endosomal 
membrane, allowing nanoparticles to leak out through small pores [31, 32]. Finally, plasmid DNA  must 
localize to the nucleus, which can be facilitated by nanomaterials that expedite cytosolic and nuclear 
trafficking [33]. In rapidly dividing cells, nuclear entry of plasmids generally occurs following nuclear 
membrane breakdown during cell division but in post-mitotic cells, import to the nucleus generally occurs 
through nuclear pores, which can be facilitated by transcription factor binding sequences in the plasmid that 
bind to importins [33]. Gene editing complexes face an additional trafficking step as proteins synthesized at 
cytosolic ribosomal sites must again localize to the nucleus to bind to and cleave genomic DNA. This could 
be especially challenging for the CRISPR/Cas system as Cas9 endonucleases must also bind sgRNA in the 
nucleus before they can form functional gene editing units. Utilization of minicircle DNA, which is more 
efficient on a per-mass basis and less immunogenic than plasmid DNA due to elimination of bacterial 
expression sequences, offers an alternative to some of these challenges and has been utilized for delivery of 
CRISPR [34], ZFN and TALEN [35] systems. The reduced size of minicircles compared to plasmids 
facilitates their cytosolic trafficking and nuclear import while the removal of sequences of bacterial origin 
reduces transcriptional silencing associated with plasmid DNA sequences [36].  
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Delivery of genome editing factors as DNA sequences also carries a substantial risk of unintentional 
genomic integration, which can induce insertional mutagenesis due to incorporation of highly active promoter 
elements in chromosomal DNA or disruption of tumor suppressor genes [37]; while the risk of insertional 
mutagenesis with non-viral delivery of plasmid DNA is generally much lower than with DNA viral vectors, 
this risk must be taken into account for translationally relevant therapies. Finally, plasmid DNA delivery is 
generally not feasible for cell types that are refractory to plasmid DNA transfection. This is especially 
problematic in immune cells, where it has been demonstrated that the same delivery system that enabled up 
to 50% editing in human embryonic kidney cells achieved less than 4% editing in CD4+ T cells [38]. This 
could potentially be due to the fact that T cells can sense the intracellular presence of foreign nucleic acids 
[39], leading to an innate immune response and prompting the need for other delivery methods. 
 
mRNA 
 Another nucleic acid delivery cargo to enable genome editing is mRNA, which can be synthesized 
from a DNA template using in vitro transcription. mRNA delivery circumvents the need for nuclear 
localization of the nucleic acid cargo as protein expression can occur following cytosolic delivery, and protein 
expression is detectable as short as 4-6 hours post-transfection [40, 41]. This virtually eliminates the risk of 
insertional mutagenesis and also reduces the probability of off-target effects as the duration of protein 
expression is much shorter for mRNA compared to DNA. Studies have shown that Cas9 protein expression 
can be effectively undetectable 72 hours post-transfection with mRNA in vitro [41] and 24 hours post-
injection in vivo [40]. One major challenge for mRNA delivery is that in CRISPR applications, the delivery of 
Cas9 mRNA and sgRNA may require specialized materials as the two have very different lengths and 
different kinetics of expression. One study showed that the optimal condition for an RNA-mediated 
CRISPR/Cas9 editing system required the Cas9 mRNA to be delivered 24 hours before sgRNA delivery [42]. 
For gene insertion applications, the need for a donor template DNA may also necessitate an alternative 
delivery mechanism as Wang and colleagues demonstrated when the authors used electroporation to deliver 
mRNA coding for ZFNs and a viral vector to deliver donor DNA [43]. 
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Proteins 
 Delivery of gene editing protein complexes synthesized outside the cell eliminates the need for 
intracellular transcription and translation, and gene editing can occur immediately following intranuclear 
delivery. This could potentially boost gene editing efficacy in post-mitotic or hard-to-transfect cells, in which 
limits to the cell’s transcriptional or translational capacity could result in lower gene editing efficacy when 
using plasmid DNA or mRNA. On the other hand, this method also reduces the cargo’s ability to enable cell 
type specificity as transcriptional targeting cannot be used. In the case of CRISPR/Cas9, there is the 
additional concern that the Cas9 protein variant from the bacterial species S. pyogenes and S. Aureas have both 
been shown to be recognized by antibodies in greater than 60% of human patients [18], which could result in 
rapid clearance of these proteins upon systemic delivery. Furthermore, Cas9 and TALENs generally cannot 
cross the cell membrane on their own, though ZFNs have been shown to have some inherent cell membrane 
permeability [44]. Due to the nucleic acid binding nature of the Cas9 protein, unmodified SpCas9 possesses a 
net charge of +20, which becomes further positively charged with addition of a nuclear localization signal 
(NLS) peptide [45]. This net positive charge of the Cas9 protein can be neutralized with protein engineering, 
by inclusion of a glutamate tag up to 20 amino acids long, which enabled direct cytosolic delivery when 
Cas9/sgRNA complexes were assembled with arginine-gold nanoparticles [45]. An alternative strategy to 
increase the plasma membrane permeability of genome editing enzymes is to fuse multiple viral SV40 nuclear 
localization signal (NLS) domains onto these proteins, which was reported to enable editing without an 
additional vector material both in vitro and in vivo [46, 47]. Similarly, cell-penetrating peptides have been 
conjugated to Cas9 and gRNAs directly to facilitate uptake and endosomal escape as self-condensed cationic 
nanoparticles, although these particles mediated <10% knockout efficiency in vitro in HEK293T cells [48]. 
 
Physical Delivery Methods 
 Delivery methods that physically disrupt the cell and nuclear membranes have been used extensively 
for delivery of ZFNs, TALENs and CRISPR but are generally limited to ex vivo delivery. Gene editing 
proteins or their DNA or RNA precursors have been directly injected into cells or embryos through the 
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process of microinjection and have been successfully used to generate disease models in rodents, but this 
technique is highly limited in the number of cells that can be edited in a timely manner [49, 50]. Other 
physical methods include electroporation, in which an electric field causes small pores to temporarily form in 
the cell membrane to allow nucleic acids and proteins to pass through, and nucleofection, which combines 
electroporation with chemically-enhanced delivery. Many groups have utilized electroporation to deliver 
nucleic acids or proteins for ZFNs, TALENs or CRISPR RNPs directly in manners that have been 
extensively reviewed, with many on-going clinical trials utilizing electroporation for delivery to T-cells [4]. 
Overall, physical delivery methods have a high potential to be used for ex vivo editing of isolated circulating 
lymphocytes ex vivo, which could potentially then be adoptively transferred into a patient for cellular therapy.  
 Additionally, hydrodynamic injection has been used in vivo to induce expression of Cas9 and gRNA 
from plasmid DNA in the liver of rodents, although this method is not regarded as translatable to humans 
[51]. Other physical delivery methods include direct mechanical disruption of cellular membranes via micro-
constriction [52] or induction of cell uptake and endosomal escape of Cas9 RNP complexes via manipulation 
of osmotic potential [53].  D’Astolfo and colleagues utilized hypertonic solutions to trigger macropinocytosis 
in vitro followed by endosomal disruption mediated by zwitterionic propanebetaines to deliver Cas9 RNP 
complexes, providing an alternative to electroporation or physical membrane disruption [53].  
Chemical material-based delivery approaches for genome editing 
Nanoparticle 
material 




Plasmid DNA 50% knockout of VEGF gene in 




Plasmid DNA Macrophage-specific knockout of netrin-1; 




Cas9 mRNA and in 
vitro transcribed 
sgRNA 
Achieved gene deletion-mediated turning on 






24% knockout of eGFP in vitro in neuron-
derived mouse embryonic stem cells and 13% 
knockout in vivo in mouse cochlea hair cells 
[59] 
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PEG-lipid Cas9 mRNA and in 
vitro transcribed 
sgRNA 
97% knockout of mouse transthyretin protein 
in liver cells for; sustained for at least 12 
months following single systemic injection 
[61] 




5.4% homology-directed repair in mouse mdx 
Duchenne muscular dystrophy model after 
intramuscular injection 
[67] 




~40% GFP knockout in vitro and 25% 






Plasmid DNA 35% gene deletion, 67% protein knockdown, 
and reduced tumor growth by >71% in HeLa 
cells after intratumoral injections in vivo 
[70] 
Table 2-3. Examples of non-viral nanoparticle-mediated CRISPR delivery. 
Lipids and lipid-like materials 
 Chemical approaches to non-viral delivery utilize biomaterials to form nanostructures that 
encapsulate genome-editing cargos and then shuttle them into cells (see Figure 2-7 for chemical structures of 
these materials).  Many lipids and lipid-like materials have been developed for the intracellular delivery of 
nucleic acids such as oligonucleotides [54], mRNA [55], and plasmid DNA [56]. For genome editing 
applications, these materials have largely been used to deliver genome editing tools in the form of nucleic 
acids (see Table 2-3 for summary). Plasmid DNA encoding a Cas9-sgRNA complex targeting VEGF was 
delivered using a PEG-PEI-cholesterol lipopolymer and achieved ~50% gene knockout in osteosarcoma cells 
in vitro and in vivo [57] while a CRISPR DNA construct with a CD68 promoter was delivered using lipid-
containing PEG-PLGA nanoparticles to enable macrophage-specific gene editing, resulting in 30% gene 
knockout in vitro and 20% in vivo [58]. Cas9 mRNA and in vitro transcribed sgRNAs were delivered by Miller 
and colleagues using a zwitterionic amino lipid library [42] and by Jiang and colleagues using N1,N3,N5-tris(2-
aminoethyl)benzene-1,3,5- tricarboxamide (TT) based lipid-like nanoparticles [40] for gene editing in vitro and 
in vivo (Figure 2-8). Noting the ability to deliver the RNAs despite their vastly different sized (100 nt for 
sgRNA and >4500 nt for mRNA), the lipidoid nanoparticles engineered by Miller and colleagues achieved 
95% knockout in vitro and detectable editing in the liver, lungs and kidney. 
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Figure 2-7. Chemical structures of materials that have been used to deliver non-viral gene editing 
complexes. (A) Zwitterionic amino lipid were used to deliver Cas9 mRNA and sgRNA [42]; (B) PPABLG 
polypeptides condensed plasmid DNA into nanoparticles for CRISPR editing [70]; (C) PASp(DET) coating 
enabled endosomal escape of CRISPR-gold constructs [67]; (D) bioreducible lipids enabled intracellular 
delivery of RNP complexes [60]; (E) PEI was used in hybrid nanoparticle systems to deliver the CRISPR 
system as RNPs [69] and plasmid DNA [57]; (F) PEG-PLGA nanoparticles enabled CRISPR editing in 
macrophages in vivo [58]. 
Lipid materials have also been explored as vehicles for genome editing proteins. Zuris and colleagues 
engineered Cas9 and TALENs fused to anionic GFP proteins to increase the negative surface charge of these 
proteins and complexed them with the commercially-available cationic lipid transfection reagent 
Lipofectamine 2000TM and demonstrated 24% gene knockout in neuron-derived mouse embryonic stem cells 
in vitro and 13% gene knockout in mouse cochlea hair cells in vivo [59]. Likewise, Wang and colleagues utilized 
more effective bioreducible lipid nanoparticles to deliver charge neutralized Cas9 RNP complexes for up to 
70% knockout in vitro [60].  Lipid materials have also shown impressive levels of gene editing after systemic 
delivery, primarily in the liver. Finn and colleagues reported that lipid nanoparticles formulated with PEG-
lipids showed excellent serum stability, and when used to deliver Cas9 mRNA and sgRNAs targeting the 




least 12 months after a single systemic injection [61]. Yin and colleagues utilized the highly effective 
lipid cKK-E12 lipid nanoparticle formulation for co-delivery to the liver of Cas9 mRNA and sgRNA highly 
modified for enhanced efficacy, demonstrating 80% gene knockout primarily in hepatocytes [62]. 
Importantly, lipid nanoparticles also have the ability to complement viral delivery strategies for genome 
editing to improve tissue specificity; Yin and colleagues reported using lipid nanoparticles to deliver Cas9 
mRNA non-virally to the liver, while using AAV encoding a sgRNA and HDR DNA template to achieve 6% 
editing correction of hepatocytes [63]. Using biologically derived materials, Kim and colleagues used cancer-
derived exosomes as the delivery vehicle for plasmid DNA encoding a CRISPR/Cas system and showed 
efficient and targeted editing in an ovarian cancer model [64]. An exosome-liposome hybrid vector developed 
by Lin and colleagues enabled CRISPR-interference in mesenchymal stem cells, which could not be 
transfected using liposomes alone [65]. These results showcase the great potential of lipid formulations for in 
vivo delivery of genome editing tools to treat genetic diseases, rivaling that of viral mediated delivery for some 
tissues such as the liver. 
 
Figure 2-8. Lipid-containing delivery systems enable gene editing after systemic injections in vivo. 
(A) Structure of the zwitterionic amino lipid used by Miller et al. [42] to formulate nanoparticles delivering the 
CRISPR/Cas9 system in the form of Cas9 mRNA and sgRNA. (B) Expression profile of Cas9 after mRNA 
delivery. (C) Systemic injection of these zwitterionic lipid nanoparticles achieved gene editing in the liver, 
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kidney, and lung (as indicated by red fluorescence). Reproduced with permission from [42]. (D) Cationic 
lipid-assisted PEG-b-PLGA nanoparticles (CLAN) developed by Luo et al. [58] delivering the CRISPR/Cas9 
system in the form of plasmid DNA showed preferential expression in macrophages (BMDM and 
RAW264.7) when using a macrophage-specific promoter (pM458). (E) Systemic injection of these 
nanoparticles enabled macrophage-specific gene editing in mice. Reproduced with permission from [58]. 
 
Polymeric materials 
 Polymeric materials have been used for the delivery of DNA, mRNA, and oligonucleotides [66]. For 
the delivery of genome editing tools, polymers have often been used in multi-component delivery systems to 
promote endosomal escape (Figure 2-9). Lee and colleagues used the endosomal disruptive polymer poly(N-
(N-(2-aminoethyl)-2-aminoethyl) aspartamide) to coat Cas9-sgRNA RNPs adsorbed onto gold nanoparticles 
and used this vehicle, which they termed CRISPR-Gold, to correct the dystrophin gene in a mouse model of 
Duchenne muscular dystrophy in vivo; despite an in vivo HDR frequency of only 5% following intramuscular 
injection, these nanoparticles mediated a statistically measurable increase in muscle strength compared to 
scramble nanoparticles [67].  CRISPR-Gold has been utilized in follow-up work to mediate genome editing in 
rodent brains following local injection using both Cas9 and Cfp1, managing to reduce mRNA and protein 
levels of the target gene by up to 50% [68]. In an alternative approach, Sun and colleagues used rolling circle 
amplification to create DNA nanoclews that enabled encapsulation of RNP complexes in a DNA based 
particle core that were then coated with the cationic polymer polyethylenimine (PEI) and achieved CRISPR-
mediated gene editing in vitro of up to 28% knockout compared to <2% knockout with PEI only as well as an 
estimated 25% knockout of eGFP in vivo following intratumoral injection of the nanoparticles [69]. Recent 
work by the labs of Cheng and Leong have demonstrated the promise of a cationic α-helical polypeptide to 
deliver Cas9 and sgRNA plasmids for enhanced efficiency at gene editing in vitro and in vivo [70],  leading to 
67% targeted protein knockdown in HeLa cells in vivo following repeated intratumoral injections and reducing 
tumor growth by >71%, consequently significantly extending survival in the HeLa xenograft mouse model 
[70]. These strategies, using cationic polymers to deliver either nucleic acids, nucleic acid neutralized RNP 
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complexes, or anionic modified RNP complexes, have all relied upon local delivery due to the cationic nature 
of the particles being utilized presenting potential systemic delivery challenges.  While this relatively high 
efficacy of cationic polymer-based materials for local delivery is promising in mice, for certain applications, it 
may face challenges in scale-up to patients due to the larger length scales required for sufficient transport and 
therapeutic coverage.  
 
Figure 2-9. Hybrid delivery systems for CRISPR/Cas9 using polymers to facilitate cellular uptake 
and endosomal escape. (A) Assembly schematic for the DNA nanoclew system in which Cas9-sgRNA 
RNPs are assembled into nanocomplexes with DNA nanoparticles coated with the cationic polymer PEI. (B) 
DNA nanoclews enabled knockout of an eGFP gene in vivo. Reproduced with permission from [69]. (C) 
Assembly schematic for CRISPR-gold, which complexed RNPs with gold nanoparticles and a PASp(DET) 
polymer. CRISPR-gold corrected the dystrophin gene in primary myoblasts from the mdx mouse model for 
Duchenne muscular dystrophy in vitro (D&E), and enabled restoration of the dystrophin gene in vivo after 
intramuscular injection (F). Reproduced with permission from [67]. 
Advances in systemic delivery strategies could be utilized to give polymeric gene editing delivery 
vehicles greater reach. The most commonly used strategy is PEGylation, in which the hydrophilic molecule 
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polyethylene glycol (PEG) is used to reduce fouling of the nanoparticle surface and increase circulation time 
[23]. More recently, the use of zwitterionic materials have gained interest as another strategy for systemic 
delivery. Recent advances in the field of systemic siRNA delivery are applicable to genome editing machinery 
nucleic acids or proteins; particularly, use of zwitterionic materials including cationic quaternary ammonium 
sulfonamide amino lipids [71] and zwitterionic phosphorylcholine-based polymer corona in a diblock polymer 
have been shown to improve systemic delivery and offer more effective alternatives to PEGylation [72].  
 Another avenue to explore is the use of polymeric materials to deliver gene editing proteins. In 
contrast to nucleic acid delivery, where cationic polymers are typically used to condense anionic nucleic acids 
into nanoparticles via electrostatic interactions, protein delivery platforms must be more flexible to 
accommodate protein molecules of various surface charges. Chang and colleagues reported a protein delivery 
system composed of a dendrimer end-capped with guanidyl groups to facilitate protein binding through 
hydrogen bonding and salt bridges as well as phenyl groups to promote endocytosis and endosomal escape 
[73]. This polymer successfully encapsulated proteins of different sizes and surface charges and promoted the 
efficient intracellular delivery of functionally-intact proteins in vitro. Yan and colleagues employed a different 
strategy in which thin polymer shells were synthesized around individual protein molecules in situ, resulting in 
a core-shell architecture in which polymer shells were covalently linked to the protein cores [74]. The authors 
showed that this system protected proteins against protease degradation and enabled efficient cellular uptake 
in vitro and in vivo of proteins that retained their efficacy following intracellular delivery without relying on 
electrostatic charge based interactions, which is beneficial for gene editing protein complexes and Cas9 RNP 
complexes which possess regions of varying charge. Recently, several groups have reported the use of 
zinc/imidazole-based metal-organic frameworks (MOF) for intracellular protein delivery [75, 76]. These 
MOF nanoparticles have been demonstrated to effectively protect protein cargo from protease digestion and 
were used by Alsaiari and colleagues to enable intracellular delivery of CRISPR RNPs, though the editing 
efficiency was quite low (30% gene knockout in CHO cells in vitro) and further optimization of this system is 
required [77]. Overall, these strategies could be adapted to delivering gene editing protein complexes, which 
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are mostly impermeable to cell membranes on their own and unsuitable for encapsulation using cationic 
polymers as they have slightly cationic surface charges. 
 
Concluding Remarks and Future Perspectives 
In August 2017, the FDA approved the first therapeutic that involved a gene therapy step as a 
medicine in the United States [78]. Tisagenlecleucel, a cell-based cancer immunotherapy for children and 
young adults with B-cell lymphoblastic leukemia, uses viruses to insert a gene encoding chimeric antigen 
receptors (CARs) into patient-derived T cells and infuses these CAR T cells back into the patient. This drug 
has achieved remission in >80% of patients who had been refractory to traditional radiation therapy [79]. 
Subsequently, the first gene therapy in the United States for use in vivo to directly treat a genetic disease was 
approved by the FDA in December 2017 [80].  The therapy, voretigene neparvovec-rzyl, uses an adeno-
associated virus (AAV2) to deliver RPE65 cDNA to patients with biallelic RPE65 mutation-associated retinal 
dystrophy and demonstrated improved vision without product-related serious adverse events [81]. The 
approval of these first gene therapy-based medicines in the United States marks the beginning of an exciting 
new era of precision medicine in which gene-based therapeutics, such as gene editing technologies, are being 
brought to market. 
 While these impressive steps forward bode well for the future clinical translation of gene editing 
technologies, their efficacy largely depends on the efficiency of intracellular delivery and the suitability of the 
delivery system for the genetic cargo being delivered. Viral delivery systems can be effective but can also have 
significant limitations to cargo size as well as potential adverse effects such as insertional mutagenesis and 
immunogenicity, which may limit many applications to modifying cells ex vivo for re-infusion into patients as 
in the case with CAR T cells [82]. The field is moving quickly as clinical trials have begun in China using 
CRISPR to engineer CAR T cells targeting lung cancer [83] and in the UK using TALENs to engineer CAR T 
cells targeting pediatric leukemia [84], and the first CRISPR-engineered CAR T cell clinical trials in the US 
were recently approved [85]. Non-viral platforms could expand the scope of gene editing therapies by 
facilitating safe and effective direct delivery to native cells in vivo. Recent studies using a non-viral polymer and 
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gold nanoparticle hybrid system resulted in effective correction of disease phenotypes in muscle cells after 
intramuscular injection [67]. Clinically-relevant levels of gene editing in the liver were achieved from systemic 
injections of lipid nanoparticles that could be promising in treating a host of inherited liver diseases such as 
primary hyperoxaluria type 1, transthyretin amyloidosis, and hepatitis B [61]. Other advances in achieving 
more targeted delivery of gene editing tools could be used to decrease the chances of off-target editing. Even 
with these advances, much work still needs to be done in order to adapt gene editing technologies to treat 
various disease types in a safe and effective way (see Outstanding Questions). Innovating genome editing 
complexes as well as nanostructured delivery vehicles with higher specificity, enhanced efficiency, and lower 
toxicity brings these promising technologies closer to the clinic, where they have the potential to precisely 
cure genetic diseases instead of merely treating disease symptoms.  
 
Outstanding Questions 
What cargo type should gene editing molecules be delivered as to maximize editing efficiency while 
minimizing off-target effects and immunogenicity in the most cell types? 
What type of non-viral delivery vehicle would best enable clinically relevant levels of gene editing in humans? 
Are gene editing technologies safe to use as a systemically delivered drug in light of P53 damage responses to 
double stranded DNA breaks? 
What is the best way to develop and implement gene editing technologies to treat diseases in which the same 
disease phenotype can be caused by multiple different genotypes in different patients? 
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Abstract 
Despite our growing molecular understanding of glioblastoma (GBM), treatment modalities remain limited. 
Recent developments in mechanisms of cell fate regulation and nanomedicine provide new avenues to treat 
and manage brain tumors via delivery of molecular therapeutics. Here we have developed bioreducible 
poly(beta-amino ester) nanoparticles that demonstrate high intracellular delivery efficacy, low cytotoxicity, 
escape from endosomes, and promotion of cytosol-targeted environmentally-triggered cargo release for 
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miRNA delivery to tumor-propagating human cancer stem cells. In this report, we combined this 
nanobiotechnology with newly discovered cancer stem cell inhibiting miRNAs to develop self-assembled 
miRNA-containing polymeric nanoparticles (nano-miRs) to treat gliomas. We show that these nano-miRs 
effectively intracellularly deliver single and combination miRNA mimics that inhibit the stem cell phenotype 
of human GBM cells in vitro. Following direct intratumoral infusion, these nano-miRs were found to 
distribute through the tumors, inhibit the growth of established orthotopic human GBM xenografts, and 
cooperatively enhance response to standard-of-care −radiation.  Co-delivery of two miRNAs, miR-148a and 
miR-296-5p, within the bioreducible nano-miR particles enabled long-term survival from GBM in mice.   
KEYWORDS: miRNA, polymer, bioreducible, brain cancer, cancer stem cell, nanomedicine 
Introduction 
 More than 50,000 new cases of malignant brain cancer are diagnosed in the U.S. each year with 
glioblastoma (GBM) being the most common and deadly form.1 Despite aggressive treatment consisting of 
surgical resection and radiotherapy/chemotherapy, the median life expectancy for GBM patients is only 14-20 
months, highlighting the need for new therapeutic approaches.2  Treatment options for GBM remain limited 
in part due to tumor cell resistance to chemotherapy/radiation and the difficulty in delivering newer targeting 
therapeutics to the brain.3-4  GBMs are highly heterogeneous at the cellular level and contain cells that vary in 
their capacity to propagate tumor growth as revealed through single cell sequencing, RNA-profiling5 and 
studies of intra-tumoral evolution.6 Among these different cell subpopulations are multi-potent stem-like cells 
(also referred to as cancer stem cells or CSCs) that are critical determinants of tumor propagation, therapeutic 
resistance, and recurrence following treatment.7 Epigenetic mechanisms that support this stem-like tumor-
propagating phenotype represent a vulnerability amenable to therapeutic targeting.8 Non-coding RNAs, in 
particular miRNAs, are emerging as critical epigenetic regulators of cell fate and oncogenesis.9 miRNAs 
selectively inhibit gene expression primarily by targeting mRNA for degradation usually via complementary 
3’-UTR seed sequences. Numerous miRNAs have been found to regulate tumorigenesis and cancer cell 
stemness by targeting tumor-suppressing or tumor promoting transcripts.10 We recently showed that the 
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coordinated actions of Oct4 and Sox2 induce a CSC state in GBM cells through a mechanism that involves 
the down-regulation of a network of miRNAs through promoter DNA methylation.11-12 We further showed 
that the repression of two of these miRNAs, miR-148a and miR-296-5p, is required for the induction of 
GBM tumor propagating capacity by Oct4/Sox2 and that their reconstitution using viral expression vectors 
efficiently inhibits the GBM stem-like phenotype.11-12 
 Therapeutically translating these advances in the molecular drivers of GBM stem cells remains a 
challenge.13 Viral gene delivery is promising but there remain potential limitations to clinical translation due to 
factors such as scalability, limited cargo size, and potential tumorigenic and immunogenic effects.14-15 Non-
viral vectors such as polymeric nanoparticles can be designed to circumvent many of these problems, but 
traditional cationic polymers such as poly(L-lysine) (PLL) and polyethylenimine (PEI) that encapsulate nucleic 
acid cargoes into nanoparticles by electrostatically-driven self-assembly are generally ineffective for utilization 
in vivo and have been shown to be minimally effective for delivery of relatively small RNA molecules.16 
Poly(beta-amino ester)s (PBAEs) are newer synthetic cationic polymers that promote superior gene delivery 
versus PEI, in part, as they contain hydrolytically-cleavable ester bonds, which reduces cytotoxicity as well as 
enhances cargo release.17 Like many gene delivery vehicles, PBAEs were first optimized for DNA delivery. 
Because RNA oligos (e.g. miRNA) are shorter and stiffer than plasmid DNA, they are often harder to 
complex into nanoparticles,18 and the materials that are effective for DNA delivery are often ineffective for 
RNA delivery.19  
In this report we create new nanoparticles consisting of state-of-the-art polymeric nanobiotechnology 
with newly discovered cancer stem cell inhibiting miRNAs to develop miRNA delivering nanoparticles (nano-
miRs) to treat gliomas. We develop and characterize nanoparticles utilizing bioreducible and cationic PBAE 
polymers capable of safely and efficiently shuttling miRNA into GBM cells, enabling escape out of the 
endosomes into the cytosol, and exhibiting an environmentally-triggered release of miRNA upon entering the 
cytosolic compartment.  For the first time, we demonstrate the use of modified PBAE-based polymers for 
the effective delivery of miRNA mimics and observed that they inhibit the stem cell phenotype of human 
GBM cells. Further, we show that this new bioreducible PBAE-based nanomedicine spreads through 
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established tumors in vivo and can be effective for therapeutic in vivo delivery of miRNA, and consequently, 
oligonucleotides in general.  Critically, the delivery of these tumor-suppressing miRNAs using these 
biomaterials inhibited the growth of established GBM xenografts and led to significant long-term survival in 
mouse models. Our findings demonstrate that identifying and validating stem cell-regulating miRNAs in 
combination with advances in nanomedicine can impact the development of therapies for targeting the 
human CSC population and treating GBM. 
 
Figure 3-1: PBAE synthesis, miRNA complexation and buffering capacity. (A) PBAE monomer 
structures are shown. (B) Polymer R646 was synthesized using a Michael addition reaction between 
monomers BR6 and S4 at a 1.01:1 BR6:S4 ratio. The resulting acrylate-terminated polymer was endcapped 
with monomer E6 to yield BR6-S4-E6 (R646). Polymer 646 was synthesized via a similar method using 
monomer B6 instead of BR6. (C) Polymer C32 was synthesized by reacting B4 with S5 at a 1:1.2 B4:S5 ratio, 
resulting in an amino alcohol terminated polymer. (D) Chemical structures of R646, 646, and C32. (E) 
Polymer-miRNA competitive binding assay; polymer to miRNA binding strength is assessed by quenching of 
YO-PRO®-1 Iodide fluorescence over increasing polymer concentrations. (F) Acid-base titration curves for 
PBAE polymers with 150 mM aqueous NaCl for comparison. pH was adjusted to pH 3 with HCl and titrated 
with NaOH. 
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Results and Discussion 
Bioreducible PBAE nano-miRs encapsulate miRNAs into nanoparticles, effectively release them in a 
reducing cytosolic environment and deliver miRNAs to human GBM in vitro. To investigate the 
miRNA delivery capabilities of bioreducibe PBAE nano-miRs and compare their performance with previous 
iterations of non-reducible PBAEs, we synthesized bioreducible polymer R646, its non-reducible analog 646, 
and C32 – a non-reducible PBAE that has been shown to be very effective at delivering DNA20 (Figure 3-1). 
The bioreducible monomer 2,2’-disulfanediylbis(ethane-2,1-diyl)diacrylate (BR6) was copolymerized with 4-
amino-1-butanol (S4) via a Michael Addition reaction at a 1.01:1 BR6:S4 ratio, and the resulting acrylate-
terminated polymer was endcapped with 2-(3-aminopropylamino)ethanol (E6) to synthesize the polymer 
BR6-S4-E6 (R646). Polymer 646 was synthesized using the same procedure, but using the non-reducible 
hexane-1,6-diyl diacrylate (B6) instead of BR6. Finally, polymer C32, which has been shown to successfully 
deliver plasmid DNA to human prostate cancer xenografts in mouse models, was synthesized by 
copolymerizing 1,4-butanediol diacrylate (B4) and 5-amino-1-pentanol (S5) at a 1:1.2 B4:S5 ratio following 
the method reported by Anderson et al.20 Polymers were characterized with gel permeation chromatography 
for molecular weight and polydispersity (Table 3-S1 and Figure 3-S14) and NMR for polymer structure 
(Figures 3-S15, 3-S16, and 3-S17). YO-PRO®-1 Iodide competition binding assay, in which YO-PRO®-1 
Iodide fluoresces upon binding miRNA and is quenched as it is displaced by polymer, shows that these 
PBAEs bound miRNA with equivalent binding affinity. pH titration curves were determined for the polymers 
using acid-base titration and showed they have equivalent buffering capacity in the physiologically-relevant 
range of pH 6-7.4, as indicated by a gradual slope at this pH range (Figure 3-1).  As all three polymers have a 
similar structure (linear PBAE polymers that contain a similar tertiary amine repeat unit in the backbone, 
Figure 3-1D), their buffering capacity is similar. To determine the optimal nano-miR formulations required to 
deliver miRNA to GBM cells, we prepared nano-miRs at increasing polymer: miRNA weight-weight ratios 
(w/w). We optimized nano-miR w/w ratios in vitro in human GBM1A CSCs at a miRNA dose of 90 nM with 
a minimum acceptable cell viability of 75%. At this dosage, R646 nano-miRs maintained cell viability of 
greater than 75% at 150 w/w while 646 and C32 achieved the same at 37 w/w (Figure 3-2A).  Additionally, 
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incubating GBM1A or GBM1B neurospheres with R646 nano-miRs using the conditions described above for 
3 hrs or 24 hrs did not have adverse effects on cell viability (Figure 3-S1). At these optimal w/w ratios, 
cellular uptake of fluorescently labeled miRNAs was assessed via flow cytometry. We found that R646 nano-
miRs achieved nearly 60-fold higher cellular uptake of miRNA compared to 646 and C32 nano-miRs 
encapsulating the same amount of miRNA (Figure 3-2B). This is most likely due to the fact that R646 
attenuated cytotoxicity, allowing us to formulate R646 nano-miRs at a much higher w/w ratio and resulting in 
smaller and more stable nanoparticles compared to C32 and 646. Lastly, we assessed functional delivery of 
bio-active miRNAs using the different nano-miR formulations. Polymers were complexed with either a non-
targeting control miRNA (Ctrl) or a combination of miRNA mimics miR-148a and miR-296-5p (Comb). 
Three days after transfection, functional delivery was assessed through qRT-PCR analysis of the expression of 
Dnmt1 and Hmga1, which are known targets of these two miRNAs.11-12 We found that R646 nano-miRs 
significantly reduced the expression of both targets while 646 and C32 nano-miRs did not (Figure 3-2C-D). 
Unlike R646 nano-miRs, canonical PBAEs did not show meaningful, statistically significant target gene 
knockdown, demonstrating the need for improved materials for polymeric nanoparticle-mediated miRNA 
delivery (Figure 3-S2). In order to rule out the possibility that differences in polymer molecular weight 
contributed to the observed difference in transfection efficacy, we synthesized R646 and 646 of similar 
molecular weight and used these polymers to deliver control or combination miRNA mimics. Our results 
showed that R646 nano-miRs again achieved significantly higher target gene knockdown and lower 
cytotoxicity compared to 646 nano-miRs formulated with matching molecular weight polymers , indicating 
that polymer characteristics beyond molecular weight are responsible for the superior performance of 
bioreducible R646 nano-miRs (Figure 3-S3). Furthermore, target gene knock-down by R646 nano-miRs was 
found to be somewhat more efficient than that achieved by commercially available RNAiMax and 




Figure 3-2: Polymer R646 attenuates cytotoxicity compared to non-reducible PBAE and effectively 
delivers miRNAs to GBM cells. (A) Nano-miR formulations were screened in GBM1A cells to identify 
optimal nano-miR formulation with >75% relative viability. Numbers on the x-axis indicate polymer-miRNA 
w/w ratios. (B) Nano-miR uptake was measured using flow cytometry after treating cells with nano-miRs 
loaded with Cy5-labeled miRNA. R646 nano-miRs had significantly higher cell uptake (****P<0.0001) than 
all other conditions assessed by One-way ANOVA with Tukey post hoc tests. (C) qRT-PCR analysis of 
expression of Dnmt1 and Hmga1 in GBM1A 3 days after treatment with nano-miRs delivering a non-
targeting control miRNA (Ctrl) or a combination of miRNA mimics miR-148a and miR-296-5p (Comb). Fold 
expression was normalized to cells treated with Ctrl miRNA only. R646 showed statistically significant 
knockdown in expression of (C) Dnmt1 and (D) Hmga1 assessed by Holm-Sidak corrected multiple t-tests 
between matched Ctrl and Comb (**P< 0.01; ***P<0.001). Bars show mean + SEM of three (qRT-PCR) or 
four wells (viability and uptake). For each target, R646 nano-miRs delivering the combination of miRNA 
mimics also showed significantly higher knockdown than all other conditions as assessed by One-way 
ANOVA with Tukey post hoc tests (*P<0.05). 































































































 We characterized the physical properties of the three nano-miR formulations by measuring 
nanoparticle hydrodynamic diameter via dynamic light scattering (DLS) and nanoparticle tracking analysis 
(NTA), zeta-potential by electrophoretic light scattering, and nanoparticle morphology by transmission 
electron microscopy (TEM). Diluted with PBS to a buffer condition of 150 mM and pH 7.4 to mimic 
physiological conditions, nano-miR size measured via NTA showed number-averaged hydrodynamic 
diameters of approximately 100 nm for all three formulations while DLS showed that R646 nano-miRs have 
an intensity-weighted z-average hydrodynamic diameter of approximately 200 nm, while 646 and C32 nano-
miRs had z-average hydrodynamic diameters of greater than one micron, indicating the presence of 
aggregates in their particle distributions (Figure 3-3A). Interestingly, we also performed DLS size 
measurements before PBS dilution (measurement in 25 mM sodium acetate buffer, pH 5) and found that all 
nano-miRs were below 200 nm in diameter (Figure 3-S5). Thus, the canonical PBAE nano-miRs were prone 
to aggregation after the initial self-assembly and following dilution into neutral physiological buffer. This 
suggests that the high w/w ratio that we were able to use with bioreducible polymer R646 (as this polymer 
was engineered to be less cytotoxic) resulted in nano-miRs that had complexed miRNA more strongly, which 
reduced nano-miR aggregation in higher salt and pH environments. Zeta-potential was slightly positive for 
R646 nano-miRs and essentially neutral for 646 and C32 nano-miRs (Figure 3-3B). TEM images show that all 
formulations formed spherical nanoparticles with R646 nano-miRs appearing slightly smaller than the 646 
nano-miRs and C32 nano-miRs (Figure 3-3C and Figure 3-S6). As R646 nano-miRs degrade in water due to 
the hydrolytic ester linkages within the R646 polymer, we wanted to evaluate whether the R646 nano-miRs 
could be formulated dry in a manner suitable for storage that would also facilitate in vivo use. We utilized a 
lyophilization procedure with sugar as a cryoprotectant and found that R646 nano-miRs maintained their 
physical properties following lyophilization with no significant change in nanoparticle diameter assessed by 
DLS or TEM (Figure 3-S7).21  
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Figure 3-3: Polymer R646 forms nanoparticles with miRNA and effectively releases miRNA in a 
reducing environment. (A) Nanoparticle hydrodynamic diameter as measured using intensity-weighted 
(DLS) or number-average (NTA) measurement showed that R646 nano-miRs had a statistically smaller 
hydrodynamic diameter via DLS as assessed by One-way ANOVA with Tukey post hoc tests (**P<0.001) 
(B) Nanoparticle zeta-potential as measured via electrophoretic light scattering showed R646 nano-miRs had 
a statistically significantly higher zeta potential assessed by One-way ANOVA with Tukey post hoc tests 
(****P<0.0001). (C) TEM images of nano-miRs showed dried particle size and spherical morphology. (D) 
Gel retention assay performed in 5 mM glutathione mimicking the intracellular environment showed short-
term miRNA release in reducing conditions. miRNA that was tightly bound within non-bioreducible PBAE 
nanoparticles was unable to run down the gel. (E) Gel retention assay performed in artificial CSF mimicking 
the extracellular environment in the brain showed long-term miRNA release in non-reducing conditions. Bars 
show mean + SEM of three independently prepared samples. 
 To determine miRNA release kinetics, we performed a gel retention assay, in which nano-miRs were 
loaded into an agarose gel, and tightly bound RNA would be unable to electrophorese under an applied 
voltage. We incubated the nano-miRs in 5 mM glutathione (GSH) to mimic the reducing cytosolic space in 
the intracellular environment.22 In the presence of GSH, miRNA from bioreducible R646 nano-miRs began 
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nano-miRs, in contrast, did not release miRNA even after 2 hr incubation (Figure 3-3D). We incubated the 
nanoparticles in artificial cerebrospinal fluid (aCSF) to mimic the redox and ionic environment in the brain 
extracellular space23 for longer times and found that for all nano-miR formulations, miRNA began to release 
after 5 hr and was completely released by 10 hr. (Figure 3-3E) These results indicate that R646 nano-miRs are 
able to release miRNA cargo rapidly in a stimuli-responsive manner upon entry into the reducing intracellular 
space due to the reduction of disulfide bonds in the polymer backbone, while non-reducible 646 and C32 
nano-miRs hold on to their cargo for much longer and eventually release miRNA after the slower hydrolysis 
of ester bonds. 
 
Figure 3-4: R646 nano-miRs can deliver multiple different miRNAs and inhibit the GBM stem cell 
phenotype. (A) Flow cytometry data of GBM1A neurospheres treated with R646 nano-miRs carrying either 
Cy3-labeled miRNA (Cy3-miR), Cy5-labeled miRNA (Cy5-miR), both RNAs (comb.) and completely 
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untreated (Unt.). Fluorescence signal of cells treated with nano-miRs carrying both miRNAs were normalized 
against the single miRNA groups. Bars show mean + SEM of four wells. (B) Flow cytometry plot of cells 
treated with nano-miRs carrying both labeled miRNAs compared to the untreated population shows 
proportional uptake of both miRNAs. (C) Expression of mature miR-148a and miR-296-5p was measured by 
qRT-PCR 3 days after transfection. (D) qRT-PCR analysis to measure expression of stem cell markers in 
GBM1A neurospheres transfected with nano-miRs. (E) Equal numbers of GBM1A transfected with nano-
miRs were cultured in neurosphere medium containing EGF/FGF for 12 days and neurosphere numbers 
(>100µm diameter) were quantified by computer-assisted image analysis. (F) Limiting dilution analyses of 
GBM1A transfected with control (Ctrl.) or miR-148a+miR-296-5p combination (Comb.) nano-miRs. 
Untransfected cells (Unt.) were used as negative control. Cells were plated in a limiting dilution manner, and 
the number of wells containing spheres was counted after 14 days to compare stem cell frequencies. One-way 
ANOVA with Tukey post hoc tests was used when performing multiple comparisons and p<0.05 considered 
statistically significant. *p<0.05 
 With the goal of simultaneously delivering multiple miRNA constructs, we investigated whether 
R646 nano-miRs were able to co-deliver two different miRNA mimics (miR-148a and miR-296-5p) to the 
same cell. To this end, we made nano-miRs containing either Cy3-labeled miRNA, Cy5-labeled miRNA, or 
both miRNAs (comb.). For nano-miRs containing both miRNAs, we mixed the two anionic RNAs together 
before adding the cationic polymer for nanoparticle self-assembly to enable miRNA multiplexing. Flow 
cytometry experiments investigating cellular uptake showed that cells treated with nano-miRs carrying both 
miRNAs increased proportionally in fluorescence (Figure 3-4A, B). Confocal imaging showed that 
endosomes in these cells contained both Cy3 and Cy5 fluorescence, confirming that the nano-miRs not only 
delivered both miRNAs into the same cell but also into the same endosomes, which indicates that two 
different miRNAs can be complexed into the same nano-miR delivery system (Figure 3-S8A). We also saw 
detectable levels of diffuse Cy5 fluorescence distributed throughout the cytosol and nucleus at 2h, suggesting 
that the R646 nano-miRs effectively escaped the endosome (Figure 3-S8B). In contrast, cytosolic RNA 
molecules have previously been difficult to image with scanning laser confocal microscopy following leading 
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non-viral gene delivery methods such as lipid nanoparticle mediated delivery.24-25 We also stained cells treated 
with Cy5-labeled miRNA nano-miRs with a lysosomal dye (pKa 4.5) and found that endosomes with Cy5 
signal did not colocalize with lysosomes at 2h , consistent with efficient endosomal escape prior to detectable 
lysosomal targeting. Our results show that a significant number of R464 nano-miRs effectively avoided 
lysosomal degradation and released their miRNA cargo in the cytosol. This is a significant improvement over 
traditional cationic polymers and nanomedicine delivery systems, for which lysosomal degradation has been a 
limitation.26-27 Overall, these results indicate that bioreducible R646 nano-miRs outperformed nano-miRs 
constructed from non-reducible polymers 646 and C32 by attenuating cytotoxicity, increasing cellular uptake 
of miRNA cargo, and effectively delivering bio-active miRNAs to the cytoplasm of GBM cells. We therefore 
chose to use R646 nano-miRs to assess in vitro and in vivo delivery of our GBM-regulating miRNA mimics. 
 Mature miRNA mimics labeled with Dy547 were complexed with bioreducible R646 to formulate 
PBAE nano-miRs and used to transfect multicellular GBM neurospheres. Fluorescence from the Dy547-
labeled miRNA was readily detectable in the multicellular spheres starting 3 hrs after the transfection and 
persisted for at least 9 days (Figure 3-S9A and Figure 3-S19). We recently showed that miR-148a and miR-
296-5p are repressed as part of an epigenetic program by which GBM cells become stem-like and tumor 
propagating.11-12 We also found that reconstituting these miRNAs individually using viral vectors inhibits the 
stem cell phenotype and tumor-propagating potential of GBM cells.11-12 To assess the bioactivity of R646-
delivered miRNAs, nano-miRs carrying control miRNA (miR-Ctrl), miR-148a mimic, miR-296-5p mimic, or 
miR-148a+miR-296-5p (comb.) were used to transfect GBM neurospheres. Total RNA concentrations were 
held fixed at 120 nM, and miR-148a or miR-296-5p were either blended with miR-Ctrl or one another, so that 
the total amount of each functional miRNA remained at 60 nM in all conditions. 
Expression of mature miRNAs was measured using qRT-PCR 3 days after transfection.  Transfecting 
GBM neurospheres with miR-148a or with miR-296-5p nano-miRs increased intracellular miRNA levels by 
24-fold and 27-fold, respectively (Figure 3-4C), and these miRNAs remained substantially elevated (15-20 
fold) for up to 12 days (the last time point examined) (Figure 3-S19C). The combination nano-miRs 
simultaneously increased miR-148a and miR-296-5p levels by 16-fold and 30-fold respectively (Figure 3-4C). 
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To directly evaluate the effects of these nano-miRs on the GBM stem cell phenotype, two patient-derived 
neurosphere lines were transfected using nano-miRs and sphere forming capacity, a quantitative marker of 
cell stemness and self-renewal, was measured. miRNA delivery by this approach significantly inhibited 
sphere-forming capacity (Figure 3-4E and 3-4F and Figure 3-S9C and 3-S9D) concurrent with the decreased 
expression of stem cell markers Sox2, Nanog, Bmi1, and Olig2 (Figure 3-4D and Figure 3-S9B) and also 
inhibited previously described miR-148a and miR-296-5p targets, Dnmt1 and Hmga1, respectively (Figure 3-
2C and 3-2D). These results supported the use of our novel bioreducible PBAE polymeric nano-miRs to 
deliver bio-active miRNAs to GBM xenografts in vivo. 
 
Figure 3-5: miR-148a and miR-296-5p co-delivery using R646 nano-miRs inhibits GBM tumor 







infusion using fluorescence microscopy and compared to adjacent H&E stained sections. The intra-tumoral 
distribution of the nano-miRs was calculated as the ratio of fluorescence area divided by tumor area X 100 in 
brain sections with the highest cross-sectional area of tumor (N=3 mice per group; right panel). (B) 
Schematic summarizing treatment schedule for in vivo delivery of nano-miRs. Animals were sacrificed 42 days 
after cell implantation and maximum tumor cross-sectional areas following treatment with nano-miRs 
representing viable tumor tissue (C) and necrotic tumor tissue (D) were quantified from H&E stained 
sections using ImageJ software. For each cohort, R646 nano-miRs delivering the bioactive miRNA mimics 
showed significantly lower viable tumor area and higher necrotic area than the animals receiving control 
(Ctrl.) nano-miR as assessed by One-way ANOVA with Tukey post hoc tests (**p<0.01 and *p<0.05). (E) 
Kaplan-Meier survival curves comparing mice treated with control nano-miRs (miR-Ctrl) or miR-
148a+miR296-5p nano-miRs (miR-Comb.). Therapy in the survival study was initiated 45 days after tumor 
cell implantation. Survival was compared across arms using the log-rank test (N=9). (**p<0.01, *p< 0.05). 
 
Bioreducible PBAE nano-miRs spread through brain tumor xenografts to deliver miRNAs. To 
circumvent the delivery obstacle posed by the blood brain barrier, we used direct intra-tumoral delivery to test 
the biological effects of our nano-miRs in vivo.28 Trans-cranial cannulas were placed with their tips within the 
right caudate/putamen of mice. One week after cannula placement, animals were implanted with Oct4/Sox2 
induced cancer stem cells (iCSCs)11 via the cannula.  iCSCs generate aggressive rapidly growing xenografts 
and represent a demanding model to assess miRNA biodistribution and in vivo bioactivities.  R646 nano-miR 
delivery was started 3 weeks after cell implantation. Twice per week for 3 weeks animals received slow 
infusions of nano-miRs containing either Dy547-labeled control miRNA or miR-148a via the cannula. Brains 
were collected and histopathologic sections were visualized using fluorescence microscopy and compared to 
the adjacent H&E stained counterparts. Dy547-labled miRNA was found to be distributed through 
approximately 60% of these large rapidly growing tumors when evaluated 25 days after the first nano-miR 
infusion and 3 days after the last infusion (Figure 3-5A). To determine if the miRNAs delivered by this 
protocol retained their biological function, we measured the expression of Dnmt1 and Dnmt3b, two well 
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described miR-148a targets.11 Tumors treated with miR-148a nano-miRs had significantly lower expression 
levels of both Dnmt1 and Dnmt3b compared to control treated animals (Figure 3-S10). To investigate the 
therapeutic potential of miRNA delivery using R646 biodegradable PBAE nanoparticles in comparison to 
ionizing radiation (I.R.), a standard of care treatment modality for GBM, tumors were established as 
described above and treated with 148a nano-miR +/-  I.R. (Figure 3-S11). Intra-tumoral delivery of miR-148a 
nano-miRs to a pre-established tumor more effectively decreased tumor size and tumor vascularity and 
increased tumor cell apoptosis as measured by caspase 3 activation than I.R. treatment alone. Combining 
148a nano-miRs with I.R. generated cooperative and potentially synergistic anti-tumor responses.   
 
miRNA co-delivery via bioreducible PBAE nano-miRs inhibits tumor growth and prolongs animal 
survival in an orthotopic model of human GBM. We have recently reported that viral-based transgenic 
expression of either miR-148a or miR-296-5p differentiated GBM stem cells and inhibited their self-renewal 
as spheres. We also found that these miRNAs independently inhibit the capacity of GBM stem cells to 
propagate glioma xenografts in vivo.11-12 We asked if reconstituting both of these stem cell inhibiting miRNAs 
using non-viral R646 nano-miRs would have cooperative effects on pre-established GBM xenografts. Human 
GBM derived neurospheres (GBM1A), which generate tumors that closely recapitulate the growth pattern 
and pathology of clinical GBM,29 were implanted in animals using an experimental paradigm similar to the 
one described above (Figure 3-5B). Tumors were then treated with R646 nano-miRs containing control 
miRNA, miR-148a, miR-296-5p, or a combination of miR-148a+miR-296-5p. Tumor burden in brains 
collected after 28 days of treatment quantified by computer-assisted morphometry was significantly decreased 
in all three groups treated with active miRNA, with the most profound effect seen in animals treated with the 
miRNA combination (Figure 3-5C and Figure 3-S12A). We also saw an increase in tumor tissue necrosis 
(Figure 3-5D) and apoptosis (Figure 3-S12B), as measured by histopathology and cleaved caspase 3 
immunohistochemistry, respectively. We find that while miR cooperativity was limited during in vitro 
evaluation, miR cooperativity is potent in vivo and consistent with our understanding of these two miRs 
targeting complementary tumor-promoting mechanisms. The substantial decrease in tumor burden observed 
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in mice treated with the multiplex nano-miRs and the more modest effects observed when delivering miR-
148a alone in both this patient-derived GBM model and the more aggressive engineered iCSC model 
predicted the therapeutic survival advantage of miR-148a + miR-296-5p multiplex nano-miRs.  
To rigorously test the efficacy of our nano-miR therapy in a survival study, animals bearing pre-
established intracranial GBM1A glioma xenografts received either control or miR-148a + miR-296-5p 
multiplex nano-miRs beginning on post-implantation day 45 and continued twice per week for 6 weeks. 
Surviving animals began to show signs of weight loss so treatment was stopped after 6 weeks (12 injections) 
on post-implantation day 87. All treated animals regained weight one week after ending treatment. All 9 
animals treated with control nanomiRs were either dead or premorbid requiring euthanasia by post-
implantation day 90. In contrast, 6 of 9 nano-miR-treated animals remained alive and healthy by post-
implantation day 133, at which time the experiment was terminated (Figure 3-5E). Histological analysis of the 
surviving animals euthanized at post-implantation day 133 revealed that 4 out of the 6 had no detectable 
tumor (Figure 3-S13). 
Conclusions 
 There is a need to develop and translate new treatment strategies for glioblastoma that are designed 
to target the subpopulation of CSCs that drive tumor propagation, therapeutic resistance, and tumor 
recurrence following conventional treatments.30 These CSCs are highly plastic and exist in a state of dynamic 
flux between CSC and non-CSC states.31 The epigenetic mechanisms driving these phenotypic transitions 
represent unexploited vulnerabilities amenable to therapeutic biological targeting.4, 8 Approaches based on the 
premise that reconstituting CSC-inhibiting miRNA toward the goal of normalizing dysregulated networks in 
cancer hold great promise.32 As is becoming evident, miRNAs regulate cell phenotypes by modulating 
multiple gene targets simultaneously. The broad targetome of naturally occurring miRNAs has numerous 
advantages over siRNAs that are engineered to target individual genes within multi-genic processes such as 
CSC regulation.32 We recently identified two candidate therapeutic miRNAs, miR-148a and miR-296-5p, 
based on their repression during the induction of GBM stemness and tumor-propagating capacity by 
Oct4/Sox2.11-12 We now show that reconstituting these miRNAs using non-viral bioreducible PBAE nano-
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miRs offers a therapeutic approach distinct from conventional cytotoxic therapy (e.g ionizing radiation or 
temozolomide) that has been shown to be insufficiently effective against CSC pools and clinical GBM.30, 33 
 A central challenge to developing nucleic acid-based modalities for targeting tumor-propagating 
CSCs is identifying and developing a suitable delivery vehicle. An optimal miRNA carrier for intra-tumoral 
delivery should be able to stably encapsulate miRNA, including combinations of miRNA, and protect it while 
in the extracellular environment and then quickly release it in the cytosolic environment. Our bioreducible 
R646 nano-miRs were found to fulfill these requirements. Using a gel retention assay, we were able to show 
that the R646 nano-miRs fully encapsulated the miRNA in non-bioreducible conditions and then released the 
miRNA in a triggered manner within 5 minutes when in a cytosol-like reducing environment.  The quick 
intracellular release of miRNA is dually important, as it significantly reduces cytotoxicity compared to non-
reducible PBAEs and cationic polymer such as PEI (Figure 3-2A and S4A), allowing higher polymer-to-
miRNA weight/weight ratios to be used and smaller, more stable nanoparticles to be formed (Figure 3-3A 
and S5). Furthermore, it allows the miRNA to enter into cellular pathways necessary for miRNA function.34-35  
 Particle sizing analysis revealed that the R646 nano-miRs are approximately 100 nm in diameter 
(Figure 3-3A). In vivo tumor distribution studies revealed that these nanoparticles can spread through brain 
tumor tissue following direct intra-tumor infusion, distributing particles through established tumors with at 
least 60% coverage (Figure 3-5A). This represents a length scale of ~2 mm from the cannula infusion site 
following a 5 μL infusion to reach the tumor margins.  The finding that the nano-miRs could spread through 
the GBM tumors is consistent with the finding that this treatment led to long-term survivors in the majority 
of the combination miRNA treated animals (Figure 3-5E).  In comparison, non-bioreducible PBAE/DNA 
nanoparticles delivered via an intratumoral infusion were recently observed to spread through a similar 
length-scale of approximately 2 mm in 9L rat glioma tumors following a larger volume 25 μL infusion36 and 
PEGylated non-bioreducible PBAE/DNA nanoparticles spread through a length-scale of ~2 mm in the 
brains of Fischer 344 rats following a 20 μL infusion.37 Thus, for non-viral nucleic acid delivery to brain 
tumors, the R646 polymeric nanoparticles, small and with relatively neutral surface charge, appear to be 
potent vehicles that are able to spread through brain tumors sufficiently to have therapeutic effect. In our 
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current study, the functional efficacy of bioreducible nano-miRs in vivo was validated and is especially 
significant as oligonucleotides are known to be more difficult to deliver by electrostatic polyplex nanoparticles 
than plasmid DNA molecules are, as oligonucleotides are typically 100-fold smaller and consequently orders 
of magnitude less multivalent than plasmids.  
 Once at the surface of individual cancer cells, the nano-miRs are able to be internalized effectively as 
demonstrated in our in vitro cellular uptake studies (Figure 3-2 and Figure 3-S9). Once internalized into a cell, 
the tertiary amines of the PBAE polymers can facilitate avoidance of lysosomes and endosomal escape by a 
sufficiently large fraction of nano-miRs that the released miRNA can be detected in the cytosol (Figure 3-1E 
and Figure 3-S8B). Through these mechanisms, the nano-miRs are able to effectively increase the intracellular 
levels of multiplexed cargo miRNA 15-30 fold (Figure 3-4C) with retention of anti-CSC bioactivity (Figure 3-
4D-F).    
Combinations of miRNAs that inhibit multiple pathways required for tumorigenesis should more 
efficiently impede tumor growth and propagation while at the same time reducing the emergence of 
resistance.30, 32 To reduce the possibility of cytostatic effects or tumors developing resistance, we explored two 
treatment modalities by either combining I.R. treatment with nano-miR-148a delivery or targeting two parallel 
pathways that contribute to GBM cell stemness and tumor propagation using R646 biodegradable PBAE 
nanoparticles to co-deliver miR-148a and miR-296-5p. miR-148a nano-miRs and ionizing radiation 
cooperatively inhibited tumor xenograft growth. This result is consistent with the relative resistance of GSCs 
to cytotoxic therapeutics and our current and previous findings that miR-148a inhibits GBM cell stemness.11, 
33 Co-delivering both miR-148a and miR-296-5p as multiplexed nano-miRs in vivo increased tumor cell death 
and reduced tumor burden more significantly than either miRNA delivered alone (Figure 3-5 and Figure 3-
S13). This cooperative therapeutic effect in vivo is consistent with the concept that cancers will be more 
responsive to strategies designed to target multiple complementary tumor-promoting pathways by 
normalizing miRNA networks and their multiple targetomes than to single miRNA or highly specific siRNA 
therapeutics. 
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To our knowledge, our current report is the first time that a bioreducible PBAE-based system has 
been evaluated for oligonucleotide delivery in vivo.  Moreover, it is the first time that PBAE-based 
nanomaterials have been formulated for miRNA delivery in vitro or in vivo. The results presented in this study 
demonstrate the promise of using R646 nano-miR systems in combination with cancer stem cell-inhibitory 
miRNAs as nanomedicine to impact the development of biological therapies for treating GBM. 
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Materials  
All chemicals used to synthesize bioreducible monomer disulfanediylbis(ethane-2,1-diyl) diacrylate 
(BR6) were purchased from Sigma-Aldrich (St. Louis, MO) and used without further purification. All other 
monomers used for polymer synthesis were purchased from Alfa Aesar (Ward Hill, MA). The following mature 
miRNA mimics used in the study were purchased from Dharmacon (GE Healthcare): hsa-miR-148a-3p (C-
300540-05-0005), hsa-miR-296-5p (C-300659-03-0005), and microRNA Hairpin Inhibitor Transfection 
Control with Dy547 (IP-004500-01-05). Fluorophore-labeled miRNA mimics were custom synthesized by 
Sigma-Aldrich (St. Louis, MO): HMC0002_Cy3s and HMC0002_Cy5s. Yo-Pro-1 iodide was purchased from 
Thermofisher. 
GBM neurosphere culture  
GBM-derived neurosphere lines (GBM1A and GBM1B) were originally derived and characterized by 
Vescovi and colleagues 1 and the iCSC line (previously designated A172-iGSC) was developed by us 2. 
Neurospheres were cultured in serum-free medium containing DMEM/F-12 (Invitrogen, Carlsbad, CA, USA), 
supplemented with 1% BSA, 20 ng/ml epidermal growth factor (EGF) and 10 ng/ml fibroblast growth factor 
(FGF). All cell lines used in the study were tested for mycoplasma and were STR profiled. 
Polymer synthesis 
Bioreducible monomer BR6 was synthesized as previously described.3 Briefly, the acrylation of bis(2-
hydroxyethyl) disulfide was carried out in tetrahydrofuran (THF) anhydrous conditions with acryloyl chloride 
as the acrylation reagent and in the presence of triethylamine (TEA). Following overnight reaction at room 
temperature, the TEA HCl precipitate was removed via filtration, THF was removed via rotary evaporation, 
and the impure product was dissolved in dichloromethane (DCM). The product was purified using aqueous 
washes of Na2CO3, followed by water, after which DCM was removed via rotary evaporation.  
Polymers R646 and 646 were synthesized using a method similar to Kozielski et al.4 in which monomer 
BR6 or hexane-1,6-diyl diacrylate (B6) was polymerized at a 1.01:1 molar ratio with monomer 4-amino-1-
butanol (S4) at 500 mg/mL in THF at 60 C for 24 h. Polymers were endcapped in THF at 100 mg/mL with 
0.2 M 2-(3-aminopropylamino)ethanol (E6) at room temperature for 1 h while stirring. Unreacted monomers 
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were removed by precipitating out polymer using diethyl ether, centrifuging at 3220 RCF, and decanting off 
ether. This was repeated, and the polymer was stored under vacuum to allow ether to evaporate. Polymer C32 
was synthesized using a method similar to Anderson et al.5 in which monomer 1,4-butanediol diacrylate (B4) 
was polymerized at a 1:1.2 molar ratio with monomer 5-amino-1-pentanol (S5) without solvent at 90°C for 24 
h. Unreacted monomers were removed by the ether purification process described above. The final polymer 
product was dissolved in dimethyl sulfoxide (DMSO) at 100 mg/mL and stored at -20 C under desiccant.  
Gel permeation chromatography  
All polymers used in this study were dissolved in BHT-stabilized tetrahydrofuran with 5% DMSO and 1% 
piperidine, filtered through a 0.2 μm PTFE filter, and measured with gel permeation chromatography (Waters, 
Milford, MA) equipped with styragel column and refractive index detector to determine molecular weight 
distribution relative to linear polystyrene standards. The calculated MW, MN and PDI of all polymers are shown 
in Supplemental Table 1.1H-NMR 
Polymers were dissolved in deuterated chloroform with tetramethylsilane as an internal standard. NMR 
spectra were acquired using a 500 mHz Bruker NMR and analyzed using TopSpin 3.5 software. NMR spectra 
for polymers R646, 646 and C32 are shown in Figures 3-S13, 3-S14, and 3-S15, respectively. 
YO-PRO®-1 Iodide polymer-miRNA competitive binding assay 
miRNA mimic was dissolved at 2 μM in 25 mM NaAc and added to YO-PRO®-1 Iodide dye (1 μM 
in NaAc) at a 1:2 miRNA: YO-PRO v/v ratio; 75 μL of this solution was distributed to each well of a black 
opaque 96-well plate. Polymers were also dissolved in NaAc at various concentrations; 25 μL of polymer 
solution was added to the miRNA/YO-PRO mix at a final concentration 0.5 μM for miRNA and YO-PRO, 
respectively, and 96 to 6 μg/mL polymer. The solution was mixed by pipetting, incubated at room temperature 
for 15 minutes while protected from direct light, and YO-PRO fluorescence was read using a BioTek® Synergy 
2 multi-mode plate reader. Fluorescence quenching correlates with polymer binding to miRNA and displacing 
the YO-PRO dye.  
pH titrations 
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All titrations were performed using a SevenEasy pH Meter (Mettler Toledo) with 10 mg of polymer 
dissolved in 10 mL of 100 mM NaCl acidified with HCL as previously described6. Polymer was then titrated 
from pH 3.0 to pH 11.0 using 100 mM NaOH added stepwise with pH of the solution recorded after each 
addition. 
Cytotoxicity 
GBM1A neurospheres were dissociated into single cells and plated on laminin-coated 96-well tissue culture 
plates (15,000 cells/well, 100 μL medium/well) and allowed to adhere for 48 hours. Polymers were dissolved 
in NaAc at the desired concentration and added to Dy547-labeled control miRNA (miCtrl) in a 1:1 volume 
ratio. The solution was mixed by pipetting and nano-miRs were allowed to form for 10 minutes. The resulting 
nano-miRs were added directly to the cell culture medium at a final RNA concentration of 90 nM and final 
polymer-miRNA weight ratios (w/w) of 150, 110, 75, and 37. Nano-miRs were incubated with the cells at 37°C 
for 2 hours, after which the particles and cell culture media were removed and fresh media was added. 24 hours 
after transfection, an MTS assay (CellTiter Aqueous One, Promega, Madison, WI) was performed according to 
manufacturer’s instructions. 
Nanoparticle uptake 
Cy5-labeled miRNA mimic was diluted with unlabeled miRNA to a final concentration of 20% labeled 
miRNA by weight. Transfections were then carried out using a final miRNA dose of 90 nM with viability 
optimized w/w ratios for each nano-miR ratio of 150 w/w for R646 and 37 w/w for 646 and C32 (15,000 
cells/well, 100 μL medium/well). Following a 2-hour incubation period, cell culture medium containing 
nanoparticles were removed and cells were gently washed with PBS. Cells were then detached from the plate 
using Accutase® Cell Detachment Solution (Sigma-Aldrich), diluted in FACS buffer (2% FBS in PBS), and 
pelleted by centrifugation. In a duplicate set of plates, cells were washed again with heparin in 150 mM PBS (50 
μg/mL) to remove surface associated but non-endocytosed nanoparticles 7. Heparin washing was shown to 
remove a fraction of polyplexes (Figure 3-S16). All cells were then analyzed using high-throughput flow 
cytometry. Cellular uptake was quantified using the geometric mean of fluorescence from each well using the 
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Cy5 signal from the FL4 detector (emission: 675/25 nm).  The persistence of the cellular uptake of fluorescently 
labeled miRNA was evaluated over time (Figure 3-S17). 
Confocal microscopy  
GBM1A cells were plated on laminin coated Nunc Lab-Tek chambered borosilicate coverglass well 
plates (155411; Thermo Fisher) at 37,500 cells/well 48 hours prior to imaging. R646 nano-miRs were formed 
with Cy3-miRNA, Cy5-miRNA, or both at a miRNA dose of 90 nM per well and 150 w/w. After one hour of 
incubation, cells were gently washed to remove polyplex nanoparticles and stained for imaging. Nuclei were 
stained with Hoechst 33342 (1:2000 dilution) and lysosomes were labeled with Cell Navigator Lysosome 
Staining dye (AAT Bioquest, Sunnyvale, CA) that has a pKa of 4.5 to accumulate in acidic vesicles. Excess 
stain was washed away and cells were imaged in live cell imaging solution at 37°C in 5% CO2. Images were 
acquired with equal exposure times using a Zeiss LSM 780 microscope with Zen software and 63x oil 
immersion lens. Specific laser channels used were 405 nm diode, 488 nm argon, 561 nm solid-state, and 639 
nm diode lasers. 
Functional delivery of bio-active miRNAs in vitro 
GBM1A cells were transfected as described above with nano-miRs carrying Dy547-labeled control 
miRNA (miCtrl), or a combination of miR-148a+miR-296-5p (Comb.). A final miRNA dose of 90 nM was 
used (for Comb. nano-miRs, miR-148a and miR-296-5p were each at a final concentration of 45 nM) and 
polymer-miRNA w/w ratios of 150 and 37 were tested. Cells were incubated with nano-miRs for 2 hours and 
harvested 3 days after transfection; qRT-PCR analysis of Dnmt1 and Hmga1 – targets of miR-148a and miR-
296-5p – was performed to assess miRNA delivery efficacy.  R646 combination miR-148a and miR-296-5p 
nano-miRs were also found to reduce cell numbers without drastically inducing cell death (Figure 3-S18). 
Optimization and in vitro screening of standard transfection reagents 
BPEI 25 kDa (Sigma Aldrich) was dissolved in 150 mM sodium chloride and mixed with miRNA to 
yield polyplexes at weight ratios between 0.5 to 32 of BPEI to miRNA. Polyplexes were added to GBM1A cells 
to give a miRNA concentration of 90 nM and incubated for two hours, after which media was fully changed. 
Cellular viability was assessed by MTT assay 24 hours later to select a permissible BPEI concentration (Figure 
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3-S3). At the BPEI concentration that had ≥ 75% viability (1 w/w) and miRNA dose of 90 nM was selected 
for in vitro delivery of bio-active miRNA experiments (as described above). 
Commercial reagents Lipofectamine  3000 and Lipofectamine  RNAiMAX (ThermoFisher) were 
used according to manufacturer’s instructions.  
Transmission Electron Microscopy 
Nano-miRs were synthesized as described above. The solution was placed onto a carbon-coated copper 
400 mesh TEM grid and allowed to settle for 30 minutes. Grids were then counter-stained with uranyl acetate 
(0.5% in distilled water) for 3 minutes, and allowed to dry. Particles were imaged using a Philips/FEI BioTwin 
CM120 transmission electron microscope. 
Nanoparticle Tracking Analysis 
Nano-miRs were prepared as described above and diluted in PBS at a 1:500 v/v ratio prior to loading 
particles into a NanoSight NS300. Particles were tracked and their size and concentration determined using 
NanoSight NTA 3.2 software. All measurements were repeated with three samples of nano-miRs to determine 
batch-to-batch variability. All particle concentrations represented are scaled so that they report the number of 
particles per volume that would be present in the in vitro transfection wells. The loading of miRNA molecules 
per particle was calculated by dividing the dose of miRNA in each transfection by the number of particles per 
well (Table 3-S3). 
Dynamic Light Scattering 
Nano-miRs were prepared as described above. Nano-miR size was measured using Dynamic Light 
Scattering (DLS) via a Malvern Zetasizer NanoZS immediately after particle formation in 25 mM NaAc and 
after dilution in PBS at a 1:6 v/v ratio. Zeta potential was measured by electrophoretic light scattering using a 
Malvern Zetasizer NanoZS and analyzed with the Smoluchowski model. Nano-miRs were measured from three 
separate formulations to account for synthesis variability. Nano-miR hydrodynamic diameter is reported as the 
mean ± SEM of the Z-average diameter. 
Gel retention analysis of nano-miRs in non-reducing vs. reducing conditions 
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Nano-miRs were formed as previously described, and diluted at a 1:100 v/v ratio in either artificial 
cerebrospinal fluid (aCSF) or PBS containing 5 mM glutathione (GSH). aCSF is a solution of ions that mimics 
the ionic composition of human CSF 8. Glutathione is present in human cells’ cytosol in concentrations ranging 
from 1 – 8 mM, while extracellular concentrations range from 5 – 50 M.9 Nano-miRs were incubated in either 
solution at 37 C while shaking, and samples were removed at 0 min, 5 min, 15 min, 30 min, and 2 h for particles 
incubated in 5 mM GSH, and 30 min, 2 h, 5 h, 7.5 h, and 10 h for particles incubated in aCSF. Upon removal 
of the nano-miRs, 30 mg/mL sucrose was added as a cryoprotectant, and samples were frozen at -80 C to stop 
the polymer degradation reaction. Particles were thawed and loaded into a 1% w/v agarose gel containing 1 
g/mL ethidium bromide and electrophoresed at 100 mV for 15 min, after which gels were visualized using 
UV light exposure.  
Nano-miR lyophilization 
 Nano-miRs were formed as previously described in 25 mM NaAc buffer, pH 5.0 by mixing solutions 
of R646 polymer and miRNA in a 1:1 ratio. Because injection volume is limited for in vivo delivery, nano-miRs 
for all lyophilized samples were synthesized using the same polymer to miRNA w/w ratio as in all earlier studies 
(150 w/w), but the total polymer concentration was 5 mg/mL to enable a higher dose to be delivered in the 
limited cannula injection volume. Endotoxin free sucrose initially dissolved at 500 mg/mL was then added to 
the nano-miRs for a final concentration of 30 mg/mL sucrose as a cryoprotectant. Nano-miRs were then 
aliquoted to tubes and frozen at -80°C and lyophilized overnight at ~20 Pa and -45°C. For in vitro 
characterization and in vivo utilization, lyophilized nano-miRs were resuspended using deionized water to a final 
polymer concentration of 16.7 mg/mL and a final isotonic sucrose concentration of 100 mg/mL. 
qRT-PCR and miRNA expression  
Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen). cDNA was made by reverse-
transcribing 1 g of total RNA using MuLV Reverse Transcriptase and Oligo (dT) primers (Applied 
Biosystems). qRT-PCR was performed with a Bio-Rad CFX detection System (Bio-Rad) and expression of 
target genes was measured using Power SYBR green PCR kit (Applied Biosystems). Samples were amplified in 
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triplicate and relative gene expression was analyzed using Bio-Rad CFX manager software and normalized to 
18S RNA. Primer sequences used were previously described 2, 10.  
For miRNA analysis, total RNA including small RNA was extracted using miRNeasy kit and 1 g of 
total RNA was used as template to generate cDNA using miScript II RT kit according to manufacturer’s 
protocol. Mature miRNA expression was detected using miScript SYBR green PCR kit using probes for RNU6 
(Cat.# MS00033740), miR-148a (MS00003556), and miR-296-5p (Cat. # MS00016401). All kits and probes 
used to detect mature miRNAs were purchased from Qiagen. 
Fluorescence imaging of intra-tumoral nanoparticle distribution 
To determine intra-tumor distribution of Dy547-labeled control nano-miRs, we took overlapping 
images of the tumor sections using 10X magnification. The fluorescent threshold was set automatically by the 
Q-Capture Pro software (Q-Imaging Corp.) using the tumor margin most distal to the injection site as 
reference. All the images were taken using the same parameters (35-40 pictures per section) and subsequently 
merged and subject to background reduction and smoothening using the Photomerge function in Adobe 
Photoshop. Background fluorescence was minimized by subtracting the fluorescence signal of images of 
control brains (not infused with nanoparticles) from that of images of brains infused with nanoparticles. Total 
tumor areas as defined by H&E staining were compared to the fluorescing areas and expressed as % of 
tumor. 
Intra-cranial nano-miR delivery 
The procedure for intra-cranial cannula implantation was adapted from Moreno-Estelles et. al. 11 
Stainless steel guide and dummy cannulas were custom ordered from PlasticsOne (Roanoke, VA). The guide 
cannula (26 gauge) was designed to have a Decon® mesh under the pedestal and cut 3 mm from the mesh. 
The guide cannula is capped with a screw-on dummy cannula 6.5 mm long so that a 0.5 mm projection 
extends past the guide to prevent blockage. Prior to surgical placement of cannulas, mice were anesthetized 
using a Ketamine (100mg/Kg)/Xylazine (10mg/kg) cocktail and mounted on a stereotactic frame. A rostro-
caudal incision was made with a scalpel, the skin is spread apart, the surface of the skull was exposed, and 
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cannulas were placed at coordinates: AP (antero-posterior) 0.0 (0 mm from bregma), L (lateral) 0.8 (0.8 mm 
right from mid-sagital line). 
Lyophilized and resuspended nano-miRs were slowly infused (5 L) into the brains (0.5 L/min with 
a 2 min wait at the end) twice a week as described for each experiment. At the end of the experiment animals 
were anesthetized and then sacrificed by perfusion using 4% paraformaldehyde (PFA) according to methods 
approved by the Animal Use and Care Committee at Johns Hopkins University. All the sectioning and 
histological analysis was performed in-house. Whole brains were collected and soaked in 4% PFA for 2 days 
then washed 1X with PBS and soaked in 30% sucrose over-night at 4°C then flash frozen using dry ice. 
Brains were embedded in Tissue-Tek® O.C.T. Compound (VWR, Radnor, PA) and 20 m sections were cut 
using the CryoStat system from Microm (Walldorf, Germany). All tumor sections were analyzed by a 
neuropahologist in a blinded fashion. For ionizing radiation experiments, a subset of animals received 
radiation either alone or in combination with the nano-miR therapy. Radiation was administered starting 3 
weeks after tumor cell implantation. Tumor-bearing mice were gently restrained in a 50ml ventilated plastic 
centrifuge tube encapsulated in lead cylinders to protect normal body parts from radiation. This ensures only 
the tumor-bearing brain will be irradiated. Animals received 300 cGy (or sham irradiation) once a week for 3 
weeks using a collimator 137Cs source. These radiation doses were without adverse side effects.  
Necrosis and apoptosis quantification  
Tumor sections were analyzed by a neuropathologist for histologic features of GBM and areas of 
necrosis and apoptosis. To measure apoptosis, tissue sections were subject to Immunohistochemical staining 
using cleaved Caspase 3 antibody (Cell Signaling, #9664) and positive cells per field were counted from 
pictures taken using 10X magnification and an automated ImageJ script. To measure necrosis, the total area 
of tumor and the necrotic area within each tumor were identified by an expert neuropathologist (Dr. Charles 
G. Eberhart) and quantified using ImageJ software from images taken at 10X magnification and represented 
as (area of necrotic tissue/area of total tumor tissue)*100. 
Tumor formation in vivo and animal survival 
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A transcranial cannula was placed so that the tip is in the right caudate/putamen of female athymic 
nude NCR Nu/Nu mice (8-week old). One week after cannula placement, animals received either GBM1A or 
iCSC tumor propagating stem cells (1.0x104 neurospheres) via the cannula and assigned into different treatment 
groups in a non-blinded, randomized manner 11. Using the same cannula, the control cohort received nano-
miRs loaded with control miRNA labeled with Dy547 and the experimental group received nano-miRs loaded 
with the indicated miRNAs.  
The number of animals used for each experiment is indicated in the corresponding figure legend. 
Tumor growth inhibition was determined by computer-assisted morphometric quantification of tumor area in 
H&E-stained histologic sections using ImageJ software and volumes calculated using volume = (square root 
of maximum cross-sectional area)3 as previously described 12. Data for all in vivo experiments are shown as the 
mean tumor area distribution of all animals used in the study. All animal procedures were approved by the 
Johns Hopkins Institutional Animal Care and Use Committee (Protocol# MO14M307), and were in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals.  
Statistical Analysis 
All experiments were performed in triplicates and repeated at least twice in each cell model (N≥6). 
Two group comparisons were analyzed for variation and significance using a two-tailed, type 1 t-test and p 
values lower than 0.05 were considered significant and symbolized by an asterisk in the graphs. One-way 
ANOVA with Tukey post hoc tests were used to analyze experiments with multiple simultaneous 
comparisons. Survival data was compiled using the Kaplan-Meier methodology and compared across arms 










Figure 3-S1: GBM1A and GBM1B neurospheres were dissociated into single cells and transfected with 
nano-miRs carrying miR-Ctrl (120 nM) using R646 polymer (150 w/w). Cell death was measured using trypan 
blue exclusion 3hrs and 24hrs after incubation with nano-miRs.  
 
 
Figure 3-S2. Functional screen results of different nano-miR formulations delivering a non-targeting control 
(Ctrl) or a combination of miRNA mimics miR-148a and miR-296-5p. Effects on expression of miRNA-target 
genes, DNMT1 and HMGA1, are shown. **p<0.01, ***p<0.001, and ****p<0.0001 
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Figure 3-S3. Functional screen using R646 and 646 polymers of similar molecular weight. Nano-miRs were 
used to deliver a non-targeting control (Ctrl) or a combination of miRNA mimics miR-148a and miR-296-5p 
(Comb). (A) Effects on expression of miRNA-target genes, DNMT1 and HMGA1, are shown. *p<0.05, 
**p<0.01, ***p<0.001, and ****p<0.0001. (B) Cell viability measured 3 days post-transfection. (C) GPC data 






Figure 3-S4. in vitro screening of standard transfection reagents PEI, Lipofectamine 3000, and RNAiMAX. 
(A) PEI-miRNA formulations were screened in GBM1A cells to identify optimal formulations with >75% 
relative viability. Numbers on the x-axis indicate polymer-miRNA w/w ratios. (B) Functional delivery of a 
non-targeting control (Ctrl) or a combination of miRNA mimics miR-148a and miR-296-5p by standard 
transfection reagents as assessed by qRT-PCR quantification of the expression of miRNA target genes 




Figure 3-S5: Nano-miR size in different pH and molarity buffers. DLS measurement of nano-miR size in 25 
mM sodium acetate (pH 5) and fold change in diameter after 1:6 dilution in 150 mM PBS (pH 7.4) show 
different nano-miR response to changes in buffer pH and salt content. 
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Figure 3-S6: Additional TEM images showing nano-miR dried size and spherical morphology. Scale bar 400 
nm.   
 
Figure 3-S7: The increased polymer concentration and lyophilization process involved in making nano-miRs 
does not change their physical properties and miRNA delivery capabilities. (A) Fresh and lyophilized R646 
nano-miR showed no statistical difference (p > 0.05) in size or zeta potential. (B) Functional delivery of 
miRNA mimics using fresh or lyophilized nano-miRs resulted the same level of knockdown of the target 






























































Figure 3-S8. R646 nanoparticles can deliver multiple different miRNAs to the same cell and escape from 
endosomes. Confocal microscopy images of cells treated with (A) R646 nano-miRs carrying Cy3 (red) and Cy5 
(cyan) labeled miRNAs show endosomal colocalization (indicated by white arrows) two hours following uptake. 
(B) Nano-miRs carrying Cy5 labeled miRNA (cyan) avoid lysosomes (yellow) at two hours after uptake. 
Cytosolic miRNA was detectable at two hours after uptake compared to controls (white asterisk). Scale bars 
















Figure 3-S9: R646 nano-miRs inhibit the GBM stem cell phenotype. GBM1A and GBM1B neurospheres 
were dissociated into single cells, seeded onto plates pre-treated with Poly-L-Lysine and transfected as 
described in the Methods section with nano-miRs carrying miR-Ctrl, miR-148a, miR-296-5p, or the 
combination (120 nM) using R646 polymer (150 w/w).  (A) Nano-miR-Ctrl labeled with Dy547 was 
visualized in the enlarging multicellular spheres 9 days after transfection using fluorescence microscopy. (B) 
qRT-PCR analysis to measure expression of stem cell markers in GBM1B neurospheres transfected with 
nano-miRs. (C) Equal numbers of GBM1B cells transfected with nano-miRs were cultured in neurosphere 
medium containing EGF/FGF for 12 days and neurosphere numbers (>100µm diameter) were quantified by 
computer-assisted image analysis. (D) Limiting dilution analyses of GBM1B cells transfected with control 
(Ctrl.) or miR-148a+miR-296-5p combination (Comb.) nano-miRs. Untransfected cells (Unt.) were used as 
negative control. Cells were plated in a limiting dilution manner, and the number of wells containing spheres 
was counted after 14 days to compare stem cell frequencies. One-way ANOVA with Tukey post hoc tests 












Figure 3-S10: miR-148a delivery using R646 nano-miRs reduces DNMT1 and DNMT3B expression in vivo. 
Immunohistochemical analysis of Dnmt1 and Dnmt3b in tumor sections treated with miR-Ctrl or miR-148a 
(left panel). Quantification of Dnmt1 and Dnmt3b expression in tumor sections treated with miR-Ctrl. or 








Figure 3-S11: miR-148a delivery using R646 nano-miRs reduces GBM tumor growth in vivo and enhances 
response to ionizing radiation (I.R.) as a standard of care. (A) Left panel: Schematic outlining in vivo 
experimental procedure. Right panel: Tumor-bearing animals received control nano-miR, 148a nano-miR, 
control nano-miR+I.R. (300 cGy/dose X 3), or 148a nano-miR+I.R as shown. Maximum tumor cross-
sectional areas were determined in H&E stained sections using ImageJ software and tumor volumes 
calculated as described in Materials and Methods. Vessel density (B) and Apoptotic index (C) were measured in 
tumor sections by analysis of anti-laminin and anti-cleaved caspase 3 immunohistochemistry, respectively. 
One-way ANOVA with Tukey post hoc tests was used when performing multiple comparisons and p<0.05 



















Figure 3-S12: miR-148a and miR-296-5p co-delivery using R646 nano-miRs inhibits GBM tumor growth. 
(A)  Representative H&E stained brain sections from mice implanted with GBM1A neurosphere cells (N=5 
for each group) treated with the indicated nano-miRs (* marks infusion cannula tracks). (B) Apoptotic index 
was measured in tumor sections by analysis of anti-cleaved caspase 3 immunohistochemistry. One-way 
ANOVA with Tukey post hoc tests was used when performing multiple comparisons and p<0.05 considered 




Figure 3-S13: Histological analysis of brains collected from survival study.  Representative H&E stained 
sections showing the histology of the tumors (A) 42 days post-implantation before starting treatment, (B) the 





Table 3-S1: Gel permeation chromatography (GPC) results indicating the number average (MN) and weight 
average (MW) molecular weight and polydispersity (PDI) of each polymer. 
 
Figure 3-S14: Gel permeation chromatography (GPC) experiments determining the effect of polymer 
endcapping on molecular weight. The molecular weight of bioreducible R646 and non-reducible 646 were 
characterized at each step of the polymer synthesis process. (A) Molecular weight data and (B) GPC traces are 
shown.  
Reducible R646 Non-reducible 646
Mn Mw PDI Mn Mw PDI
Pre-endcap 2052 2430 1.184 2517 3212 1.276
Post-endcap, 
no ether wash 1955 2276 1.162 2457 3061 1.231
Post-endcap, 
ether wash 2162 2731 1.263 3047 3617 1.273






































Figure 3-S15: H1-NMR spectrum of polymer R646 (CDCl3, 500 MHz). Proton peaks are labeled with letters 






Figure 3-S16: H1-NMR spectrum of polymer 646 (CDCl3, 500 MHz). Proton peaks are labeled with letters 














Figure 3-S17: H1-NMR spectrum of polymer C32 (CDCl3, 500 MHz). Proton peaks are labeled with letters 












Figure 3-S18: Effects of heparin washing on uptake experiments. Flow cytometry plot of cells treated with 
R646 nano-miRs encapsulating Cy5-tagged miRNA show changes in average cellular fluorescence with and 




















Figure 3-S19: Persistence of R646 nanoparticle-mediated intracellular delivery of labeled control miRNA to 
GBM neurospheres. GBM1A neurospheres were dissociated into single cells, and transfected with miR-Ctrl 
(120 nM) with and without R646 polymer (150 w/w).  (A) miR-Ctrl labeled with Dy547 was visualized 3 hr 
and 24hrs after transfection using fluorescence microscopy.  (B) Dy547-labeled control miRNA (miR-Ctrl) 
delivered to GBM neurospheres was detectable via fluorescence microscopy through at least 12 days 
following transfection. *p< 0.05 (C) qRT-PCR to measure expression of mature miR-148a and mature miR-






Figure 3-S20: R646 nano-miRs reduce cell numbers without drastically inducing cell death. GBM1A and 
Mayo39 GBM cells were transfected with miR-Ctrl or miR-148a/miR-296-5p combination (120 nM) using 
R646 polymer. Untreated (unt.) cells were used as control for nanoparticle toxicity.  Nano-miRs were 
incubated with cells for 2 hours. Cell number (A) and viability (B) was measured 4 days after transfection 
using Trypan blue. *p< 0.05 
 
 
Table 3-S2: Nano-miR concentration as measured by NTA and the calculated miRNA molecules per particle 
for each nano-miR formulation. As all miRNA loaded was bound in nano-miRs (Figure 7- 3E) and a dose of 
90 nM miRNA was used in the nano-miR formulation, miRNA molecules per particle was calculated using 
the equation:  
RNA loading = RNA Concentration
NP Concentration . 
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Abstract 
Together, medulloblastoma (MB) and atypical teratoid/rhabdoid tumors (AT/RT) represent two of 
the most prevalent pediatric brain malignancies. Current treatment involves radiation, which has high risks of 
developmental sequelae for patients under the age of three. New safer and more effective treatment 
modalities are needed. Cancer gene therapy is a promising alternative, but there are challenges with using 
viruses in pediatric patients. We developed a library of poly(beta-amino ester) (PBAE) nanoparticles and 
evaluated their efficacy for plasmid delivery of a suicide gene therapy to pediatric brain cancer models—
specifically herpes simplex virus type I thymidine kinase (HSVtk), which results in controlled apoptosis of 
transfected cells. In vivo, PBAE-HSVtk treated groups had a greater median overall survival in mice implanted 
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with AT/RT (p=0.0083 vs. control) and MB (p<0.0001 vs. control). Our data provides proof of principle for 
using biodegradable PBAE nanoparticles as a safe and effective nanomedicine for treating pediatric CNS 
malignancies. 
 




 Malignant CNS tumors are the most common solid tumor in children.1 Of those, medulloblastoma 
(MB) accounts for about 20 percent of all pediatric CNS tumors.2 However, in children younger than 6 
months of age, atypical teratoid/rhabdoid tumors (AT/RT) are the most common malignant central CNS 
tumor.3 Historically, it has been difficult to distinguish these two cancers based on radiology alone, 
particularly since both occur almost exclusively in the cerebellum. Current diagnostic criteria of AT/RT 
require immunohistochemistry (IHC) characterization of SMARCB1/INI1 or evidence of SMARCA4/BRG1 
deletion and/or mutation of 22q11.2 to distinguish it from MB.4-5   
 Of note, the prevalence of these two tumors in pediatric populations younger than three years of age 
complicates treatment; chemotherapy is often used to delay or avoid radiotherapy in infantile 
medulloblastoma,6 while lack of effective therapies for AT/RT often requires use of initial radiotherapy for 
treatment despite the risk of neurologic sequelae that arises from early childhood radiation.7 Even with 
radiation and surgery, patients with AT/RT report a dismal prognosis with median overall survival of 1 year.8-
9 Therefore, expansion of new treatment modalities for these malignancies is imperative for improving 
mortality outcomes in these pediatric populations.  
 We recently explored the potential of a new nanomedicine, poly(beta-amino ester) (PBAE) 
nanoparticles containing plasmid DNA encoding the suicide gene herpes simplex virus I thymidine kinase 
(HSVtk), as a gene therapy for treating adult glioma.10 We found that in a preclinical glioma rat study, the 
nanoparticles could spread through the tumor and there was a  significant increase in median overall survival 
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in vivo.10 The well-characterized safety profile and effectiveness of PBAE nanoparticles for gene delivery—
along with the ability to engineer these particles to avoid unwanted immunogenic risks—make them a 
promising candidate for pediatric malignancies,11-15 although this direction has not been previously 
investigated. Of note, there has been a recent emergence of interest in using nanoparticles for gene delivery in 
pediatric malignancies, with cationic lipid-polymer hybrid nanoparticles (CLPNs) showing in vivo transfection 
efficacy in childhood rhabdomyosarcoma.16  
 Specifically, PBAEs are a class of polymeric nanoparticles that can be engineered to contain primary, 
secondary, and tertiary amines with hydrolytically cleavable ester bonds that allow for effective DNA binding 
and encapsulation, endocytosis within the host cell, subsequent endosomal escape, and intracellular DNA 
release for transcription and translation of the exogenous gene of interest.17 Previous studies have shown that 
PBAEs can be safe and effective DNA delivery vectors both in vitro across multiple tissue types as well as in 
vivo in retinal and brain tissue.11-13 Furthermore, PBAE polymers degrade quickly under physiological 
conditions, thereby minimizing nanoparticle cytotoxicity as well as maximizing successful delivery of nucleic 
acids.18 Notably, PBAEs also demonstrate biomaterial-mediated cell type specificity, and are able to selectively 
transfect tumor tissue over healthy tissue in the brain13, 19 and liver.20-21  
 Additionally, convection-enhanced delivery (CED) has been shown to be an effective method for 
locally delivering PBAEs to tumor sites in vivo by maintaining a pressure gradient that enhances diffusion of 
the particles throughout the tumor mass.22 In a previous study, we demonstrated increased distribution of 
particles using CED in vivo.10 Therefore, this study aims to investigate the efficacy of PBAE nanoparticles for 
intracellular delivery of nucleic acids such as plasmid DNA encoding HSVtk to show proof of principle that 
these polymeric nanoparticles can be used as a safe and effective method for treatment delivery in MB and 








Small molecule monomers: 1,4-butanediol diacrylate (B4; CAS 1070-70-8), 3-amino-1-propanol (S3, 
CAS 156-87-6), 4-amino-1-butanol (S4, CAS 13325-10-05), 5-amino-1-pentanol (S5, CAS 2508-29-4), and 1-
(3-aminopropyl)-4-methylpiperazine (E7, CAS 4572-031) were purchased from Alfa Aesar (Ward Hill, MA, 
USA); 1,5-pentanediol diacrylate (B5, CAS 36840-85-4) was purchased from Dajac Laboratories (Feasterville-
Trevose, PA, USA); 2-(3-aminopropylamino)ethanol (E6; CAS 4461-39-6) was purchased from Sigma Aldrich 
(St. Louis, MO, USA). LipofectamineTM 2000 and Lipofectamine 3000TM were purchased from ThermoFisher 
(Waltham, MA, USA). 25 kD branched poly(ethylenimine) was purchased from Sigma Aldrich (St. Louis, 
MO, USA). The pEGFP-N1 plasmid (GFP) was purchased from Elim Biopharmaceuticals (Hayward, CA, 
USA) and the herpes simplex virus type 1-derived thymidine kinase (HSVtk) gene was cloned into the 
pcDNA3.1 vector; both plasmids were amplified by Aldeveron (Fargo, ND, USA). For cell staining in in vitro 
cell killing assays, Hoechst 33342 and propidium iodide were purchased from Invitrogen (Carlsbad, CA, 
USA). CellTiter 96 AQueous One MTS assay was purchased from Promega (Madison, Wisconsin, USA). 
Ganciclovir was purchased from Invivogen (Carlsbad, CA, USA). 
 
Polymer Synthesis and Characterization 
B and S monomers were reacted at a molar ratio of 1.1:1 at 90qC with stirring overnight to form 
acrylate-terminated base polymers. Base polymers were then dissolved in anhydrous THF at 167 mg/mL and 
added to end-capping E monomers (0.5 M in THF) at a 3:2 volume ratio and allowed to react at room 
temperature with stirring for 1 hour, at which time polymers were washed twice in diethyl ether to remove 
unreacted monomers and oligomers. Solvents were removed in a vacuum desiccant chamber for 2 days, at 
which point polymers were dissolved in DMSO at 100 mg/mL, and single-use aliquots were stored at -20qC 
with desiccant.  
 Nuclear magnetic resonance spectroscopy (NMR) was used to characterize polymer structure via 1H 
NMR in CDCl3 (Bruker 500 MHz) and analyzed using TopSpin 3.5 software (Billerica, MA, USA). Gel 
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permeation chromatography (Waters, Milford, MA) measurements were performed to measure polymer 
molecular weight and polydispersity. Polymers were dissolved in BHT-stabilized tetrahydrofuran and 5% 




 Nanoparticles were prepared in the same manner as for transfections and diluted in 150 mM PBS to 
determine nanoparticle characteristics in neutral isotonic buffer. Hydrodynamic diameter was measured via 
dynamic light scattering at 1:6 dilution in PBS using a Malvern Zetasizer NanoZS (Malvern Panalytical, 
Malvern, UK). Zeta potential was measured via electrophoretic light scattering on the same Malvern 
Zetasizer. For characterization of lyophilized nanoparticles, nanoparticles were first resuspended in water 
following the same procedure as in vivo experiments and then diluted in PBS to the same polymer 
concentration as freshly prepared nanoparticles before measurement using dynamic light scattering. 
Transmission electron microscopy (TEM) images were acquired using a Philips CM120 (Philips Research, 
Cambridge, MA, USA). Nanoparticles were prepared at a polymer concentration of 1.8 mg/mL in 25 mM 
sodium acetate buffer (NaAc), and 30 PL were added to 400-square mesh carbon-coated TEM grids and 
allowed to dry for 20 min, at which point grids were rinsed with ultrapure water and allowed to fully dry 
before imaging.  
 
Cell Culture 
 Human BT-12 atypical teratoid/rhabdoid tumor (AT/RT) cells (obtained from C. Eberhart’s 
laboratory, Johns Hopkins University, Baltimore, MD, USA) were cultured in Dulbecco’s Modified Eagle 
Media (DMEM; ThermoFisher, Waltham, MA, USA) supplemented with 10% FBS and 1% 
penicillin/streptomycin. D425 group 3 medulloblastoma cells (obtained from C. Eberhart’s laboratory, Johns 
Hopkins University, Baltimore, MD, USA) were cultured in Minimum Essential Medium (MEM; 
 123 




 BT-12 cells were seeded onto 96 well tissue culture plates at a density of 15,000 cells per well in 100 
PL complete medium and allowed to adhere for 48 hours before transfection. D425 cells were seeded at a 
density of 15,000 cells per well 24 hours prior to transfection (transfection was done with cells in suspension 
as D425s did not adhere to tissue culture plates). To form nanoparticles, plasmid DNA and polymer were 
first dissolved separately in 25 mM NaAc buffer (pH 5) at the desired concentration and then mixed together 
at a 1:1 volume ratio. Nanoparticles were allowed to self-assemble for 10 minutes at room temperature before 
being added to cells. Nanoparticles were incubated with cells for 2 hours, at which time cells were replenished 
with fresh complete medium. To test the transfection efficacy of lyophilized nanoparticles, nanoparticles were 
first resuspended in water and then added to cells in complete cell culture medium to achieve a final DNA 
dose matching that delivered by freshly prepared nanoparticles (600 ng DNA per well). Nanoparticle-
mediated cytotoxicity was assessed 24 hours post-transfection using CellTiter 96 AQueous One MTS cell 
proliferation assay (Promega, Madison, Wisconsin, USA) following manufacturer’s instructions. Transfection 
efficacy was assessed 48 hours post-transfection via flow cytometry using a BD Accuri C6 flow cytometer 
(BD Biosciences, Franklin Lakes, NJ, USA). N = 4 +/- SEM. 
 Transfections using commercially-available non-viral transfection reagents Lipofectamine 2000TM and 
Lipofectamine 3000TM (ThermoFisher, Waltham, MA, USA) were performed according to manufacturer 
instructions. 
 
Nanoparticle Uptake and Endocytosis Pathway Inhibition 
Cellular uptake of nanoparticles was measured using nanoparticles encapsulating 20% Cy5-labeled 
DNA (prepared using previously published protocols23) and 80% unlabeled plasmid DNA. Nanoparticles 
were prepared and added to cells in the same manner as for in vitro transfections described above. After 2 h 
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incubation with cells, nanoparticles were removed and cells were washed once with PBS before being 
prepared for flow cytometry experiments. Nanoparticle uptake was quantified both as percentage of cells with 
Cy5 fluorescence after gating against untreated cells as well as by using the geometric mean Cy5 fluorescence 
intensity normalized to that of untreated cells. 
To investigate the relationship between polymer structure and endocytosis pathways leading to 
nanoparticle uptake and transfection, BT-12 cells were pre-treated with small molecule drugs inhibiting 
specific endocytosis pathways for 1 h prior to the addition of nanoparticles. Endocytosis inhibitors were used 
at the highest concentrations that did not lead to significant levels of inhibitor-mediated cytotoxicity and are 
as follows: 16 Pg/mL chlorpromazine, 1.5 mg/mL methyl-β-cyclodextrin, 36 Pg/mL genistein, and 3.5 
Pg/mL cytochalasin-D. After 1 h pre-incubation with inhibitors, nanoparticles were added to cells and 
incubated for an additional 2 h, after which cells were prepared for flow cytometry for uptake experiments or 
replenished with fresh complete media for transfection experiments.   
 
In Vitro HSVtk Cell Killing Assay 
 For HSVtk cell killing assays, transfection was performed as described above using HSVtk and GFP 
plasmids, respectively. Ganciclovir (Invivogen, San Diego, CA, USA) was resuspended in PBS at 5 mg/mL 
following manufacturer’s instructions and diluted to desired concentrations using complete cell culture media. 
On days 1, 3, and 5 after transfection, cells were treated with fresh ganciclovir-containing media. On day 7 
post-transfection, cells were stained with Hoechst 33342 nuclear stain (1:1000 dilution) and propidium iodide 
(1:500 dilution) for 20 minutes and imaged and analyzed using Cellomics Arrayscan VTI with live cell imaging 




 All animal work was done in strict adherence of the policies and guidelines of the Johns Hopkins 
University Animal Care and Use Committee (ACUC Mouse Protocol Mo17M185). For intracranial tumor 
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implantation, 6-8 week old male athymic nude mice (Charles River, Wilmington, MA, USA) were anesthetized 
using a Ketamine (100 mg/kg)/Xylazine (10 mg/kg) cocktail and mounted on a stereotactic frame. A rostro-
caudal incision was made with a scalpel, the skin was spread apart, the surface of the skull was exposed and 
cleaned with 100% ethanol, and a small hole was made using an electric drill in the skull 2 mm posterior to 
the coronal suture and 2 mm lateral to the sagittal suture. Stainless steel cannulas (C212SG PlasticsOne®, 
Roanoke, VA, USA) were implanted into the hole in the skull. 5e5 BT-12 cells and 1.25e5 D425 cells were 
respectively implanted into mouse brains into the left striatum through cannulas. 
 
In Vivo Nanoparticle Administration 
 Xenograft tumors were allowed to form for 10 days for BT-12 and 7 days for D425, at which time 
nanoparticle administration began. For in vivo injections, nanoparticles were lyophilized after initial formation 
as described previously.24 Briefly, nanoparticles were formulated at in vitro optimized polymer-to-DNA w/w 
ratio but with the total polymer concentration at 5 mg/mL; sucrose was added at a final concentration of 30 
mg/mL as a cryoprotectant. Lyophilized nanoparticles were resuspended in sterile water at a final isotonic 
sucrose concentration of 100 mg/mL immediately before intracranial administration. Mice were anesthetized, 
and the original incision was opened. Convection-enhanced delivery (CED) was performed using a 26-gauge 
needle stereotactically placed at a depth of 3 mm and an UltraMicroPump (UMP3) with SYS-Micro4 
Controller (World Precision Instruments, Sarasota, FL, USA) was used to infuse nanoparticles at a rate of 0.5 
PL/min.25 10 PL nanoparticles were injected per animal, after which the needle was maintained in the cortex 
for another 5 min to avoid backflow. Following needle removal, the incision was closed and the animal was 
allowed to awaken and recover. 
 
HSVtk Survival Studies 
 After tumor inoculation, mice were randomized and divided into 3 groups (n=10), each group 
receiving GFP nanoparticles, HSVtk nanoparticles, or sham PBS treatment, respectively. Mice implanted with 
BT-12 were treated with 447 nanoparticles (90 w/w) while mice implanted with D425 were treated with 537 
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nanoparticles (90 w/w). Mice received nanoparticle infusions on days indicated in Figure 4-6 for a total of 3 
infusions. All mice received intraperitoneal administration of 50 mg/kg ganciclovir daily on days 10-40 for 
BT-12 implanted mice and days 7-28 for D425 implanted mice after the first nanoparticle infusion. Animals 
were monitored daily and assessed for neurological impairment.  
 
Data Analysis and Statistics 
 All in vitro experiments were performed with n=4 unless otherwise noted. Survival data was compiled 
using the Kaplan-Meier methodology and compared across arms using the Mantel-Cox log-rank test. All 
statistical tests were performed using the GraphPad Prism6 software.   
 
Results 
PBAE nanoparticles enable efficient DNA delivery to AT/RT and MB cells in vitro 
We synthesized a small library of PBAEs by co-polymerizing small molecule monomers via Michael 
addition reactions between amines and diacrylates following previously reported protocols (Figure 4-1A).26 
Briefly, diacrylate “B” monomers were reacted with primary amine-containing “S” monomers (90qC, 
overnight) to produce acrylate-terminated polymers, which were then end-capped with amine-containing “E” 
monomers (25qC, 1 hour). The presence of acrylate-terminated polymers following the first step of synthesis 
was confirmed via 1H NMR with three characteristic acrylate peaks in the 5.5-6.5 ppm range, which 
disappeared after end-capping reaction (Figure 4-S1). The cationic polymers were mixed with anionic 
plasmid DNA in acidic buffer to self-assemble into nanoparticles, which were found to be 100-200 nm in 
diameter with slightly positive surface charges (Figure 4-1B). 
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Figure 4-1. PBAE chemical structures and nanoparticle characteristics. (A) PBAEs are synthesized 
from B, S, and E monomers via Michael addition reactions. Structures of top polymers used in this study are 
shown. (B) Hydrodynamic diameter and zeta potential measurements of top nanoparticle formulations as 
measured by dynamic light scattering, n = 3. (C) Representative TEM images of 447 and 537 nanoparticles, 
respectively; scale bar = 200 nm. 
We performed nanoparticle transfection screens on two cell lines established from pediatric patient 
samples; D425 is a well-characterized Group 3 medulloblastoma cell line,27 and BT-12 is a highly-cited 
AT/RT cell line that has been used in pre-clinical studies using HDAC inhibitors,28 IGF-IR antisense 
oligonucleotides,29 and neutralizing antibodies30-31 for exploring treatment.32-33 Using a GFP reporter plasmid 
for the initial nanoparticle screen, we found that several PBAE nanoparticle formulations enabled >50% 
transfection in both cell lines with minor levels of cytotoxicity (Figure 4-2). PBAE nanoparticles also enabled 
significantly higher transfection compared to commercially-available transfection reagents such as 25 kD 
branched PEI and Lipofectamine 3000TM (Figure 4-3). Based on our screening results, we chose polymer 1-
(3-aminopropyl)-4-methylpiperazine end-capped poly(1,4-butanediol diacrylate-co-4-amino-1-butanol) (447) 
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at a polymer-to-DNA weight-to-weight (w/w) ratio of 90 as the optimal formulation for BT-12 and polymer 
1-(3-aminopropyl)-4-methylpiperazine end-capped poly(1,5-pentanediol diacrylate-co-3-amino-1-propanol) 
(537) at 90 w/w for D425.  
 
Figure 4-2. In vitro nanoparticle screening in D425 and BT-12 cells. Transfection efficacy shown as 
percent GFP positive cells (A) and (B) metabolic activity after treatment with different nanoparticle 
formulations; n = 4. (C) Fluorescence microscopy images of both cell lines transfected with their respective 
optimal nanoparticle formulations (537, 90 w/w for D425; 447, 90 w/w for BT-12); scale bar = 200 Pm. 
We performed nanoparticle uptake experiments in which nanoparticle were formulated to deliver 
20% Cy5 labeled DNA, and we characterized nanoparticle uptake in BT-12 cells by assessing intracellular Cy5 
fluorescence. Our results showed that 447 90 w/w and 537 90 w/w nanoparticle formulations resulted in the 
highest levels of cellular uptake as measured by the geometric mean Cy5 fluorescence intensity (Figure 4-4). 
These optimized nanoparticle formulations were used for their respective cell lines for the remaining 
experiments. Uptake pathways leading to transfection were further investigated using an endocytosis pathway 
inhibition assay in which BT-12 cells were pre-treated with small molecule drugs inhibiting clathrin-mediated 
endocytosis, lipid raft-mediated endocytosis, caveolin-mediated endocytosis, and macropinocytosis, 
respectively, before incubation with nanoparticles. Our results demonstrated that polymer end-group 
structure played an important role in determining the pathway through which nanoparticles were internalized. 
 129 
For example, 446 nanoparticle uptake was significantly inhibited by methyl-β-cyclodextrin, which was not the 
case for 447 or 537. 
 
Figure 4-3. PBAE nanoparticles enable higher transfection than commercially-available transfection 
reagents. (A) Formulation 447 nanoparticles enabled significantly higher transfection in BT-12 cells 
compared to 3 commercially-available transfection reagents; statistical significance assessed by ordinary one-
way ANOVA Dunnett’s multiple comparisons test (n = 4; ****p<0.001). (B) Nanoparticles caused negligible 
levels of cytotoxicity; metabolic activity/cell viability measured by MTS assay and normalized to non-
transfected control (n = 4). (C) Fluorescence microscopy images of cells transfected with different reagents; 
scale bar = 200 Pm. 
PBAE-HSVtk nanoparticles activate ganciclovir prodrug to induce cell killing in vitro 
 We next investigated the in vitro cell killing capabilities of PBAE nanoparticles encapsulating the 
HSVtk suicide gene. 447 nanoparticles delivering a plasmid encoding HSVtk or GFP were used to transfect 
BT-12 cells. Transfected and untransfected controls were replenished with cell culture media containing 
varying doses of ganciclovir (GCV) on days 1, 3, and 5 post-transfection. Live/dead cell imaging on day 7 
post-transfection revealed that GCV treatment in HSVtk transfected cells resulted in >65% cell death at all 3 
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GCV doses (Figure 4-5). Similar treatment in GFP-transfected cells did not incur any cytotoxicity, suggesting 
that cell killing required GCV activation by cells expressing HSVtk. Untransfected cells treated with GCV 
also did not incur appreciable cytotoxicity, indicating that the GCV doses used did not cause non-specific cell 
death.   
 
Figure 4-4: Effect of endocytosis pathway on nanoparticle uptake and transfection. (A) Cellular uptake 
of nanoparticles encapsulating Cy5-labled DNA. Nanoparticle uptake is expressed as the percentage of cells 
containing Cy5 signal as well as the geometric mean Cy5 fluorescence intensity (n = 4). (B) Uptake (top) and 
transfection (bottom) of select polymers (all nanoparticles were formulated at 90 w/w) after endocytosis 
pathway inhibition (n = 4). Chlorpromazine was used to inhibit clathrin-mediated endocytosis; methyl-β-
cyclodextrin – lipid raft-mediated endocytosis; genistein – caveolin-mediated endocytosis, and cytochalasin-D 
– macropinocytosis. Uptake and transfection are expressed as the fluorescence intensity of each inhibitor-
treated condition normalized to the no inhibitor group. Statistical significance was determined using 2-way 
 131 
ANOVA with Dunnett’s multiple comparisons test as compared to the no inhibitor group for each polymer 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, **** p ≤ 0.0001.) 
Nanoparticles administered via CED significantly prolong survival in mouse xenograft models in vivo 
 The robustness of PBAE nanoparticles delivering HSVtk suicide gene therapy was further evaluated 
in two orthotopic mouse xenograft models, using BT-12 and D425 cells, respectively. Nanoparticles 
encapsulating either HSVtk or GFP were formulated at the same optimal w/w as in vitro experiments and 
lyophilized with sucrose as a cryoprotectant following previously published protocols,10, 24 for ease of storage 
and to facilitate future manufacturing scalability. To validate our nanoparticle lyophilization procedure, 
lyophilized nanoparticles were resuspended in water following the same procedure was for in vivo injections 
and characterized using dynamic light scattering. We found that lyophilized nanoparticles were not statistically 
different in hydrodynamic diameter or zeta potential compared to freshly prepared nanoparticles (Figure 4-
S2). Furthermore, lyophilized nanoparticles achieved similar levels of in vitro transfection as fresh 
nanoparticles delivering the same DNA dose, further confirming that lyophilization did not significantly alter 
nanoparticle properties.  
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Figure 4-5. PBAE nanoparticles delivering HSVtk enables cell killing in vitro. (A) BT-12 cells were 
transfected with nanoparticles encapsulating either GFP or HSVtk plasmid DNA (447, 90 w/w, 600 ng/well), 
and only cells transfected with HSVtk showed high levels of cell death upon GCV treatment. Un-transfected 
cells (UT) were treated with GCV only as negative control. (n = 4). (B) Fluorescence microscopy images of 
BT-12 cells treated with indicated nanoparticle formulations at 45 Pg/mL GCV 7 days post-transfection. 
Cells were stained with Hoechst 33342 nuclear dye (blue) or propidium iodide for dead cells (magenta). Scale 
bar = 100 Pm. 
To evaluate in vivo nanoparticle efficacy in intracranial tumor models, athymic nude mice were 
inoculated with 5e5 BT-12 cells or 1.25e5 D425 cells, respectively. Tumors were allowed to form for 7-10 
days, after which time nanoparticle treatment began at day 7 for mice implanted with BT-12 cells and day 10 
for mice implanted with D425 cells. Each treatment group received 3 nanoparticle infusions through 
convection-enhanced delivery (CED); mice received 2 Pg total DNA dose for each infusion. The first day of 
treatment was designated as day 0, at which point survival tracking began. Mice also received daily 
intraperitoneal (i.p.) injections of GCV for the entirety of the treatment period (Figure 4-6).  
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Figure 4-6. Convection-enhanced delivery of PBAE nanoparticles significantly extended survival in 
mouse orthotopic xenograft models in vivo. (A) Schematic of in vivo study: PBAEs self-assembled into 
nanoparticles with plasmid DNA, which were infused intratumorally via CED; mice also received 
intraperitoneal injections of GCV prodrug, which were activated in transfected cells, leading to tumor cell 
killing and extended survival. (B) Treatment schedule and Kaplan-Meier survival curves for each tumor 
model; n = 10 animals per group. 
 In both tumor models, survival of the GFP nanoparticle group closely followed that of the untreated 
control group, mirroring the results of our in vitro cell killing assay. Nanoparticles delivering HSVtk 
significantly extended survival in both tumor models (p = 0.0083 for BT-12 and p < 0.0001 for D425, as 
determined by Mantel-Cox log-rank tests). Mice bearing BT-12 tumors had median survival of 35 days when 
untreated, and survival was extended to 42 days (20% longer) with HSVtk nanoparticles. D425 tumors were 
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more aggressive, with untreated median survival at 19 days and with HSVtk nanoparticle treatment, median 
overall survival at 31 days (63% longer) (Figure 4-6).   
 
Discussion 
 In this work, we synthesized a small library of poly(beta-amino ester)s (PBAEs) and examined their 
ability to functionally deliver plasmid DNA encoding a suicide gene to pediatric CNS malignancies. The small 
size of the nanoparticles (Figure 4-1) contributed to successful delivery to BT-12 (an AT/RT cell line) and 
D425 (a MB cell line) in vitro. Within the same polymer type, transfection efficacy generally increased with 
increasing polymer-DNA w/w ratio while cell viability decreased (Figure 4-2); both phenomenon could be 
partly explained by the fact that higher polymer doses increase the positive charge of the nanoparticles as well 
as the number of positively-charged molecules interacting with cells overall, which could simultaneously 
increase nanoparticle uptake and cytotoxicity by perturbing and disrupting the cellular membrane.34 
While polymer 447 was equally effective at transfecting both cell lines (45% GFP positive in BT-12 
and D425), some polymers were only effective at transfecting one cell line and not the other. For example, 
446 enabled transfection exclusively in BT-12 while 457 exclusively transfected D425. To investigate the 
mechanism by which polymer structure affects transfection efficacy, we studied nanoparticles formulated 
with polymers 446, 447, and 537 at 90 w/w and their interactions with BT-12 cells. From Figure 4-2A, we 
see that 446 and 447 nanoparticles enabled similar levels of transfection in this cell line while 537 
nanoparticles achieved significantly lower transfection levels. Previous studies have reported that molecular 
weight correlated positively with nanoparticle transfection efficacy in several polymeric nanoparticle 
systems.35-36 This was not the case here as polymers 446 and 447 enabled significantly higher transfection than 
polymer 537 despite having a significantly lower molecular weight (Table 4-S1). The differential transfection 
levels also do not appear to be dependent on nanoparticle physical characteristics as 447 and 537 
nanoparticles do not have statistically significant differences in hydrodynamic diameter or zeta potential 
(Figure 4-1).  
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Previous work suggests that this cell-type specificity may be in part due to the structure of polymer 
endgroups,11, 37 which can lead to differential uptake pathways resulting from different nanoparticle-
membrane interactions.38 To test this hypothesis, we performed endocytosis pathway inhibition studies on 
nanoparticles formulated from polymers 446, 447, and 537. BT-12 cells were pre-treated with small molecule 
drugs to inhibit specific endocytosis pathways, and nanoparticles were added to cells to study the endocytosis 
pathways responsible for nanoparticle uptake and DNA transfection (Figure 4-4B). Compared to polymers 
end-capped with E7, uptake inhibition of 446 nanoparticles by methyl-β-cyclodextrin was significantly higher, 
indicating that lipid raft-mediated endocytosis was a major uptake pathway for this polymer structure. Across 
all three polymer structures, genistein caused very high levels of uptake inhibition without high levels of 
transfection inhibition, indicating that caveolin-mediated endocytosis was a rather wasteful endocytosis 
pathway through which nanoparticles were taken up but did not lead to transfection. Chlorpromazine 
inhibited 60-80% nanoparticle uptake, corresponding to 30-50% transfection inhibition. This indicates that 
clathrin-mediated endocytosis is a major pathway for leading to transfection. Taken together, our results 
demonstrate that subtle changes in PBAE polymer structure can lead to significant changes in the endocytosis 
and transfection behavior of nanoparticles. These results do not provide a conclusive explanation for how 
certain structures lead to higher transfection levels than others, however, suggesting that nanoparticle 
trafficking steps between endocytosis and gene expression such as endosomal escape, intracellular migration, 
and nuclear penetration should be further explored to elucidate the mechanisms behind biomaterial-mediated 
cell type specificity.   
Furthermore, while BT-12 cells formed monolayers, D425 cells have been documented to grow as 
macrospheroids39 and were transfected in suspension. Our results show that PBAE nanoparticles could be 
tailored for cell type-specific transfection as well as penetrate and transfect 3D cellular macrospheroids. This 
data suggest that certain nanomedicine formulations may be potentially useful for pediatric CNS malignancies 
in general (447 and 537), while other nanomedicine formulations may be able to further improve efficacy for 
patients with particular tumors (446 and 457). Of note, optimized PBAE formulations significantly 
outperformed leading commercially-available transfection reagents such as Lipofectamine 3000TM.   
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 In vitro assays showed robust and specific cell killing in cells treated with HSVtk nanoparticles and 
GCV prodrug. GCV treatment alone, with or without nanoparticle-mediated transfection of a reporter gene, 
did not result in appreciable levels of cytotoxicity. Interestingly, formulation 447 nanoparticles enabled 45% 
transfection in BT-12 (as assessed via GFP reporter gene screening) but resulted in >65% cell death when 
used to deliver HSVtk. This is due to a well-documented bystander effect in the HSVtk-GCV system, 
whereby a fraction of transfected cells can lead to cell death in the greater cell population by releasing 
activated GCV into the cell medium or through gap junctional intercellular communication.39 This is an 
advantage of a suicide gene therapy approach, as the treatment does not rely on 100% transfection efficacy to 
have a broad effect on a tumor. 
 In vivo survival studies demonstrated the efficacy of using PBAE nanoparticles carrying HSVtk for 
treating MB and AT/RT. Of note, the increased median overall survival in mice with AT/RT or MB that 
were treated with PBAEs carrying HSVtk showed a more impressive therapeutic effect when compared to 
our previous studies on GBM in rat models.10 Furthermore, in tumors like MB, which have since been 
characterized as having one of four possible molecular subtypes,33 the customizability of PBAE formulations 
lends itself well to the optimization of personalized nanomedicine technology between these different tumor 
groups. 
It should be noted that PBAEs are not restricted to delivering genes such as HSVtk, as they have 
been validated as vectors for the delivery of other nucleic acids such as siRNA19 and miRNA24 as well.  Our 
data demonstrates proof of principle that PBAEs can be used to deliver genes of interest to MB and AT/RT 
tumors with significant therapeutic effect. This finding offers a promising alternative avenue to our current 
limited treatment modalities, with PBAE nanomedicine opening the door to safe and effective non-viral gene-
based therapies for pediatric CNS malignancies.  
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Table 4-S1. Gel permeation chromatography (GPC) characterization of polymers. The number-average 




Figure 4-S1. 1H NMR spectra of (A) acrylate-terminated and (B) end-capped polymers. Acrylate peaks 
(5.5-6.5 ppm) disappeared after end-capping. Polymer structures with labeled peaks are also shown.  
 
 
Figure 4-S2. Nanoparticle characterization before and after lyophilization. (A) Freshly prepared 
nanoparticles and nanoparticles resuspended in water after lyophilization were characterized for size and zeta 
potential using DLS (n = 3). (B) Functional performance of lyophilized nanoparticles were tested using 
lyophilized 447 nanoparticles to transfect BT-12 cells (n = 4); scale bar = 300 µm. Statistical significance 
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Abstract 
The CRISPR/Cas9 system is a powerful gene editing tool with wide-ranging applications, but the safe and 
efficient intracellular delivery of CRISPR components remains a challenge. In this study, we utilized 
biodegradable poly(beta-amino ester) nanoparticles to co-deliver plasmid DNA encoding Cas9 and sgRNA, 
respectively, to enable gene knockout following 1-cut edits as well as gene deletion following 2-cut edits. We 
designed a reporter system that allows for easy evaluation of both types of edits: gene knockout can be 
assessed by a decrease in iRFP fluorescence while deletion of an expression stop cassette turns on a red-
enhanced nanolantern fluorescence/luminescence dual reporter. Nanoparticles enabled up to 70% gene 
knockout due to small indels as well as 45% gain-of-function expression after a 600-bp deletion edit. The 
efficiency of 2-cut edits is more sensitive than 1-cut edits to Cas9 and sgRNA expression level. We 
demonstrate promising biodegradable nanoparticle formulations for gene editing. Our findings also provide 
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new insights into the screening and transfection requirements for different types of gene edits, which are 
applicable for designing non-viral delivery systems for the CRISPR/Cas9 platform.  
 
Introduction 
The CRISPR/Cas9 gene editing system consists of a short guide RNA (sgRNA) conferring target 
sequence specificity which complexes with the Cas9 endonuclease to enable site-specific DNA cleavage.1-3 
This could result in gene knockout following non-homologous end joining (NHEJ) or, in the presence of a 
repair template, gene knock-in through homology-directed repair (HDR). Targeting sgRNAs to two sites 
flanking a genomic region of interest can result in the complete removal of the gene segment following 
NHEJ, which could be important in the silencing of genetic elements with no open reading frames such as 
microRNAs or long noncoding RNAs.4, 5 CRISPR-mediated gene editing is contingent upon nuclear 
colocalization of both the Cas9 protein and sgRNA, and efficient intracellular delivery of CRISPR 
components remains a challenge. 
Viral vectors have been demonstrated to be effective for delivery but are more challenging to 
produce for both pre-clinical and clinical studies and restricted in cargo size. This is problematic as the Cas9 
gene is over 4 kb long, and delivery using adeno-associated viruses (AAVs; packaging capacity ~4.7 kb) 
sometimes require that different CRISPR components be packaged in separate viral particles, introducing 
complexity and potentially reducing efficacy.6, 7 Synthetic vectors are largely agnostic to cargo size, and several 
recent reports have demonstrated strategies for non-viral intracellular delivery of the CRISPR/Cas9 gene 
editing platform. These include nanoparticle delivery of Cas9 and sgRNA as a ribonucleoprotein (RNP) 
complex 8-12 or in the form of Cas9 mRNA and sgRNA.13, 14 Cas9 and sgRNA encoded in plasmid DNA is 
another delivery format for CRISPR gene editing. Plasmid DNA can be easily constructed using standard 
molecular cloning techniques to include different Cas9 structures,15, 16 multiplex sgRNA,17 and transcriptional 
targeting elements for cell type-specific editing.18 Furthermore, large libraries of biomaterials previously used 
for plasmid DNA delivery can be screened for CRISPR gene editing in a high-throughput manner19 to yield 
optimal formulations for gene editing in different applications.  
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It is important to note that delivery of CRISPR gene editing complexes in the form of plasmid DNA 
carries several potential safety concerns that must be taken into account when designing translationally 
relevant therapeutics. For example, there is a risk of plasmid DNA unintentionally integrating into the host 
genome, inducing insertional mutagenesis when highly active promoter elements are inserted into oncogenes 
or disrupt tumor suppressor genes.20 Furthermore, plasmid DNA encoding Cas9 and sgRNA increases the 
persistence time of CRISPR RNPs inside the cell, which has been shown to increase off-target editing.21 In 
this respect, delivery of CRISPR gene editing complexes in the form of mRNA or proteins has the benefit of 
low persistence time and reduced off-target editing. As effective non-viral delivery vehicles for mRNA or 
protein complexes are still somewhat lacking, however, CRISPR delivery in these formats can often suffer 
from low serum tolerance or poor in vivo efficacy.22 
Although several studies have reported strategies for non-viral CRISPR plasmid delivery,18, 23-26 most 
involve gene knockout applications using sgRNA designed to enable cleavage at a single site, and none to our 
knowledge have investigated the transfection requirements for gene deletion after cleavage at multiple sites. 
In this study, we designed a novel reporter system for easy detection of gene knockout following CRISPR-
mediated cleavage at one genomic site (1-cut edit) as well as gene deletion following DNA cleavage at two 
sites flanking a region of interest (2-cut edit). We used poly(beta-amino ester)s (PBAEs), a class of 
biodegradable cationic polymers that has been shown to be effective at plasmid DNA delivery,27 for 
intracellular delivery of plasmid DNA encoding both the Cas9 endonuclease and sgRNA, respectively, and 
demonstrate that these polymeric nanoparticles enable efficient 1-cut as well as 2-cut edits. Moreover, we 
systematically varied transfection parameters to probe the relationship between the expression of CRISPR 
components and the subsequent efficacy of different types of CRISPR-mediated edits. Our results provide 
important insights on the threshold gene expression levels required for 1- and 2-cut edits in easy-to-transfect 
as well as hard-to-transfect cell lines.  
 
Results 
Polymeric Nanoparticles for Gene Delivery 
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Polymer 446, which has been shown previously to be effective at plasmid DNA delivery to a variety 
of cells,28, 29 was used to transfect HEK-293T cells (Figure 5-1A). The newly developed branched polymer 
7,8-4-J11 enabled higher transfection efficacy in B16-F10 murine melanoma cells30 (Figure 5-S1) and was 
used to transfect these cells. Both polymers formed nanoparticles 100-200 nm in diameter with positive zeta 
potentials (12-25 mV) (Figure 5-1B). Transfection efficacy as assessed with a GFP reporter plasmid showed 
that >80% cells were transfected in both cell lines (Figure 5-1C). However, when geometric mean 
fluorescence was used to quantify expression, 293T cells achieved expression that was nearly 1 order of 
magnitude higher than B16 cells. 
 
Figure 5-1. PBAEs form nanoparticles with plasmid DNA and enable transfection in HEK293T and 
B16-F10 cells. (A) Polymer structures for 446 and 7,8-4-J11, which were used to transfect HEK-293T and 
B16,F10 cells, respectively. (B) Nanoparticle hydrodynamic diameter and zeta potentials as measured by 
















































































































































formulated at 30 w/w. (C) Transfection efficacy as measured by nanoparticles delivering GFP; 600 ng/well 
dose was used. Bars show average + SEM; N = 4. (D) TEM image of 7,8-4-J11 nanoparticles. Scale bar = 
100 nm. 
 
Gene Knockout Following 1-Cut Edits 
The efficiency of 1-cut edits was assessed in 293T cells constitutively expressing a destabilized form 
of GFP (GFPd2). GFPd2 is ubiquitinylated for rapid degradation and has a half-life of around 2 hours 
(compared to a half-life of 26 hours for wildtype GFP).31 This allows for rapid detection of gene knockout, 
which can be assessed by a decrease in GFP fluorescence following transfection with nanoparticles 
encapsulating two plasmids encoding the Cas9 endonuclease and a sgRNA targeting GFP, respectively. 
Nanoparticles co-delivering both plasmids enabled co-expression, generating 70% gene knockout as assessed 
by decrease in GFP fluorescence and 24% gene knockout as assessed by TIDE analysis of genomic DNA; 
formulations delivering either component alone had negligible effects (Figure 5-2A). A kinetic study revealed 
that gene knockout reached maximal levels on day 3 and was maintained for over 3 weeks (Figure 5-2B). 
The Surveyor® mutation detection assay was performed on cells treated with the combination nanoparticles 
or each component alone (Figure 5-2C) and confirmed that edits occurred only when both CRISPR 
components were delivered. Sanger sequencing revealed that most edits were single base-pair indels (Figure 
5-2D & 5-S2), which likely caused frameshift mutations and subsequent gene silencing.  
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Figure 5-2. 446 nanoparticles enable sustained and robust gene knockout in HEK-293T cells. (A) 
GFP knockout experiments in HEK-GFPd2 cells showed gene knockout only when plasmids coding for 
both components were co-delivered. Gene knockout was assessed by flow cytometry analysis of loss of GFP 
fluorescence and using TIDE analysis of Sanger sequencing data of genomic DNA of treated cells. N = 4, 
data presented as mean + SEM. (B) Gene knockout was sustained over the 3-week experiment. N = 4. (C) 
Surveyor mutation detection assay confirms genomic DNA cleavage in Cas9+/sgRNA+ treatment group. 
(D) Sanger sequencing of edited cells suggest that all edits were small indels. sgRNA targeting region 
highlighted in grey; PAM site highlighted in red.  
 
Gain-of-Function Edits after 2-Cut Stop Cassette Deletion 
We designed a reporter system based on the Ai9 mouse32 in which an expression stop cassette 
consisting of two SV40 terminators in series was placed upstream of a red-enhanced nanolantern (ReNL) 
fluorescence-luminescence dual reporter33 (Figure 5-3A). This CRISPR-stop expression cassette was cloned 
into a piggyBac transposon plasmid to facilitate genomic integration at high efficiency after co-transfection 
with a piggyBac transposase plasmid.34 A near-infrared fluorescent protein (iRFP670)35 was also incorporated 


































































(FACS). Thus, this system can be easily used to generate stably-expressing reporter cell lines for rapid read-
out of knockout as well as deletion mutations. 
 
Figure 5-3. Deletion of an expression stop cassette following 2-cut edits result in gain-of-function 
ReNL expression. (A) Schematic demonstrating that complete removal of the dual-SV40 stop cassette 
results in turning on of ReNL. (B) 2-cut gene deletion efficiency in cells treated with Cas9 and different 
sgRNAs as assessed by flow cytometry for turning on of ReNL fluorescence reporter (fluorescent reporter), 
gel electrophoresis-based genomic DNA analysis for total % editing (total edits), and % editing leading to 
ReNL expression (effective edits).  N = 4; data presented as mean + SEM. (C) Gel electrophoresis of PCR 
products of the genomic region surrounding the stop cassette show differential banding patterns in treated 
cells. (D) Fluorescence microscopy image of untransfected control cells and cells transfected with Cas9+sg1 
or Cas9+sg2+sg3 plasmids, respectively. Scale bar = 200 µm.  
The sgRNA sequence sg1, which was designed to remove both SV40 sequences (cut sites indicated 
by blue arrows in Figure 5-3A) via a 630 bp deletion, resulted in turning on of ReNL expression in nearly 
50% of cells when co-transfected with Cas9 plasmid. In contrast, sgRNA sequences sg2 or sg3 were designed 
to only remove one SV40 sequence and yielded negligible levels of ReNL expression. A plasmid containing 
both sg2 and sg3 sequences governed by two U6 promoters (sg2+sg3) also resulted in turning on of 
expression through the deletion of both SV40 sequences (Figure 5-3B). Gain of ReNL fluorescence 
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increased steadily after nanoparticle transfection, reaching a plateau at 3 days (Figure 5-S3). Therefore all 
experiments assessing the efficacy of 2-cut edits were performed at 3 days post-transfection. Genomic DNA 
of cells treated with each sgRNA was PCR amplified for the 800 bp region immediately surrounding the stop 
cassette. Gel electrophoresis of the PCR products revealed unique banding patterns for each sgRNA (Figure 
5-3C). For cells treated with sg1, a faint band around 150 bp corresponded to the deletion of around 630 bp 
and the complete removal of both SV40 sequences. The banding pattern for cells treated with sg2 or sg3 
showed a band around 500 bp indicating the removal of only one SV40 sequence (270 bp deletion). As flow 
cytometry results showed negligible ReNL expression in these cells, this demonstrates that the remaining 
SV40 sequence was sufficient for blocking transcription of the downstream ReNL sequence and that removal 
of both SV40 sequences (>450 bp deletion) was necessary for gain-of-function ReNL expression.  For cells 
treated with the combination sg2+sg3 plasmid, a faint band around 500 bp was observed, indicating that only 
one SV40 sequence was deleted in a fraction of edits, and a second band around 300 bp indicated that both 
SV40 sequences were deleted in other cells. Thus the level of editing that led to functional turning on of 
ReNL (termed Effective Edits in Figure 5-3B) was lower in these cells than the total editing level.  
RT-qPCR of cells transfected with combination Cas9 and sg1 plasmids revealed that Cas9 mRNA 
levels stayed relatively constant throughout all time points evaluated (Figure 5-4A). Western blots over the 
same time course showed that Cas9 protein levels steadily accumulated after transfection; expression levels 
peaked at day 2 and became virtually undetectable after 11 days (Figure 5-4B & 5-S6). sgRNA levels 
plateaued after 48 hours (Figure 5-4C), and the same trend was observed in ReNL mRNA levels after stop 
cassette removal (Figure 5-4D).  
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Figure 5-4. Expression kinetics of CRISPR components after co-delivery of Cas9 and sg1 plasmids in 
293T cells. Cas9 mRNA (A, red curve) and protein expression (A, blue curve; B) were measured over time 
in HEK-293T cells. (C) sgRNA and (D) ReNL mRNA expression kinetics. N = 2 for qRT-PCR experiments; 
N = 1 for western blots.  
Expression Thresholds for 1-Cut and 2-Cut Edits  
In order to assess the expression levels necessary to achieve 1-cut knockout edits and 2-cut gain-of-
function edits, respectively, we varied the dosage of plasmid DNA delivered in nanoparticles. In 293T cells 
engineered to express the CRISPR-stop gene construct, a GFP reporter was used to gauge transfection levels. 
Results showed that lowering the total DNA dose from 600 to 300 ng did not change the percentage of cells 
positively expressing GFP, but the geometric mean of fluorescence decreased by nearly 50% (Figure 5-5A). 
This effect can be observed in flow cytometry histograms as the 300 ng treatment yielded a larger population 
of cells with low GFP fluorescence compared to the 600 ng treatment (Figure 5-5D, left panel). Lowering 
total DNA dose significantly decreased levels of 2-cut deletion edits (Figure 5-5B) but did not significantly 
change the levels of 1-cut knockout edits (Figure 5-5C).  
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Figure 5-5. DNA dosage titration reveals different threshold expression requirements for 1-cut and 2-
cut edits. (A) DNA dosage decrease from 600 ng to 300 ng did not change the overall percentage of GFP-
positive cells but significantly decreased the geometric mean of expression. Dosage decrease significantly 
decreased the efficacy of 2-cut gene deletion edits (B) but not 1-cut iRFP knockout edits (C). Statistical 
significance determined by Holm-Sidak corrected multiple t tests; **p <  0.01, ***p < 0.001. Data presented 
as mean + SEM; N = 4. (D) Flow cytometry plots of cells treated with different DNA doses.  
 
We varied the total DNA dose delivered over a wider range in order to more thoroughly probe the 
effect of transfection efficacy on gene editing levels (Figure 5-6A). Plotting percent editing as a function of 
Cas9 mRNA expression levels revealed a logarithmic relationship for 1 cut edits (R2 = 0.9550) and a linear 
relationship for 2-cut edits (R2 = 0.9195). Transfection levels were further varied by manipulating cellular 
metabolic rates through incubation temperature variation (Figure 5-6B). Cells were transfected using the 
same nanoparticle formulation delivering the same DNA dose, after which they were either incubated at 
standard 37qC or treated with a transient “cold shock” via incubation at 30qC. Transfection efficacy, as 
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measured by Cas9 mRNA expression levels, increased significantly in cold-shocked cells; the same trend was 
observed for the level of 2-cut edits. Interestingly, cold shock treatment did not significantly change the level 
of 1-cut editing efficiency, which is consistent with the results from dose titration experiments.  
 
Figure 5-6. 1-cut and 2-cut edits in easy-to-transfect HEK-293T cells and hard-to-transfect B16-F10 
cells. (A) 1-cut edit efficiency correlated logarithmically with level of transfection as indicated by qRT-PCR 
measurement of Cas9 mRNA expression while 2-cut edit efficiency correlated linearly in 293T cells. (B) In 
B16 cells, transient cold shock after transfection significantly increased transfection efficacy (measured by 
Cas9 mRNA expression levels) as well as 2-cut editing efficiency but no significant change was seen in 1-cut 
editing efficiency as assessed by Holm-Sidak corrected multiple t tests; *p <  0.05, **p < 0.01. (C) B16 cells 
achieved minimal levels of 2-cut edits; 1-cut edits were lower compared to 293T cells, but the difference is 
smaller. Data in (B) and (C) shown as mean + SEM; N = 4. Differences in editing are observed in flow 
cytometry histograms (D-E). 
 
1-cut knockout of iRFP expression and 2-cut gain-of-function edits were also performed on B16-F10 
murine melanoma cells, which achieved lower levels of transfection compared to 293T cells. This was seen 
both when transfection was assessed using the geometric mean fluorescence of GFP expression when using a 














































































































(Figure 5-4 & 5-S5). The lower transfection level in B16 cells was reflected most notably in the results for 2-
cut editing, where the ReNL fluorescence observed in B16 cells was 1 order of magnitude lower than 293T 
cells (Figure 5-6C & 5-6D). Interestingly, the effect of lower transfection efficacy was less pronounced for 1-
cut iRFP knockout experiments. Although lower knockout levels were observed in B16 compared to 293T 
cells, the difference was much smaller (12% for B16 and 33% for 293T). Representative flow cytometry 
histograms showed that in 293T cells, 1-cut editing produced a new iRFP-negative peak while no such peak 
was observed in B16 cells, which showed an overall population shift of iRFP expression (Figure 5-6E). Since 
each cell very likely contains several copies of iRFP integrated into the genome,36 the peak in 293T cells 
indicates that 1-cut editing produced a small population of cells with complete iRFP knockout whereas the 
edited population in B16 cells lost some but not all copies of iRFP, and the incomplete iRFP knockout in this 
population resulted in a general shift in fluorescence. Combined, this validates results seen earlier with dose 
titration as well as temperature modulation experiments and confirms our hypothesis that 1-cut knockout 
edits require a lower expression threshold compared to 2-cut edits.  
Standard transfection reagents were also used to assess 2-cut editing efficiency. For both cell lines, 
the commercially available cationic polymer transfection reagent jetPrime® resulted in significantly lower 
editing levels than PBAE nanoparticles (Figure 5-S7). The commercially available cationic lipid transfection 
reagent LipofectamineTM 3000 enabled significantly higher editing than earlier generation linear PBAE 
polymer 446 in 293T cells but did not achieve significantly higher levels of editing than the newly developed 
next-generation branched PBAE polymer 7,8-4-J11in harder-to-transfect B16 cells. Notably, LipofectamineTM 
3000 caused significantly higher levels of cytotoxicity than both PBAE nanoparticle formulations, further 
demonstrating the advantage of using a biodegradable gene delivery system.  
A multiplex tRNA-gRNA expression system 
 To facilitate a simpler method for multiplex CRISPR editing, we designed a tRNA-gRNA expression 
system17 which utilizes the cell’s endogenous tRNA processing machinery to generate multiple sgRNAs 
(Figure 5-7A). Using a simple Golden Gate assembly strategy, we created a plasmid in which the targeting 
sequences and gRNA scaffolds of sg2 and sg3 are arrayed in tandem with pre-tRNA, with all components 
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governed by a single U6 promoter. Mature sgRNA is released after processing of the primary RNA transcript 
by tRNA-processing RNases. When transfected into cells alongside the Cas9 plasmid, this tRNA-gRNA 
plasmid enabled similar levels of 2-cut editing as the plasmid in which a U6 promoter governed each sgRNA 
(Figure 5-7B). This demonstrates that the multiplex tRNA-gRNA expression system effectively expressed 
both sgRNAs required for 2-cut editing.  
 
Figure 5-7. A tRNA-gRNA expression system for multiplex editing. (A) Schematic of a multiplex 
sgRNA expression system in which multiple tRNA-gRNA units are arrayed in tandem. The primary RNA 
transcript is processed by the endogenous tRNA machinery, releasing mature sgRNAs. (B) The tRNA-gRNA 
plasmid coding for sg2 and sg3 results in similar levels of 2-cut editing compared to a plasmid in which each 
sgRNA is governed by an individual U6 promoter (sg2+sg3). Statistical analysis was assessed by one-way 
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In this work, we demonstrated that both linear and branched PBAE nanoparticles co-delivering two 
DNA plasmids encoding Cas9 and sgRNA, respectively, can achieve efficient gene editing in both 1-cut 
knockout as well as 2-cut gene deletion applications. We created a novel CRISPR-stop reporter system that 
can be used to assess both types of edits: an iRFP fluorescent reporter can be silenced by indels after 1-cut 
edits while an expression stop cassette upstream of a ReNL reporter can be deleted using 2-cut edits for gain-
of-function ReNL expression. This expression cassette was cloned into a piggyBac transposon system and 
can be used to generate stably-expressing cell lines to investigate gene editing efficacy in vitro, eliminating the 
need to culture primary cells from the Ai9 mouse,37 on which our reporter system is based. This system 
further has the potential to be used as an in vivo reporter for live-animal imaging studies of effective 2-cut 
gain-of-function ReNL expression using the red-shifted luminescent properties of ReNL. Using two cell lines 
stably expressing this construct – easy-to-transfect HEK-293T and hard-to-transfect B16-F10 – we further 
investigated the transfection requirements for each type of gene editing. 
Several recent studies have demonstrated the feasibility of using polymeric nanoparticles, including a 
different PBAE formulation,38 to deliver CRISPR gene editing components in the form of plasmid DNA.18, 23-
25 All of these systems have exclusively investigated the use of 1-cut editing to achieve gene knockout, and 
none have presented a systematic study of the expression levels required for 1-cut and 2-cut edits. The 
removal of a gene segment requires sgRNA to target two sites flanking the region of interest and is 
significantly more difficult than 1-cut knockout edits.5 To date, only 3 studies have reported the use of non-
viral delivery vectors for 2-cut gene deletion by delivering Cas9 mRNA and sgRNA14 or RNP complexes12, 37, 
but plasmid delivery with polymeric nanoparticles to achieve this type of deletion has not been previously 
reported.  The use of DNA plasmids to encode Cas9 overcomes the manufacturing challenges of producing 
large scales of Cas9 mRNA or Cas9 protein, but the intracellular delivery and expression of exogenous DNA 
can be more challenging than the delivery of its downstream products. 
We evaluated two types of PBAE nanoparticles to encapsulate Cas9 and sgRNA plasmids for 
intracellular delivery of gene editing complexes. One of these was the well-published linear PBAE polymer 
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446 that has shown efficacy in multiple cell types and one was a newly developed branched PBAE polymer 
7,8-4-J11, and both were found to be useful for developing efficacious biodegradable nanoparticles for gene 
editing. The cationic polymer and anionic DNA self-assembled into nanoparticles 100-200 nm in diameter 
with positive zeta potentials (12-25 mV) (Figure 5-1). Previous reports have shown that high levels of co-
delivery can be achieved by pre-mixing plasmids prior to nanoparticle assembly.39 Using this strategy, we 
showed successful co-delivery of CRISPR plasmids that enabled robust 1-cut gene knockout (Figure 5-2). 
More importantly, we demonstrated a versatile gene deletion platform in which a single sgRNA targeting sites 
flanking the region of interest or a combination of sgRNAs targeting sites throughout the region of interest 
both resulted in successful removal of the entire gene segment (Figure 5-3). Successful deletion of up to 630 
bp could be easily visualized through the gain-of-function expression of a ReNL fluorescence/luminescence 
dual reporter. 
Evaluation of the expression kinetics of Cas9 and sgRNA revealed that Cas9 mRNA maintained at 
high levels throughout the time period tested (4.5-48 hr), while sgRNA expression reached peak levels at 48 
hr and plateaued out thereafter (Figure 5-4). The plateau observed in the expression of sgRNA (but not 
Cas9) in the short term is likely due to a difference in the expression kinetics of the U6 promoter driving 
sgRNA expression compared to the CMV promoter driving Cas9 expression. After a slower start, sgRNA 
rapidly accumulated inside the cell, eventually reaching a plateau at which point the expression of additional 
copies of sgRNA was likely balanced out by plasmid dilution through cellular division. This is a common 
pattern seen in transient gene expression induced by nanoparticle transfection,40 and we would expect 
expression levels of both Cas9 and sgRNA to drop at longer time points. Indeed, when we evaluated Cas9 
protein accumulation at longer time periods, we found that Cas9 protein levels declined steadily after 48 
hours and was virtually undetectable at 11 days post transfection (Figure 5-S6). Compared to delivery of 
CRISPR components in mRNA or protein form, where Cas9 protein expression decreased to below levels of 
detection after 3 days,21 the long Cas9 persistence time following plasmid DNA delivery raises concerns of 
off-target editing. It is important to note that the risk of off-target editing following synthetic nanoparticle 
delivery of CRISPR plasmids is significantly lower than when viral vectors are used for gene editing. 
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However, these risks can be further mitigated by using Cas9 variants41, 42 that have been engineered to have 
enhanced proofreading and lower off-target editing rates compared to wildtype Cas9. 
We further explored the transfection requirements for 1-cut and 2-cut edits by titrating the total 
DNA dose delivered. Interestingly, decreasing total DNA dose from 600 ng to 300 ng significantly decreased 
the level of 2-cut editing but did not affect the level of 1-cut edits (Figure 5-5). The same trend was observed 
when transfection efficiency was varied by treating transfected cells with a minor “cold shock” (Figure 5-6). 
A brief cold shock slowed the rate of cellular division, which enhanced protein accumulation in expressing 
cells and decreased the rate of plasmid DNA dilution in the cell population. This increased transfection 
efficiency and the level of 2-cut edits, which is consistent with previous reports using cold shock treatment to 
enhance the editing efficiency of ZFN-mediated gene disruption43 or CRISPR-mediated homology-directed 
repair.44 In contrast, cold shock treatment did not significantly change the efficiency of 1-cut edits. Recent 
studies on the enzyme kinetics of sgRNA-Cas9 RNPs have reported that while Cas9-sgRNA binding (k = 6.1 
s-1), target DNA binding (t1/2 = 4-40 s), and DNA cleavage events (k = 25-90 s-1) happen very quickly,45 the 
release of DNA cleavage products is extremely slow (t1/2 = 43-91 h),46 causing Cas9 to be virtually a single 
turnover enzyme. Taken together with these results, our data suggest that 2-cut edits have a much higher 
expression threshold than 1-cut edits because twice the number of DNA cleavage events are required for 
successful edits to occur.  
The expression thresholds of 1-cut and 2-cut edits have important implications on gene editing in 
different cell types. To demonstrate this, we compared the gene editing efficiency in easier-to-transfect HEK-
293T and harder-to-transfect B16-F10 cells. HEK-293T cells were derived from the parent HEK-293 human 
embryonic kidney cell line and further modified with the SV40 large T antigen.47 The SV40 large T antigen 
causes plasmid DNA containing the SV40 origin of replication to unwind inside HEK-293T cells, allowing 
for plasmid DNA replication and high levels of transfection.48 HEK-293T cells are widely known to be an 
easy-to-transfect cell line and are commonly used for the production of recombinant proteins49 and viral 
vectors50 after transient plasmid DNA transfection using commercially-available transfection reagents. B16-
F10 cells are a well-established murine melanoma cell line that are commonly used for tumor inhibition 
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studies.51 B16-F10 cells have been reported to be much more difficult to transfect with non-viral vectors,52 
which is in part due to significantly lower nanoparticle uptake levels (Figure 5-S8).  
Although the top nanoparticle formulation for each cell line achieved >80% transfection as assessed 
by percentage of total cells transfected, the level of expression, as assessed by the normalized geometric mean 
of expression of a GFP reporter, was 1 order of magnitude higher for 293T cells (Figure 5-1). This 
discrepancy was reflected in the level of 2-cut edits as B16 cells showed very minimal levels of ReNL 
expression after stop cassette deletion (Figure 5-6). In contrast, the difference in editing efficiency between 
the two cell lines was much smaller for 1-cut iRFP knockout (<3-fold difference compared to nearly 44-fold 
difference for 2-cut edits). These results further validate our hypothesis that the efficiency of 2-cut edits 
correlates more strongly with the level of DNA expression. Taken together, we have demonstrated that low 
levels of DNA transfection severely limit 2-cut editing efficiency. One solution for improving 2-cut editing 
efficiency is to deliver CRISPR components in RNP form, which we recently demonstrated enabled >40% 2-
cut editing in B16 cells after nanoparticle delivery of CRISPR RNPs targeted to excise the transcription stop 
cassette.53 This demonstrates that bypassing limits in DNA transfection altogether may be a viable way to 
achieve efficient 2-cut editing in hard-to-transfect cell lines such as B16 cells.   
Finally, we designed and implemented a tRNA-gRNA plasmid in which the expression of multiplex 
sgRNAs is governed under a single U6 promoter. The expression of two sgRNAs required for turning on of 
ReNL fluorescence in these tRNA-gRNA tandem repeats enabled similar levels of editing compared to that 
of a plasmid in which each sgRNA is governed by its own U6 promoter (Figure 5-7). This expression system 
has the advantage of ease of synthesis as upwards of 6 sgRNAs can be arranged in tandem using a single 
Golden Gate assembly reaction.17 More importantly, the tRNA-gRNA system reduces the need for repeating 
U6 promoters, enabling the use of a much smaller plasmid construct especially at high numbers of sgRNAs. 
Originally developed for use in rice plants,17 this system has also been adapted for use in yeast54 and 
zebrafish.55 To our knowledge, this is the first time it has been adapted for gene editing in mammalian cells.  
In summary, we have demonstrated that PBAE nanoparticles co-delivering plasmids encoding Cas9 
and sgRNA can achieve 1-cut knockout as well as 2-cut deletion edits. We designed a novel reporter system 
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whereby both modes of edits can be easily evaluated. 2-cut deletion events required much higher levels of 
transfection than 1-cut gene knockout edits, which we demonstrated by titrating the DNA dosage delivered, 
treating transfected cells with a transient cold shock, and comparing editing efficiencies in two cell lines with 
different transfection efficacy. The PBAE/DNA nanoparticles optimized here are promising for DNA-based 
non-viral gene editing. Further, the results presented herein have implications on the design and screening of 
next-generation non-viral delivery vehicles broadly for CRISPR/Cas9 gene editing.  
Materials and Methods 
Materials 
Small molecules used as monomers for polymer synthesis were obtained as follows: bisphenol A 
glycerolate (1 glycerol/phenol) diacrylate (B7; 411167), trimethylolpropane triacrylate (B8; 246808), 2-(3-
aminopropylamino)ethanol (E6; 09293), and N,N-diethyldiethylenetriamine (J11; 518832)56 were purchased 
from Sigma-Aldrich; 1,4-butanediol diacrylate (B4; 32780) and 4-amino-1-butanol (S4; A12680) were 
purchased from Alfa Aesar. The following plasmids were purchased from Addgene: hCas9 (41815),3 
gRNA_GFP-T2 (41820),3 pCAG-GFPd2 (14760),31 PBCAG-eGFP (40973),57 piRFP670-N1 (45457),35 
tubulin-ReNL_pcDNA3 (89530).58 PB-CMV-MCS-EF1a-RFP PiggyBac plasmid (PB512B-1) and PiggyBac 
transposase expression plasmid (PB200A-1) were purchased from System Biosciences. sgRNA gBlock 
sequences were purchased from IDT and the expression stop cassette was synthesized by SynBio-Tech 
(Monmouth Junction, NJ). Restriction enzymes and T4 DNA ligase for molecular cloning were purchased 
from New England BioLabs.  
Polymer Synthesis 
Polymer 446 was synthesized by reacting monomers B4 and S4 at a molar ratio of 1.1:1 at 90qC with 
stirring overnight. The B4-S4 polymer was dissolved in anhydrous THF at 167 mg/mL and added to 
monomer E6 (0.5 M in THF) at a 3:2 volume ratio and reacted at room temperature for 1 hour. The end-
capped polymer was washed in diethyl ether twice to remove unreacted monomers and oligomers. Solvents 
were removed in a vacuum desiccant chamber and polymer was dissolved in DMSO at 100 mg/mL, then 
stored at -20qC with desiccant. Polymer 7,8-4-J11 was synthesized by reacting monomers B7, B8, and S4 at an 
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overall vinyl:amine ratio of 2.2:1 and monomer concentration of 200 mg/mL in anhydrous DMSO at 90qC 
with stirring overnight; the acrylate monomer composition was 80% B7 and 20% B8 by mole fraction. 
Polymer end-capping and purification were done following the same procedure as polymer 446 but using 
monomer J11. 
Nanoparticle Characterization 
Nanoparticle hydrodynamic diameter was measured via dynamic light scattering (DLS) using a 
Malvern Zetasizer NanoZS (Malvern Instruments). Samples were prepared in 25 mM sodium acetate (NaAc), 
pH 5.0, and then diluted 1:6 in 150 mM PBS to determine hydrodynamic diameter in neutral, isotonic buffer. 
Zeta potential was measured by electrophoretic light scattering on the same instrument. Transmission 
electron microscopy (TEM) images were captured using a Philips CM120 (Philips Research) on 400 square 
mesh carbon coated TEM grids. Samples were prepared at a polymer concentration of 1.8 mg/mL at 30 w/w 
in 25 mM NaAc and 30 PL were allowed to coat TEM grids for 20 minutes. Grids were then rinsed with 
ultrapure water and allowed to fully dry before imaging.  
Cell Culture and Cell Line Preparation 
HEK-293T and B16-F10 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
ThermoFisher) supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were induced to 
constitutively express fluorescent protein constructs using the PiggyBac transposon/transposase system. The 
GFPd2 gene was cloned into the PB-CMV-MCS-EF1a-RFP plasmid using restriction enzyme cloning to 
create a PiggyBac transposon plasmid containing the GFPd2 gene. A sequence containing iRFP and 
transcription stop sequences was cloned into the PBCAG-eGFP plasmid backbone, and the ReNL gene was 
inserted into this plasmid using restriction enzyme cloning to create a PiggyBac transposon plasmid 
containing the iRFP-STOP-ReNL sequence (plasmid available on Addgene). Each transposon plasmid was 
co-transfected with the PiggyBac transposase plasmid into HEK-293T and/or B16-F10 cells using 
nanoparticles as described below. Fluorescent protein signal from DNA not integrated into the cell genome 
was allowed to fade over 5 passages, after which positive cells were isolated using fluorescence-assisted cell 
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sorting (FACS). Cells were further expanded for 3 more passages and sorted again to generate stably-
expressing cell lines. 
sgRNA Design and Preparation 
Single guide RNAs were designed using the CRISPR.mit.edu platform and ordered as gBlocks 
containing the U6 promoter, a unique 20 bp targeting sequence, and the duplex optimized sgRNA scaffold 
from IDT.5 The gBlocks were cloned into the pCAG-GFPd2 plasmid backbone using restriction enzyme 
cloning. sgRNA plasmids were transformed into DH5D competent E. coli (NEB), grown out overnight at 
37qC in 5 mL LB broth liquid cultures, and plasmid DNA was harvested using QIAprep miniprep kit 
(Qiagen). Plasmid DNA was characterized using NanoDrop spetrophotomoter (ThermoFisher) and sequence 
confirmed via Sanger sequencing before use in transfections. All sgRNA target sequences are listed in Table 
S2 and plasmids are available on Addgene. 
The gRNA-tRNA plasmid containing multiplex sgRNA constructs under a single U6 promoter was 
synthesized according to the protocol by Xie et al.17 Briefly, the pGTR construct containing a sgRNA scaffold 
sequence fused to a tRNA fragment  was synthesized as a gBlock from IDT and cloned into a plasmid via 
restriction enzyme cloning. This pGTR plasmid was used as the template DNA for PCR reactions which 
produced amplicons used in a hierarchical Golden Assembly process to generate a DNA fragment containing 
the tRNA-gRNA tandem arrays. This fragment was then cloned into a backbone plasmid containing a U6 
promoter via restriction enzyme cloning. The sequences for the pGTR sequence and PCR primers used are 
listed in Table S3.  
Transfection 
Cells were plated at 15,000 cells per well (HEK-293T) or 10,000 cells per well (B16-F10) in 100 PL 
complete medium in CytoOne 96 well plates (USA Scientific) and allowed to adhere overnight. Polymers and 
DNA were dissolved separately in 25 mM NaAc at the desired concentrations and then mixed together via 
pipetting. Nanoparticles were allowed to self-assemble for 10 minutes and then 20 PL of the nanoparticle 
solution was added per well for a final volume of 120 PL and 600 ng DNA per well unless otherwise noted; 
for transfection experiments using the CRISPR/Cas9 system, the Cas9 and sgRNA plasmids were used at a 
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1:1 weight ratio. For example, in order to formulate nanoparticles that would deliver 600 ng DNA per well in 
96 well plates at a polymer-to-DNA weight ratio of 60 (60 w/w), plasmid DNA was first dissolved in 25 mM 
NaAc at 0.06 mg/mL and polymer dissolved at 3.6 mg/mL. These two solutions were then mixed at a 1:1 
volume ratio and allowed to self-assemble into nanoparticles. The N/P ratio is 34.5 for the 446 60 w/w 
formulation and 14.5 for the 7,8-4-J11 30 w/w formulation (Calculation 5-S1). Nanoparticles were incubated 
with cells for 2 hours at 37qC, at which point the media and nanoparticles were removed and replaced with 
fresh complete media. Commercially available transfection reagents jetPrime® (Polyplus) and 
LipofectamineTM 3000 (ThermoFisher) were used as instructed by the manufacturer. For cold shock 
treatment, cells were transfected using standard transfection procedures and allowed to recover at 37qC after 
media change for 6 hours before being moved to 30qC. Cells were maintained at 30qC for 3 days, after which 
time they were moved back to 37qC.  
Transfection and gene editing efficacies were evaluated via flow cytometry using a BD Accuri C6 
flow cytometer (BD Biosciences). For nanoparticle screening experiments using a GFP reporter gene, 
transfection was quantified via two methods: 1) the percentage of cells positively expressing GFP when gated 
against untreated cells was reported as % positive expression; 2) the geometric mean fluorescence intensity in 
the FL1 channel (corresponding to GFP) for each treated well was normalized against that of untreated 
control wells, and the normalized geometric mean expression was reported. CRISPR knockout was quantified 
by normalizing the geometric mean fluorescence of treated wells to that of wells transfected with Cas9 
plasmid only. Gain of fluorescence was quantified as the percentage of cells positively expressing the 
fluorescent protein when gated against untreated control. Gene editing in gene deletion experiments was also 
assessed by luminescence readings using Promega Nano-Glo® Luciferase assay system (Promega) measured 
with a Synergy2 plate reader (Biotek) with open optics and normalized to untreated control. Cell viability was 
assessed 24 hours post-transfection using MTS CellTiter 96 Aqueous One cell proliferation assay (Promega). 
(N = 4 ± SEM). Unless otherwise stated, flow cytometry to assess gene editing efficacy was performed on 
day 3 post-transfection.  
Surveyor Assay 
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Genomic DNA from cells transfected with the combination Cas9-sgRNA plasmids and 
untransfected control were isolated using GeneJET genomic DNA purification kit (ThermoFisher). A 660 bp 
region flanking the predicted cut site was PCR amplified, and the PCR products were purified using 
QIAquick PCR purification kit. 400 ng of PCR amplicons were hybridized, and the Surveyor assay was 
performed using Surveyor® Mutation Detection Kit (IDT) following manufacturer’s instructions. The uncut 
and cut DNA products were then run on a 2% agarose gel stained with ethidium bromide in 
tris/borate/EDTA (TBE) buffer and imaged under UV light.  
TIDE Analysis to Assess 1-Cut Editing Efficiency 
 Sanger Sequencing was performed on purified PCR products from Surveyor assays. Sequencing data 
was uploaded to the online TIDE analysis tool (https://tide.deskgen.com/ 
) to assess 1-cut editing efficiency. 
Gel Electrophoresis Assay to Assess 2-Cut Editing Efficiency 
 Genominc DNA from 293T-CRISPR-stop cells transfected with Cas9 and sgRNA plasmids or 
untransfected controls were isolated as described above. An 800 bp region flanking the predicted cut sites was 
PCR amplified, and PCR products were purified as described above. Standard gel electrophoresis was 
performed on PCR products using 2% agarose gel stained with ethidium bromide in TBE buffer at 80V for 
45 minutes and imaged under UV light to reveal unique banding patterns. Band intensities were quantified 
using ImageJ image processing software and % editing was calculated using the method reported by 
Schumann et al.59 Edits where >450 bp were deleted were quantified as Effective Edits leading to gain-of-
function ReNL expression while all deletion edits were quantified as Total Edits for each sample.  
Sanger Sequencing to Detect Gene Editing 
PCR products for the Surveyor assay were cloned into plasmid vectors using NEB PCR Cloning kit 
and transformed into DH5D competent E. coli (NEB). 30 colonies were grown out in 5 mL liquid cultures 
overnight and the plasmid DNA was isolated and characterized by Sanger sequencing. 
qRT-PCR 
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Cells transfected with the combination Cas9-sgRNA plasmids in a 12-well plate were collected, and 
total RNA including small RNAs (<100 nt) were extracted using miRNeasy Mini kit (Qiagen). RNA was 
reverse transcribed using iScript cDNA synthesis kit (Bio-Rad), and qRT-PCR was run on a StepOnePlus 
Real-Time PCR system (ThermoFisher) using SYBR Green PCR Master Mix (ThermoFisher). The qPCR 
program is as follows: 95qC for 10 min.; 95qC 15 sec, 55qC 30 sec, and 60qC 30 sec for 40 cycles. Primers 
used for qRT-PCR are listed in Table S1. Results are shown as fold expression over E-actin. 
Western Blotting 
Transfected cells in 12-well plates were lysed in a solution of 1X RIPA buffer and 1X 
Protease/Phosphatase Inhibitor Cocktail (ThermoFisher). The lysate was cleared by centrifugation, protein 
concentration was determined using Pierce Micro BCA assay (ThermoFisher), and samples were denatured in 
Laemmli sample buffer (Bio-Rad) in the presence of DTT. 50 Pg proteins were loaded into 4-15% TGX 
Precast Protein Gels (Bio-Rad). Proteins were then transferred to a PVDF membrane using a Pierce Power 
Blotter (ThermoFisher). Membranes were blocked in 5% non-fat milk for 1 hr at RT and probed with 
primary antibodies against Cas9 (Cell Signaling Technologies 14697; 1:500) or E-actin (Abcam ab8226; 
1:10,000) at 4qC overnight. Secondary antibodies were applied at RT for 1 hr (m-IgGK BP-HRP; Santa-Cruz 
Sc-516102; 1:1000). The membrane was developed with Amersham ECL Western Blotting Detection Reagent 
(GE Healthcare) and imaged using an ImageQuant LAS 4000 CCD imager (GE Healthcare). Semi-
quantitative analysis of Cas9 protein expression was done by calculating band intensities using ImageJ image 
analysis software and normalizing the intensity of Cas9 bands to that of E-actin.  
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Figure 5-S1. GFP transfection screen results for B16-F10 cells. Fluorescence microscopy images (A) and 
flow cytometry results (B) show that branched PBAE polymer 7,8-4-J11 (30 w/w) transfects B16 cells more 
efficiently than canonical linear PBAE polymer 446 (60 w/w). Data presented as mean + SEM; N = 4. Scale 





Figure 5-S2. TIDE quantification of indel frequencies. Sanger sequencing data of the genomic DNA of 
HEK-GFP cells treated with nanoparticles delivering CRISPR plasmids were quantified by TIDE analysis. N 










































































































Figure 5-S3. ReNL expression time course after 2-cut edits in HEK cells. HEK cells were transfected 
on day 0 and gain of ReNL expression was monitored on selected days to determine the expression timeline 




Figure 5-S4. Microscopy images of ReNL gain of expression. 2-cut CRISPR cleavage with sg1 or 
combination of sg2+sg3 turn on expression of ReNL by removal of two SV40 polyA sequences. Scale bar = 
200 μm. 





























Figure 5-S5. Expression kinetics of CRISPR components in B16 cells. mRNA expression levels of 
sgRNA (A) and ReNL (B). Cas9 mRNA (C, red curve) and protein (C, blue curve; D) expression levels 
over time. N = 2 (data shown as mean ± SEM) for qRT-PCR experiments; N=1 for western blots. 
 
Figure 5-S6. Long-term Cas9 accumulation in 293T cells. Western blotting was performed on indicated 
days after transfection of Cas9 and sgRNA plasmids in HEK-293T cells and Cas9 protein expression levels 
were quantified as fold expression over 𝛃-actin based on image analysis of band intensities (n=1). 
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Figure 5-S7. Comparison to commercial transfection reagents. Gain of expression from 2-cut edits and 
viability of cells using commercial reagents and PBAEs in (A) 293T and (B) B16 cells as measured by ReNL 
luminescence. Data presented as mean + SEM; N=4. Statistical significance assessed by one-way ANOVA 
with Dunnett post-hoc tests as compared to the PBAE treated group (446 or J11, respectively); *p < 0.05, 
****p < 0.0001 
 
 
Figure 5-S8. Nanoparticle uptake analysis in B16 and 293T cells. Flow cytometry analysis of cellular 
uptake of nanoparticles encapsulating 20% Cy5-labeled DNA. Data shown as mean + SEM; N=4. Statistical 









































































































Target Sequence Notes 
GFP FWD: CTGGTCGAGCTGGACGGCGACG 
REV: CACGAACTCCAGCAGGACCATG 





Amplicon size: 755 bp 
hCas9 FWD: GGAGTTGACGCCAAAGCAATCC 
REV: AGATTTAAAGTTGGGGGTCAGCC 




Amplicon size: 147 bp 
sgRNA1 
FWD: ACATTATACGGTTTCAGAGC 




Amplicon size: 250 bp 




Amplicon size: 218 bp 
Table 5-S1. PCR primer sequences. 
 
Plasmid Name Addgene ID Description 
PB-iRFP-STOP-ReNL 113965 Piggybac transposon plasmid CRISPR gene deletion 
activatable fluorescence. Constitutive iRFP670 under EF1A 
promoter, CMV promoter with two SV40 polyA followed by 
red-enhanced nanolantern (ReNL) 
sg1 113966 Single short guide RNA targeting 
GTATAGCATACATTATACG 
sg2 133967 Single short guide RNA targeting 
TACCACATTTGTAGAGGTT 
sg3 133968 Single short guide RNA targeting 
CAATGTATCTTATCATGTC 




sg2+sg3 133970 Double short guide RNA targeting 
TACCACATTTGTAGAGGTT & 
CAATGTATCTTATCATGTC 
sgiRFP1 133972 Single short guide RNA targeting 
GATCGAGTTCGAGCCTGCGG in iRFP670 sequence 
sgiRFP2 133973 Single short guide RNA targeting 
GCGCGTTCTTTGGACGCGA in iRFP670 sequence 
sgiRFP3 133974 Single short guide RNA targeting 
CGTGATGTTGTACCGCTTC in iRFP670 sequence  
Table 5-S2. Plasmids deposited with Addgene 
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SpeI restriction enzyme site 
HindIII restriction enzyme site 
gRNA scaffold 
pre-tRNA 
AGTTAGTTtctagaACAAAGCACCAGTGG tRNA-start_F primer 
XbaI restriction enzyme site 
GAACCTCTACAAATGTGGTA sg2 protospacer sequence; 
overlapping base pairs used in 
Golden Gate primers 
TAGGTCTCCACAAATGTGGTAGTTTTAGAGCTAGAA sg2_F primer 
ATGGTCTCATTGTAGAGGTTCTGCACCAGCCGGGAA sg2_R primer 
GCAATGTATCTTATCATGTC sg3 protospacer sequence; 
overlapping base pairs used in 
Golden Gate primers 
TAGGTCTCCTCTTATCATGTCGTTTTAGAGCTAGAA sg3_F primer 
ATGGTCTCAAAGATACATTGCTGCACCAGCCGGGAA sg3_R primer 
CAATGTATaagcttAAAAAAAAAAGCACCGACTCG gRNA-end_R primer 
HindIII restriction enzyme site 
Table 5-S3. DNA and primer sequences used to generate multiplex tRNA-gRNA plasmid. The 
pGTR sequence was cloned into a backbone plasmid via restriction enzyme cloning using SpeI and HindIII. 
The pGTR plasmid was then used as the PCR template for amplifying gRNA-tRNA sequences for Golden 
Gate assembly. To synthesize a multiplex plasmid containing both sg2 and sg3, PCR amplicons were 
generated using the following pairs of primers: tRNA-start_F + sg2_R (amplicon 1); sg2_F + sg3_R 
(amplicon 2); sg3_F + gRNA-end_R (amplicon 3). Amplicons 1-3 were then purified, ligated by Golden Gate 
assembly, and cloned into a backbone vector containing a single U6 promoter using restriction enzyme 
cloning with XbaI and HindIII. 
 
Calculation 5-S1. N-P ratios of PBAE/DNA nanoparticles. Gel permeation chromatography was used to 
measure the molecular weight of polymers 446 and 7,8-4-J11, respectively. The number averaged molecular 
weight (MN) was 5935 Da for 446 and 6943 Da for 7,8-4-J11. Using polymer MN and the molecular weight of 
individual monomers, the nitrogen (N) weight fraction was calculated to be 0.055 for 446 and 0.046 for 7,8-4-
J11. The average phosphate (P) weight fraction for DNA was calculated to be 0.095. Taken together, 446 
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Abstract 
Functional co-delivery of plasmid DNA and RNA oligonucleotides in the same nanoparticle system is 
challenging due to differences in their physical properties as well as their intracellular locations of function. In 
this study, we synthesized a series of reducible branched ester-amine quadpolymers (rBEAQs) and 
investigated their ability to co-encapsulate and deliver DNA plasmids and RNA oligos. The rBEAQs are 
designed to leverage polymer branching, reducibility, and hydrophobicity to successfully co-complex DNA 
and RNA in nanoparticles at low polymer to nucleic acid w/w ratios and enable high delivery efficiency. We 
validate the synthesis of this new class of biodegradable polymers, characterize the self-assembled 
nanoparticles that these polymers form with diverse nucleic acids, and demonstrate that the nanoparticles 
enable safe, effective, and efficient DNA-siRNA co-delivery as well as non-viral CRISPR-mediated gene 




The introduction of exogenous genetic material into mammalian cells has been widely used in the 
laboratory to modulate gene expression and induce cellular reprogramming,1 differentiation,2-3 and 
programmed cell death.4-6 Recently, these technologies have begun moving into the clinic and mark the 
beginning of a new paradigm for genetic medicine.7-8 Traditional gene therapies involve the delivery of DNA, 
often in the form of plasmids or mini-circle DNA9, into target cells. RNA oligonucleotides such as short 
interfering RNA (siRNA) can enable target-specific gene silencing,10-11 and single guide RNAs (sgRNAs) 
complex with Cas9 endonucleases to achieve site-specific gene editing via the CRISPR/Cas9 system.12-13 The 
biological functionality of these nucleic acids depend heavily on their successful intracellular delivery.14 
Although non-viral vectors delivering either plasmid DNA or siRNA have been widely reported, very 
few studies have been able to functionally co-deliver both in the same nanoparticle system. This can be 
challenging as DNA and RNA oligonucleotides are vastly different in size (5,000 bp vs. 20 bp) and 
stiffness.15-16 In this study, we synthesized a series of reducible branched ester-amine quadpolymers (rBEAQs) 
and investigated their ability to form nanoparticles that could functionally co-deliver plasmid DNA and RNA 
oligonucleotides. The rBEAQs were designed based on recent studies that have demonstrated that 
hyperbranched cationic polymers are superior than their linear counterparts at DNA17-20 and 
oligonucleotide21-22 delivery in multiple polymeric vector systems. The branched polymer architecture could 
increase the charge density of each polymer molecule, allowing for stronger nucleic acid binding affinity.23 
Disulfide bonds are another useful functionality as they can enable environmentally-triggered cargo release in 
the reducing cytosolic environment. They can be incorporated into delivery vectors as polymer side chains,24 
crosslinking moieties between polymer chains,25 and part of the polymer backbone26, and have been used 
successfully in several siRNA delivery systems. Finally, increasing polymer hydrophobicity has been shown to 
improve nanoparticle stability and increase DNA27 as well as siRNA delivery efficacy.28 
Using a facile one-pot Michael addition reaction, we were able to tune the reducibility and 
hydrophobicity of the polymers by simply adjusting the monomer ratios. We found that the nucleic acid 
binding affinity, release kinetics, nanoparticle uptake, and functional nucleic acid delivery could be modulated 
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in a highly controlled manner. Our nanoparticle system enabled up to 77% DNA transfection and 66% 
siRNA-mediated knockdown. More importantly, delivery of Cas9 DNA and sgRNA enabled 40% gene 
knockout, further highlighting the robustness of this co-delivery system. 
 
2. Materials and Methods 
2.1 Materials 
2-Hydroxyethyl disulfide (CAS 1892291), triethylamine (CAS 121448), acryloyl chloride (CAS 
814686), bisphenol A glycerolate (1 glycerol/phenol) diacrylate (B7; CAS 4687949), trimethylolpropane 
triacrylate (B8; CAS 15625895), 2-(3-aminopropylamino)ethanol (E6; CAS 4461396), L-buthionine-
sulfoximine (CAS 83730534), and solvents were purchased from Sigma Aldrich (St. Louis, MO). 4-Amino-1-
butanol (S4; CAS 133251005) was purchased from Alfa Aesar (Tewksbury, MA). Plasmids pCAG-GFPd2 
(14760) and piRFP670-N1 (45457) were purchased from Addgene (Cambridge, MA). PB-CMV-MCS-EF1a-
RFP PiggyBac plasmid (PB512B-1) and PiggyBac transposase expression plasmid (PB200A-1) were 
purchased from System Biosciences (Palo Alto, CA). Negative control siRNA (1027281) was purchased from 
Qiagen (Germantown, MD). GFP siRNA targeting the sequence 5’-GCA AGC TGA CCC TGA AGT TC-3’ 
(P-002048-01) was purchased from Dharmacon (Lafayette, CO). Cy5-labeled siRNA (SIC005) was purchased 
from Sigma Aldrich.  
2.2 Polymer Synthesis  
Bioreducible monomer 2,2-disulfanediylbis(ethane-2,1-diyl) diacrylate (BR6) was synthesized using a 
method similar to Kozielski  et al.26 Briefly, 2-hydroxyethyl disulfide was acrylated with acryloyl chloride (1:1.1 
molar ratio in dichloromethane) in the presence of excess triethylamine. After filtering out the precipitate, the 
product was washed with water, dried with sodium sulfate, and the solvent was removed by rotary 
evaporation. 
For polymer synthesis, monomers BR6, B7, B8, and S4 were dissolved in anhydrous 
dimethylsulfoxide (DMSO) according to the B monomer molar ratios listed in Table S1 for an overall vinyl: 
amine ratio of 2.2:1 at a concentration of 150 mg/mL. After overnight reaction at 90qC with stirring, the 
 183 
polymers were end-capped by reacting with monomer E6 (0.2 M final concentration in DMSO) at room 
temperature for 1 hr. The end-capped polymers were purified by 2 diethyl ether washes, after which 
remaining solvent was removed in a vacuum chamber. Polymers were dissolved in DMSO at 100 mg/mL and 
stored in aliquots at -20qC under desiccant. 
2.3 Yo-Pro-1 Iodide Nucleic Acid Binding Assay 
Yo-Pro-1 iodide fluorescent dye (Invitrogen) was mixed with siRNA at a final concentration of 0.5 
PM Yo-Pro and 0.5 PM scRNA in 25 mM sodium acetate (NaAc, pH 5.0). Polymers were dissolved in NaAc, 
and 25 PL polymer solution was mixed with 75 PL RNA/Yo-Pro solution per well in 96 well black bottom 
plates. The solutions were incubated at 37qC for 20 minutes before fluorescence readings were taken on a 
fluorescence multiplate reader (Biotek Synergy 2). To measure siRNA binding in reducing conditions over 
time, polymer concentration was set at the lowest concentration at which each polymer achieved >80% 
quenching. The polymer/siRNA/Yo-Pro solution was mixed with 10 PL glutathione solution (final 
concentration 5 mM) and incubated at 37qC. Fluorescence readings were taken at the indicated time points. 
2.4 Polymer Characterization: NMR and GPC 
Polymer structure was characterized by nuclear magnetic resonance spectroscopy (NMR) via 1H 
NMR in CDCl3 (Bruker 500 MHz) and analyzed using TopSpin 3.5 software. To measure polymer molecular 
weight and polydispersity, polymers were dissolved in BHT-stabilized tetrahydrofuran with 5% DMSO and 
1% piperidine, filtered through a 0.2 μm PTFE filter, and measured with gel permeation chromatography 
against linear polystyrene standards (Waters, Milford, MA). 
2.5 Gel Retardation Assay 
Nanoparticles were synthesized by dissolving polymer and siRNA separately in NaAc buffer at the 
desired concentrations. The solutions were mixed at a 1:1 volume ratio and nanoparticles were allowed to 
self-assemble at room temperature for 10 minutes, after which, nanoparticles were incubated in the presence 
of 5 mM glutathione or 150 mM PBS at 37qC. Samples were taken at various time points and frozen at -80qC 
to stop the reaction. For gel retardation assays of R6,7,8_64 nanoparticles co-encapsulating plasmid DNA 
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and siRNA, nucleic acids were first pre-mixed at 1:1 volume ratio and then mixed with polymer to allow for 
nanoparticle self-assembly. Polymer dosage was varied from 10 w/w to 0 w/w (free nucleic acids). Samples 
were loaded onto a 1% agarose gel using 30% glycerol as loading buffer. Gel electrophoresis was performed 
in TAE buffer at 100 V for 15 min, after which the gel was imaged under UV. 
2.6 Nanoparticle Characterization 
Nanoparticles were prepared as described above and diluted in 150 mM PBS to determine particle 
size and surface charge in neutral isotonic buffer. Hydrodynamic diameter was measured via nanoparticle 
tracking analysis at 1:500 dilution in PBS using a NanoSight NS300, while zeta potential was measured at 1:6 
dilution in PBS via electrophoretic light scattering on a Malvern Zetasizer NanoZS (Malvern Panalytical). To 
characterize nanoparticle stability over time in physiological conditions, nanoparticle size was also measured 
at 1:6 dilution in 10% serum-containing cell culture medium once per hour for 9 hours using a Malvern 
Zetasizer Pro (Malvern Panalytical). Transmission electron microscopy (TEM) images were acquired with a 
Philips CM120 (Philips Research). Nanoparticles were prepared at a polymer concentration of 1.8 mg/mL in 
25 mM NaAc, and 30 PL were added to 400-square mesh carbon coated TEM grids and allowed to coat grids 
for 20 min. Grids were then rinsed with ultrapure water, counterstained with uranyl acetate (0.5% in distilled 
water), and allowed to fully dry before imaging. 
2.7 Cell Culture and Cell Line Preparation 
HEK-293T human embryonic kidney and Huh7 human hepatocellular carcinoma cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM; ThermoFisher) supplemented with 10% FBS and 1% 
penicillin/streptomycin. A PiggyBac transponson/transposase system was used to generate cell lines 
constitutively expressing a destabilized form of GFP (GFPd229). The GFPd2 PiggyBac transposon plasmid 
was created by inserting the GFPd2 gene into the PB-CMV-MCS-EF1a-RFP PiggyBac plasmid through 
standard restriction enzyme cloning. The transposon plasmid was then co-transfected with the PiggyBac 
transposase expression plasmid into cells using the method described below. Cells underwent 2 transfections 
and were then grown out for 5 passages to allow fluorescence signal from transient transfections to fade. 
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Positively-expressing cells were isolated via fluorescence-assisted cell sorting (FACS), and colonies grown 
from single cells were grown out to establish stably expressing cell lines.  
2.8 Transfection 
Cells were seeded onto 96 well tissue culture plates at a density of 15,000 cells per well in 100 PL 
complete medium and allowed to adhere overnight. Nanoparticles were formed immediately prior to 
transfection as described above. For experiments delivering siRNA only, each nanoparticle condition was 
formulated with a scrambled control RNA (scRNA) or an siRNA targeting GFP (siGFP) with a final RNA 
concentration of 100 nM per well. For experiments co-delivering siRNA and DNA, nanoparticles were 
formulated with a final dose of 200 ng DNA per well in addition to 100 nM scRNA or siGFP, respectively, 
for a final total nucleic acid dose of 400 ng per well. Nanoparticles co-encapsulating DNA and siRNA were 
formed by pre-mixing the nucleic acids at 1:1 volume ratio in NaAc buffer prior to mixing with polymer 
solution. Prior to the addition of nanoparticles, cell culture medium was replaced with 100 PL serum-free 
media. 20 PL of nanoparticles were added per well and incubated with cells for two hours, at which point the 
nanoparticle/media mixture was replaced with fresh complete media. Knockdown of GFPd2 fluorescence 
was assessed via flow cytometry one day post transfection using a BD Accuri C6 flow cytometer (BD 
Biosciences). Knockdown was quantified by normalizing the geometric mean of fluorescence of wells treated 
with siGFP to that of wells transfected using the same nanoparticle formulation delivering scRNA. For co-
codelivery experiments, DNA transfection was quantified as the percentage of cells positively expressing 
iRFP when gated against untreated controls. (N = 4 +/- SEM.) 
Transfections in which sodium bicarbonate (NaHCO3) was used to increase nanoparticle pH were 
done by forming nanoparticles in acidic NaAc buffer as previously described and then mixing with 50 
mg/mL NaHCO3 buffer (pH 9) at 1:1 volume ratio before adding to cells. Transfections using commercially-
available non-viral transfection reagents Lipofectamine 2,000TM, Lipofectamine 3,000TM (ThermoFisher), and 
jetPrime® (Polyplus) were performed according to manufacturer instructions. 25 kD bPEI was used at 1 
w/w in DNA-siRNA co-delivery experiments.  
2.9 Cellular Uptake and Viability 
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Cy-5 labeled siRNA was diluted 1:5 in unlabeled siRNA and used to formulate nanoparticles as 
described above. Nanoparticles were added to cells in serum-free media and incubated for two hours, at 
which point cells were washed once with PBS and detached via trypsinization. Cells were further washed with 
heparin (50 Pg/mL in PBS) to remove nanoparticles adhering to cells, resuspended in FACS buffer (2% FBS 
in PBS), and nanoparticle uptake was quantified by flow cytometry. Cell viability was assessed 24 hr post-
transfection using MTS CellTiter 96 Aqueous One cell proliferation assay (Promega) following 
manufacturer’s instructions. Cell viability of treated cells were normalized to that of untreated cells; N = 4 
+/- SEM.  
2.10 Glutathione Inhibition with L-buthionine-sulfoximine (BSO) 
L-buthionine-sulfoximine (BSO) was dissolved in cell culture media at 2,000 PM. Cells were allowed 
to settle for three hours after plating, at which time 50 PL of media was replaced by 50 PL BSO solution for 
1,000 PM final BSO concentration, which has been shown to effectively inhibit intracellular glutathione 
levels.30 Cells were incubated for 24 hr with complete medium containing 1,000 PM BSO, which was replaced 
with serum-free BSO medium immediately before transfection. After two hours incubation with 
nanoparticles, cells were replenished with fresh BSO-containing complete medium and incubated for 24 hr, at 
which point cell viability and flow cytometry assays were performed.  
2.11 Confocal Microscopy 
 HEK-293T cells were plated on Nunc Lab-Tek 8 chambered borosilicate coverglass well plates 
(155411; Thermo Fisher) at 30,000 cells/well one day prior to transfection in 300 µL phenol red free DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin. R6,7,8_64 nanoparticles were prepared as 
described above at 10 w/w ratio using pre-mixed Cy3 labeled siRNA and Cy5 labeled plasmid DNA at a 1 
w/w ratio of nucleic acids. Cy5 labeled plasmid DNA was prepared as previously described31-32 and mixed at 
4 w/w ratio with unlabeled eGFP-N1 plasmid DNA. Nanoparticles were then diluted into media and added 
to cells at a total nucleic acid dose of 1,000 ng/well and incubated for two hours. Prior to imaging, cells were 
then stained with Hoechst 33342 at a 1:5,000 dilution for nuclei visualization. Images were acquired over a 
19,660 µm area at Nyquist limit resolution using a Zeiss LSM 780 microscope with Zen Blue software and 
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63x oil immersion lens. Specific laser channels used were 405 nm diode, 488 nm argon, 561 nm solid-state, 
and 639 nm diode lasers. Laser intensity and detector gain settings were maintained across all image 
acquisition. 
2.12 CRISPR Gene Editing 
 The template used for in vitro transcription of sgRNA targeting GFP was synthesized as a gBlock 
from IDT (sequence listed in Table S2). In vitro transcription was performed using a MEGAshortscript T7 
Transcription kit (Invitrogen) according to manufacturer’s instructions, and the sgRNA product was purified 
using MEGAclear Transcription Clean-up kit (Invitrogen). Cas9 plasmid DNA (41815)12 was purchased from 
Addgene and amplified by Aldeveron (Fargo, ND). For co-delivery transfections, DNA and sgRNA were 
delivered using R6,7,8_64 nanoparticles as described above. Gene knockout was assessed using flow 
cytometry 5 days post-transfection unless otherwise noted. 
2.13 Statistics 
 Prism 6 (Graphpad, La Jolla, CA) was used for all statistical analyses and curve plotting. Statistical 
tests were performed with a global alpha value of 0.05. Unless otherwise stated, absence of statistical 
significance markings where a test was stated to have been performed signified no statistical significance. The 
statistical test used and the number of experimental replicates were listed in the captions for each figure. 
Statistical significance was denoted as follows: *p<0.05; **p<0.01, ***p<0.001, ****p<0.0001.  
3. Results and Discussion 




Figure 6-1. Monomer structures and proposed mechanism for polymer function. (A) B and S 
monomers were co-polymerized to form acrylate-terminated base polymers, which were then (B) end-capped 
with monomer E6. (C) These polymers self-assembled into nanoparticles with anionic nucleic acids and (D) 
partially degraded at reducible linkages in the reducing cytosolic environment, allowing for intracellular cargo 
release.  
Polymers were synthesized following a facile one-pot Michael addition reaction in which acrylate 
monomers BR6 and B8 were copolymerized with amine-containing monomer S4 (Scheme 6-1). After end-
capping with monomer E6, this class of polymers is referred to as R6,8_N, where N denotes the branching 
B8 monomer content in the polymer backbone (i.e. R6,8_20 contains 20% B8). In the polymer series 
containing the additional diacrylate monomer B7, polymers are referred to as R6,7,8_M, where M denotes the 
B7 monomer content in the polymer backbone. For acrylate-terminated base polymer synthesis, B and S 
monomers were dissolved in anhydrous DMSO at 150 mg/mL (monomer concentrations >400 mg/mL 
resulted in complete gelation), and step-wise polymerization reaction was allowed to proceed overnight at 
90qC with stirring. The chemical structures of base polymers were determined via NMR spectroscopy, which 
verified that the polymers were acrylate terminated by three distinct acrylate peaks at 5.5-6.5 ppm (Figure 6-
S1). Polymer end-capping with monomer E6 was performed at room temperature for 1 hr and confirmed by 
 189 
the disappearance of these peaks. Molecular weight data was obtained from GPC analysis, which showed that 
with increasing B8 content, both Mn and Mw values generally increased (Table 6-1). For R6,7,8-4-6 polymers, 
for which B8 content was fixed at 20%, molecular weight did not change significantly with varying B7 
content, suggesting that molecular weight is largely controlled by polymer branching and crosslinking effects 
contributed by triacrylate monomer B8.  
  
Table 6-1. Molecular weight data from GPC characterization and monomer composition calculated 
from 1H NMR spectra. 
3.2 siRNA Delivery: Gene Knockdown, Cellular Uptake, and Cytotoxicity 
R6,8-4-6 polymers were used to deliver siRNA targeting GFP (siGFP) in HEK-293T cells stably 
expressing a destabilized form of GFP with short half-life (GFPd2).29 At 100 nM siRNA dose and 180 
polymer-siRNA w/w ratio, R6,8_20 achieved 75% knockdown with negligible cytotoxicity (Figure 6-1A). All 
branched polymers in the R6,8_N series with the exception of R6,8_80 achieved significantly higher 
knockdown than the linear polymer (R6,8_0). Knockdown levels peaked with R6,8_20 and R6,8_40 (Figure 
6-S2), and the same trend was observed for nanoparticle uptake (Figure 6-1B). Previous studies have 
demonstrated that nanoparticle uptake and transfection efficacy increased with increasing polymer molecular 
weight.33-34 This was not the case in our polymer system as R6,8_60 and R6,8_80 had the highest molecular 
weight but achieved relatively poor knockdown. This could in part be due to the fact that increasing polymer 
branching resulted in lower cell viability caused by decreasing reducible BR6 monomer content. Indeed, when 
Polymer 
Name Mn Mw PDI
Monomer Fraction in Polymer
BR6 B7 B8
R6,8-4-6
R6,8_0 2,224 2,682 1.21 1.00 -- --
R6,8_20 3,168 4,038 1.27 0.75 -- 0.25
R6,8_40 4,050 5,896 1.46 0.54 -- 0.46
R6,8_60 4,943 9,949 2.01 0.36 -- 0.64
R6,8_80 4,675 8,728 1.87 0.23 -- 0.77
R6,7,8-4-6 
(20% B8)
R6,7,8_16 4,511 7,616 1.69 0.62 0.17 0.21
R6,7,8_40 4,570 7,435 1.63 0.41 0.40 0.19
R6,7-8_64 4,438 7,066 1.59 0.17 0.63 0.20
 190 
cells were pre-treated with L-buthionine-sulfoximine (BSO) to inhibit cellular production of glutathione, the 
main intracellular reducing agent,35 nanoparticle-mediated cytotoxicity significantly increased (Figure 6-1C). 
This increased toxicity was beyond the additive effects of either nanoparticle or BSO treatment alone, 
indicating that the cell’s inability to reduce disulfide bonds after glutathione blockade induced higher levels of 
cell death and confirming our hypothesis that polymer reducibility attenuated cytotoxicity by enabling them to 
rapidly degrade to relatively non-toxic oligomers. Thus, the bio-reducibility of the rBEAQ nanoparticles is 
designed to both enable environmentally-triggered release upon entering the cytosol and as a mechanism to 
limit potential cytotoxicity of the branched polymers by quickly breaking them down into smaller 
components once they reach their target inside the cell. 
 
Figure 6-2. R6,8-4-6 polymers enable efficient intracellular siRNA delivery. (A) Gene knockdown and 
cytotoxicity of nanoparticles delivering 100 nM siRNA at 180 w/w. Statistical analysis was assessed by one-
way ANOVA with Tukey post-hoc tests. N = 4. (B) Nanoparticle uptake measured by flow cytometry after 
treatment of nanoparticles containing Cy5-labeled siRNA. N = 4. (C) Pre-treatment with 1,000 µM L-
buthionine-sulfoximine (BSO) shows that intracellular glutathione blockade did not change knockdown levels 
but significantly increased polymer-mediated cytotoxicity as assessed by Holm-Sidak corrected multiple t-
tests; R6,8_20 nanoparticles (180 w/w) were used to deliver 100 nM siRNA. N = 4. (D) Nanoparticle 
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hydrodynamic diameter and (E) zeta potential measured using dynamic light scattering. Bars show average + 
SEM; N = 3. (F) Representative TEM image of R6,8_40 nanoparticles.  
 
To elucidate the mechanism by which moderately branched polymers achieved the highest levels of 
knockdown, we assessed the physical characteristics of the nanoparticles. All polymers in the series formed 
nanoparticles with hydrodynamic diameters around 100 nm (Figure 6-1D). Nanoparticles formed with the 
linear polymer had negative surface charge, and zeta potential generally became increasingly positive with 
increased polymer branching (Figure 6-1E). This is likely due to the fact that increased branching resulted in 
increasing numbers of secondary amine-containing end-groups per polymer molecule, which are positively 
charged in pH 5 NaAc buffer. The increased cationic charge of moderately-branched polymer nanoparticles 
likely contributes to nanoparticle uptake and siRNA-mediated knockdown in vitro, which is consistent with 
many published reports.36-38 This trend does not apply to very highly branched polymers, however, in part 
due to the high levels of cytotoxicity incurred by these nanoparticle formulations.  
3.3 siRNA Binding and Environmentally-triggered Release 
A competitive binding assay using Yo-Pro-1 iodide (Yo-Pro) was used to assess siRNA binding 
strength in R6,8-4-6 polymers. Yo-Pro dye fluoresces upon nucleic acid binding, and quenching of 
fluorescence after polymer outcompetes the dye for siRNA binding was used as a measure of binding 
strength. Increasing polymer branching increased siRNA binding strength, which was seen in both end-
capped (Figure 6-2A) as well as acrylate-terminated polymers (Figure 6-S3A). Plotting knockdown as a 
function of the polymer EC50 w/w of siRNA binding (where lower EC50 w/w corresponds to tighter siRNA 
binding and higher degree of polymer branching) revealed a biphasic response (Figure 6-2B). Binding affinity 
and degree of knockdown both increased approximately 4-fold from R6,8_0 to R6,8_20 and decreased 
steadily when B8 content exceeded 40%. This suggests that an optimal range for siRNA binding affinity 
exists, and polymers that bind too tightly cannot release siRNA to achieve efficient knockdown while those 
that do not bind tightly enough cannot form nanoparticles that effectively promote nanoparticle 
internalization.39-40 siRNA binding affinity, along with other nanoparticle biophysical and chemical properties 
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such as the size, surface charge, and bio-reducibility discussed earlier all contribute to the differential gene 
silencing effects seen here. For polymers with the same B8 content, end-capped polymers exhibited stronger 
binding than their acrylate-terminated counterparts (Figure 6-S3B). These results suggest that polymer 
branching increases siRNA binding via two mechanisms. The first is mediated by increased branching 
structure in the polymer backbone, which increases the molecular weight of the polymer and drives stronger 
binding through greater hydrophobic effects. The second is mediated by increased branching endpoints, 
which increases the number of end-capping molecules. As the secondary amines in the polymer end-groups 
are positively-charged in pH 5 NaAc buffer, they further increase siRNA binding through electrostatic 
interactions.  
 
Figure 6-3. Polymer branching and reducibility can be modulated to control siRNA binding affinity 
and release kinetics. (A) Yo-Pro-1 iodide binding competition assay of R6,8-4-6 polymers to assess siRNA 
binding affinity. N = 4. (B) % knockdown plotted as a function of polymer EC50 w/w for siRNA binding. N 
= 4. (C) Gel retardation assays (N = 1) and (D) Yo-Pro binding assay (N = 4) were performed on 
nanoparticles incubated in 5 mM glutathione to mimic intracellular reducing environments and nucleic acid 
release slowed as the polymers became more branched with less frequent bio-reducible linkages.   
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We next investigated siRNA release kinetics of R6,8-4-6 nanoparticles in 5 mM glutathione to mimic 
the reducing intracellular environment.35 Nanoparticles were sampled at specific time points and standard gel 
electrophoresis was performed to assess siRNA release (Figure 6-2C). The linear polymer released siRNA 
almost instantaneously, and release was complete by 1 hr. Increased polymer branching slowed siRNA release 
considerably, with R6,8_20 beginning release at 1 hr and higher branching polymers at 7 hr. The same trend 
was observed when a Yo-Pro binding assay was performed with nanoparticles incubated over time in 
reducing buffer conditions (Figure 6-2D). These results indicate that siRNA binding and release can be 
modulated in a highly controlled manner by changing the ratio between branching and reducible monomers 
and that siRNA release can be designed to occur in an environmentally-triggered manner via reduction of 
disulfide bonds. However, we have also shown that blocking intracellular glutathione levels did not 
significantly decrease the observed level of siRNA-mediated knockdown (Figure 6-1C), which suggests that 
other polymer degradation mechanisms such as the hydrolysis of ester bonds over a period of 4-6 hr41 could 
also contribute to siRNA release from nanoparticles. Incorporation of disulfide linkages in the rBEAQ 
polymers helps ensure fragmentation of the polymers into small oligomers, reducing cytotoxicity, and enables 
higher doses, branching, or w/w formulation ratios of the polymers to be safely utilized. 
3.4 Co-delivery of siRNA and DNA 
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Figure 6-4. Hydrophobic R6,7,8-4-6 polymer series enables efficient co-delivery of DNA and siRNA. 
Co-delivery efficacy of R6,8-4-6 (0% B7) and R6,7,8-4-6 nanoparticles encapsulating 400 ng total nucleic acid 
in 293T (A) and Huh7 (B). N = 4. (C) Fluorescence microscopy images of HEK-293T cells treated with 
R6,7,8_16 nanoparticles co-delivering 200 ng siRNA and 200 ng DNA (10 w/w formulation). Scale bar 100 
µm. (D) R6,7,8_64 completely encapsulated plasmid DNA and siRNA at 10 w/w as seen by a gel retardation 
assay. (E) Confocal microscopy images of 293T cells treated with R6,7,8_64 nanoparticles co-delivering Cy3-
siRNA, Cy5-DNA, and unlabeled GFP plasmid DNA (0.5:0.4:0.1 composition by weight) at 3 hr and 24 hr 
post-uptake. Cy3 and Cy5 signal colocalization could be seen at 3 hours post-uptake (white arrows). At 24 
hours post-uptake, diffuse Cy3-siRNA signal could be seen in the cytosol (white asterisk) while some Cy5-
DNA signal was detected in the nucleus (yellow arrows) and some cells were visibly expressing GFP. Scale 
bar 20 µm.  
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As moderately branched polymers have been shown to maintain strong nucleic acid binding affinity 
while effectively releasing siRNA cargo in the reducing cytosolic environment, we hypothesized that they may 
be suitable for the co-delivery of plasmid DNA and siRNA. R6,8_20 (the top polymer for siRNA delivery) 
was used to encapsulate 200 ng each of siGFP siRNA and a plasmid DNA encoding iRFP670. R6,8_20 
nanoparticles enabled efficient co-delivery to HEK-293T cells (Figure 6-3A), resulting in 66% siRNA-
mediated knockdown and 77% DNA transfection with negligible cytotoxicity (Figure 6-S4A). The same 
formulation achieved much lower delivery efficiency in harder-to-transfect Huh7 cells (23% knockdown and 
5% transfection; Figure 6-3B), prompting the need to develop more effective polymers for co-delivery. To 
this end, we investigated the effect of polymer hydrophobicity by incorporating monomer B7 at ratios 
indicated in Table 6-S1 to synthesize the R6,7,8-4-6 polymer series. B7 was chosen as it contains a bisphenol 
A group, which has been shown to bind DNA via hydrophobic effects42 and enable high efficiency DNA 
transfection.27, 43-44 B7-containing polymers effectively complexed nucleic acids at very low w/w, forming 
nanoparticles around 150 nm in diameter and +6 to +16 mV in zeta potential (Figure 6-S5). R6,7,8_64 
nanoparticles at a 10 w/w ratio were quite stable in complete cell culture medium mimicking physiological 
conditions for several hours with a hydrodynamic diameter doubling time >4 hours as assessed by DLS 
(Figure 6-S5D). In contrast, R6,8-4-6 polymers with 0% B7 content formed much larger nanoparticles (270 
nm) with -11 mV zeta potential at 10 w/w. B7-containing polymers were used at significantly lower w/w 
formulations compared to R6,8-4-6 polymers used for siRNA complexation earlier because R6,7,8-4-6 
polymers incurred significantly higher cytotoxicity than the R6,8-4-6 polymers, limiting their use to very low 
w/w formulations (Figure 6-S4B). Nevertheless, B7-containing polymers enabled higher levels of 
knockdown and transfection at 10 w/w in HEK-293T cells (Figure 6-3A and 6-3C), though the difference 
was less notable when R6,8-4-6 polymers were used at higher w/w. More strikingly, R6,7,8-4-6 polymers 
enabled significantly higher co-delivery in Huh7 cells compared to R6,8-4-6 at all w/w formulations, with the 
best formulation achieving 53% knockdown and 37% transfection (Figure 6-3B). A gel retardation assay 
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demonstrated that R6,7,8_64 completely condensed both plasmid DNA and siRNA at 10 w/w, and 
decreasing polymer dose resulted in siRNA release at 5 w/w and DNA release at 1 w/w (Figure 6-3D).  
We further explored the intracellular delivery location of siRNA and DNA using confocal laser 
scanning microscopy, which demonstrated different fates for internalized siRNA and DNA. At an early 3 
hour timepoint following nanoparticle treatment, most endosomes possessed both siRNA and DNA, while at 
24 hours post-treatment, diffuse cytosolic siRNA was detectable in most cells and the occasional z-slice 
revealed some Cy5 labeled plasmid DNA in the nucleus (Figure 6-3E). Using a mix of fluorescently labeled 
plasmid DNA and unlabeled plasmid DNA, we were also able to detect a fraction of the cells expressing a 
fluorescent reporter protein GFP at 24 hours post-transfection, which was undetectable in cells at 3 hours 
post-treatment (Figure 6-S6). 
Studies have shown that polymers optimized for DNA delivery may not be optimal for siRNA and 
vice versa.45 This may be due to the differences in size and charge density between DNA and siRNA as well as 
their intracellular sites of action. Bishop et al. approached this problem with a polymer-coated gold 
nanoparticle system where siRNA and DNA were adsorbed onto the nanoparticle using different polymers in 
a layer-by-layer synthesis scheme; the optimal formulation in this study resulted in 34% knockdown and 14% 
transfection in human brain cancer cells.46 Another study using poly(L-lysine) polyplexes for co-delivery of 
siRNA and DNA to HEK-293T cells showed >80% knockdown but achieved <10% DNA transfection.47 
The delivery system reported herein achieved significantly higher co-delivery in both HEK-293T cells as well 
as harder-to-transfect Huh7 human liver cancer cells. These polymers are easy to formulate into nanoparticles 
via self-assembly in a single step, and enabled more efficient co-delivery of both DNA and siRNA compared 
to several leading commercially available non-viral transfection reagents (Figure 6-S7).  
We further compared the DNA-siRNA co-delivery efficacy of the system presented herein with that 
of using nanoparticle formulations previously optimized for the delivery of each nucleic acid separately 
(Figure 6-S8). In the latter strategy, plasmid DNA was encapsulated using polymer 446 at 60 w/w 
(previously optimized for DNA delivery48) and siRNA was encapsulated using polymer R646 at 120 w/w 
(previously optimized for siRNA delivery49). The two nanoparticles were formulated separately and added to 
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cells after nanoparticle formation. In the single nanoparticle strategy, the same amount of nucleic acids was 
pre-mixed and co-encapsulated in R6,7,8_64 nanoparticles (10 w/w). Our results show that using the dual 
nanoparticle delivery strategy, siRNA knockdown levels were significantly lower than that achieved by the 
single nanoparticle co-delivery strategy while DNA transfection levels were similar. Furthermore, when 
polymers 446 and R646 were used to formulate nanoparticles at 10 w/w for direct comparison with polymer 
R6,7,8_64, both siRNA and DNA delivery levels were significantly lower. These results indicate that co-
encapsulation of multiple nucleic acid cargo types in the same nanoparticle system has the advantages of 
higher transfection efficiency as well as greater simplicity in formulation; this is especially important for 
potential clinical translation as it could greatly simplify the synthesis and regulatory approval processes.  
3.5 Co-delivery of Cas9 DNA and sgRNA for CRISPR-mediated Gene Editing 
 
Figure 6-5. Co-delivery of anti-GFP sgRNA and Cas9 plasmid enables CRISPR-mediated gene 
knockout. (A) HEK-293T cells were transfected with R6,7,8_64 10 w/w nanoparticles encapsulating Cas9 
DNA and sgRNA at the indicated nucleic acid molar ratios. N = 4. (B) Flow cytometry histograms of 
CRISPR- or siRNA-treated cells. CRISPR treatment produced a completely GFP-negative population (null) 
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while siRNA treatment mainly resulted in a general population shift to lower GFP fluorescence (low). (C) 
Gene suppression kinetics of CRISPR and siRNA treated cells. N = 4. 
 
Next, we co-encapsulated Cas9 plasmid DNA and sgRNA targeting GFP in our nanoparticles for 
intracellular delivery of the CRISPR/Cas9 gene editing system within one biodegradable nanoparticle. Gene 
knockout, which can be assessed by a decrease in GFP fluorescence, is contingent upon co-delivery of both 
components as the Cas9 endonuclease must assemble with sgRNA to form a functional ribonucleoprotein 
(RNP) complex. This is a rigorous test of co-delivery as the two components must be present in the same cell 
as well as remain bioactive at the same time in order for editing to occur. Our results showed that R6,7,8_64 
nanoparticles enabled 40% gene knockout in HEK-293T cells (Figure 6-4A). Delivery of either component 
alone did not result in appreciable levels of knockout, confirming the need for co-delivery. The optimal 
sgRNA-Cas9 molar ratio was 33. Interestingly, we saw a distinct GFP-negative population (GFP null) in 
CRISPR-treated cells which was not observed in cells treated with GFP siRNA (Figure 6-4B). siRNA-
mediated gene silencing downshifted the GFP fluorescence of the entire population of treated cells while 
CRISPR-mediated knockout completely turned off GFP in a fraction of cells. Kinetic studies showed that 
siRNA-mediated gene silencing faded rapidly, and fluorescence returned to pre-treatment levels after 11 days 
(Figure 6-4C). In contrast, CRISPR-mediated silencing peaked after 5 days and remained constant for the 
entirety of the period tested. Our results suggest that gene silencing mediated by siRNA knockdown or 
CRISPR knockout could be suitable for different therapeutic goals. The former has a faster onset and results 
in significant but transient downregulation in the entire population of treated cells. The latter takes longer to 
reach peak levels but can produce a sustained and binary downregulation in a smaller fraction of the 
population.  
It is important to note that all transfection experiments so far have been performed in serum-free 
medium. It has been widely reported that the presence of serum may decrease transfection efficacy by 
inducing polyplex disruption and aggregation.50 On the contrary, some studies have also demonstrated that 
the presence of serum proteins may prevent disassembly of nanocomplexes.51 To investigate the performance 
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of our nanoparticle system in serum conditions, R6,7,8_64 nanoparticles (10 w/w) were formulated with 
siRNA or Cas9 DNA and sgRNA and administered to cells in complete medium (10% serum). The presence 
of serum significantly reduced transfection efficacy in both cases (Figure 6-S9). However, when NaHCO3 
was added to the nanoparticle formulation to increase nanoparticle pH prior to addition to the cells, 
transfection in both cases increased back to similar levels as in serum-free conditions. The addition of anionic 
compounds to nanoparticles to increase transfection in serum conditions has been utilized in other delivery 
systems52 and is a viable strategy to stabilize polymeric polyplexes.       
 
4. Conclusions 
We synthesized a new series of reducible branched ester-amine quadpolymers (rBEAQs) that enabled co-
delivery of plasmid DNA and RNA oligonucleotides in the same biodegradable self-assembled nanoparticle 
system. Our best formulation achieved 77% DNA transfection and 66% siRNA-mediated knockdown in 
HEK-293T cells, and 37% transfection and 53% knockdown in Huh7 cells. More importantly, co-delivery of 
Cas9 DNA and sgRNA in the same non-viral nanoparticles enabled 40% CRISPR/Cas9-mediated gene 
knockout. To our knowledge, this is the first time that CRISPR-mediated gene editing has been achieved 
through the co-delivery of Cas9 plasmid and sgRNA. The effective co-delivery of plasmid DNA and RNA 
oligonucleotides reported here, as well as the ability to leverage bio-reducibility, hydrophobicity, and polymer 
branching to enable effective co-delivery in different cell types, may prove useful for applications such as 
novel combinatorial gene therapies and genome editing. 
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Table 6-S1. Backbone B monomer composition for R6,8-4-6 and R6,7,8-4-6 polymer series. 
 






R6,8_0 100% 0% 0%
R6,8_20 80% 0% 20%
R6,8_40 60% 0% 40%
R6,8_60 40% 0% 60%
R6,8_80 20% 0% 80%
R6,7,8-4-6 
(20% B8)
R6,7,8_16 64% 16% 20%
R6,7,8_40 40% 40% 20%










Figure 6-S1. Polymer structural information. (A) H1-NMR spectra of acrylate-terminated and end-capped 
R6,8_20 polymer (CDCl3, 500 MHz). Red box indicates the presence of acrylate peaks, which disappeared 
after end-capping. (B) Chemical structure of end-capped R6,8_20.  
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Figure 6-S2. Knockdown (A) and cytotoxicity (B) of R6,8-4-6 nanoparticles at lower w/w 
formulations. Nanoparticles encapsulated 100 nM siRNA dosage. Knockdown of GFP fluorescence was 
normalized against cells treated with non-targeting scrambled RNA (scRNA); n = 4. 
 
 
Figure 6-S3. Yo-Pro binding assay for acrylate-terminated polymers. (A) Increasing polymer branching 
increased binding affinity for acrylate-terminated polymers. (B) Endcapped polymers (E6) showed higher 
binding affinity than acrylate-terminated polymers (Ac). N = 4.  
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Figure 6-S4. Polymer-mediated cytotoxicity for R6,7,8-4-6 nanoparticles co-delivering DNA and 
siRNA in HEK-293T and Huh7 cells. (A) Cytotoxicity mediated by optimal formulations of R6,7,8-4-6 
nanoparticles as well as R6,8-4-6 nanoparticles co-delivering 400 ng total nucleic acid. (B) R6,7,8-4-6 
nanoparticles mediated high levels of toxicity at higher w/w formulations. N = 4. 
 
Figure 6-S5. Nanoparticle characterization. Hydrodynamic diameter (A) and zeta potential (B) confirm 
that B7-containing polymers formed smaller, more positively charged nanoparticles at low w/w formulations. 
Size and zeta potential measurements done via DLS using nanoparticles diluted in PBS. N = 3. (C) TEM 
image of R6,7,8_64 nanoparticles containing DNA and siRNA. (D) R6,7,8_64 nanoparticles (10 w/w) only 
moderately aggregated over the time-span of four hours in 10% serum-containing medium. N = 2. 
 210 
 
Figure 6-S6. Confocal microscopy of co-delivered DNA and siRNA. HEK-293T cells were transfected 
with polymer R6,7,8_64 nanoparticles formed at a 10 w/w ratio between polymer and nucleic acids. Cy3-
siRNA, Cy5-DNA and eGFP-DNA were pre-mixed before nanoparticle encapsulation at a mass ratio of 
50:40:10. At 3 hours after nanoparticle exposure, many endosomes visibly contain both Cy3 and Cy5 signal 
for siRNA and DNA respectively. At 24 hours post-treatment, diffuse Cy3-siRNA fluorescence is detectable 
while Cy5-DNA fluorescence is punctate and GFP is visibly being expressed by some cells. Scale bar 50 µm. 
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Figure 6-S7: DNA and siRNA co-delivery with leading commercially-available transfection reagents. 
R6,7,8_64 nanoparticles (10 w/w) and non-viral transfection reagents Lipofectamine 2,000TM, Lipofectamine 
3,000TM, jetPrime®, and 25 kD bPEI (1 w/w) were used to co-deliver DNA and siRNA to HEK-293T and 
Huh7 cells. R6,7,8_64 nanoparticles generally performed better or as well as leading commercially-available 





Figure 6-S8: Nucleic acid co-encapsulation outperforms DNA and siRNA delivery with their 
respective previously-optimized nanoparticle formulation. R6,7,8_64 nanoparticles were formulated with 
200 ng each of pre-mixed plasmid DNA and siRNA at 10 w/w before nanoparticles were added to cells 
(Single NP). Polymer 446 (optimal for DNA delivery) and polymer R646 (optimal for siRNA delivery) were 
formulated separately with their respective cargos and each nanoparticle formulation was added separately to 
cells, with 200 ng of DNA and siRNA, respectively, delivered (dual NP). The single NP strategy 
outperformed the dual NP strategy when NPs were formulated at high w/w (60 w/w for 446 and 120 w/w 
for R646) as well as at low w/w (10 w/w for 446 and R646, respectively). R6,7,8_64 polymers were always 
used at 10 w/w, demonstrating its higher delivery efficiency. Huh 7 cells were used in this experiment. N = 4. 
Statistical analysis was assessed by one-way ANOVA with Tukey post-hoc tests. 
  































Figure 6-S9: R6,7,8_64 nanoparticle delivery efficacy in serum-containing medium. R6,7,8_64 
nanoparticles (10 w/w) containing (A) siRNA or (B) Cas9 DNA and sgRNA were administered to cells in 
cell culture medium with or without 10% FBS. The presence of serum significantly decreased transfection in 
both cases. The addition of NaHCO3 solution to increase the pH of nanoparticles prior to adding to cells led 
to recovery in transfection efficacy. N = 4 for all experiments. Statistical analysis was assessed by one-way 
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Abstract 
Efficient cytosolic protein delivery is necessary to fully realize the potential of protein therapeutics. Current 
methods of protein delivery often suffer from low serum tolerance and limited in vivo efficacy. Here, we 
report the synthesis and validation of a new class of carboxylated branched poly(beta-amino ester)s that can 
self-assemble into nanoparticles for efficient intracellular delivery of a variety of different proteins. In vitro, 
nanoparticles enabled rapid cellular uptake, efficient endosomal escape, and functional cytosolic protein 
release into cells in media containing 10% serum. Moreover, nanoparticles encapsulating CRISPR/Cas9 
ribonucleoproteins (RNPs) induced robust levels of gene knock-in (4%) and gene knock-out (> 75%) in 
several cell types. A single intracranial administration of nanoparticles delivering a low RNP dose (3.5 pmol) 
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induced robust gene editing in mice bearing engineered orthotopic murine glioma tumors. This self-
assembled polymeric nanocarrier system enables a versatile protein delivery and gene editing platform for 
biological research and therapeutic applications.  
 
Introduction 
Since the introduction of the first recombinant protein drug– human insulin1 – in 1982, the number 
of therapeutic proteins and the frequency of their use have dramatically increased. These diverse and dynamic 
macromolecules have been used to treat diseases ranging from metabolic disorders to cancer2 and are 
important in applications such as genome editing3 and synthetic biology.4 However, their high molecular 
weight and overall hydrophilicity render most proteins essentially membrane impermeable,5 limiting most 
current protein therapeutics to extracellular targets. As proteins have the potential to target intracellular 
pathways with high specificity and fewer side effects,6 it is imperative to develop novel strategies for efficient, 
functional, and cytosolic protein delivery. 
Cytosolic protein delivery vehicles must overcome several barriers such as cargo encapsulation, 
cellular internalization, escape from endo/lysosomes, and cytosolic cargo release.7 One well characterized 
approach is the covalent modification of the protein of interest with protein transduction domains (PTDs) 
such as the TAT protein from human immunodeficiency virus.8 This strategy has been shown to enable rapid 
cellular internalization of a wide variety of proteins but requires chemical modifications that could alter the 
bioactivity of the native protein. More recently, several studies have reported the use of self-assembled 
protein delivery vehicles based on lipid-like,9 polymeric,10 or hybrid materials.11-13 These methods still face 
limitations such as the need for purification steps, low protein loading efficiency, and limited applicability to 
certain cargo types, prompting the need for improved self-assembled protein delivery systems. 
Hyperbranched cationic poly(E-amino ester)s (PBAEs) have recently generated interest as an efficient 
gene delivery material for highly negatively-charged nucleic acids.14-16 These amphiphilic, pH-sensitive 
polymers are synthesized via facile Michael addition reactions and have been shown to possess robust 
transfection capabilities under challenging conditions as well as efficient endosomal escape properties. 
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However, cationic polymers such as PBAEs form self-assembled nucleic acid nanoparticles mainly through 
electrostatic interactions, which are generally insufficient to encapsulate proteins of diverse surface charge.  
In this study, we synthesized and validated a new biomaterial class of hyperbranched PBAE 
containing both cationic and anionic charges.  This was accomplished through polymer end-capping with 
carboxylate ligands derived from amino acid-like precursors. Polymers were assembled into nanoparticles 
with proteins by simple mixing in aqueous buffer. We hypothesized that the carboxylate ligands can enhance 
polymer-protein interactions for nanoparticle assembly via increased hydrogen bonding and hydrophobic 
effects in addition to electrostatic interactions. Furthermore, we found that differential polymer end-group 
hydrophobicity affected protein complexation capabilities as well as nanoparticle internalization and 
endosomal escape. Our delivery platform enabled functional cytosolic delivery of proteins ranging from 27 
kD to 160 kD in molecular weight with varying surface charges. Encapsulation of Cas9 ribonucleoproteins 
(RNPs) enabled efficient gene editing in vitro and in vivo, further highlighting the robustness and therapeutic 
utility of these nanocarriers.  
 
Results 
Polymer synthesis and screening 
Hyperbranched PBAEs were synthesized via a step-wise copolymerization reaction between acrylate-
containing monomers bisphenol A glycerolate (1 glycerol/phenol) diacrylate (B7) and trimethylolpropane 
triacrylate (B8), and amino alcohol monomer 4-amino-1-butanol (S4). B monomers were added in molar 
excess to yield acrylate-terminated polymers, which were end-capped with the diamine-containing small 
molecule 1,3-diaminopropane (E1) to yield E1 base polymers (Figure 7-1A). These polymers underwent a 
second round of end-capping reactions with carboxylate ligands (Figure 7-S1), which were synthesized via 
reaction of a series of amino acid-like precursors with acryloyl chloride. Ligands were named according to the 
number of carbon atoms between the amide and carboxylic acid groups, with C1 deriving from the amino 
acid glycine (Figure 7-S2). Five carboxylate ligands ranging from C1 to C10 were synthesized to investigate 
the effect of end-cap hydrophobicity on the protein encapsulation and delivery capabilities of the polymers. 
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We hypothesized that the combination of the biodegradable and hyperbranched polymer backbone, which 
has been shown to be amphiphilic and pH sensitive,15 and carboxylate end-capping ligands, capable of 
forming hydrogen bonds and salt bridges with proteins, would result in a versatile protein delivery polymer 
platform.  
 
Figure 7-1. Design and characterization of self-assembled carboxylated branched PBAE protein 
nanoparticles. (A) Assembly of carboxylated branched PBAEs with proteins. (B) Structures of carboxylate 
ligands C1-C10, arranged in order of increasing hydrophobicity. (C) Hydrodynamic diameter and zeta 
potentials of nanoparticles formulated with BSA (30 w/w) as measured by DLS. Data presented as mean+SD 
(n=3). Statistical comparisons of nanoparticle diameter were performed with one-way ANOVA with 
Dunnett’s post-hoc tests against the C5 group. *P<0.05, **P<0.01. Similar statistical comparisons were made 
with zeta potential data and no significant differences were observed. (D) Representative TEM images of 
C5/BSA nanoparticles.    
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To investigate the protein encapsulation capabilities of the polymers, we formulated self-assembled 
polymeric nanoparticles with bovine serum albumin (BSA). At a polymer-protein weight ratio (wt/wt) of 30, 
all carboxylate terminated polymers in the series formed nanoparticles ranging 200-500 nm in hydrodynamic 
diameter with surface charges close to neutral (Figure 7-1C), whereas the E1 terminated polymer, useful for 
self-assembly with nucleic acids,17 failed to effectively form nanoparticles with BSA. The diameter of the 
nanoparticles formulated from carboxylated polymers had a biphasic response dependent on the number of 
carbon atoms between the amide and carboxylic acid groups. Polymers end-capped with ligands C5 and C7 
formed the smallest nanoparticles, and polymers with lower or higher end-cap carbon length formed much 
larger nanoparticles. Moreover, the same biphasic response was observed functionally when these polymers 
were used to deliver FITC-labeled BSA intracellularly (Figure 7-2A). In all four cell lines evaluated (CT-2A 
murine glioma, HEK-293T human embryonic kidney, B16-F10 murine melanoma, and MSC-083 primary 
human adipose-derived mesenchymal stem cells), polymers surface engineered with C5 or C7 moieties 
enabled the highest levels of intracellular nanoparticle-mediated protein uptake. These data indicate that end-
cap hydrophobicity and the spacing length between charges play a major role in the interactions between 
polymer and protein during nanoparticle self-assembly, which in turn affects interactions between 
nanoparticles and cells during cellular uptake. The high levels of protein nanoparticle uptake did not result in 
significant levels of cytotoxicity and the viability of cells treated with nanoparticles was >70% for all polymers 
and cell lines tested when polymers were used at standard conditions <0.15 mg/mL (Figure 7-S3). 
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Figure 7-2. Carboxylated PBAE nanoparticles mediate cytosolic protein delivery. (A) Average 
fluorescence intensity of cells treated with carboxylated PBAE nanoparticles encapsulating FITC-BSA (300 
ng FITC-BSA per well, 20 w/w). Data presented as mean+SD (n=4); statistical significance determined by 
one-way ANOVA with Dunnett’s post-hoc tests comparing uptake levels to that of the nanoparticle 
formulation achieving the highest levels of FITC-BSA uptake in each cell line. ***P<0.001, ****P<0.0001. 
(B) Uptake by HEK cells in the presence of different endocytosis inhibitors; CPZ=chlorpromazine, 
MCD=methyl-β-cyclodextrin, GEN=genistein, CYD=cytochalasin-D. Data presented as mean±SD; 
statistical significance determined by one-way ANOVA with Dunnett’s post-hoc tests as compared to the 
control group (n=4). *P<0.05, **P<0.01, ****P<0.0001. (C) Confocal images of HEK cells treated with 
C5/FITC-BSA nanoparticles or protein alone for 4 h. Scale bar = 10 µm. 
 
When nanoparticle internalization pathways were probed by selectively inhibiting endocytosis 
pathways using small molecule drugs, we found that pre-treatment with cytochalasin-D decreased 
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nanoparticle uptake by over 80%, suggesting that nanoparticles were internalized primarily by 
macropinocytosis (Figure 7-2B). Methyl-E-cyclodextrin and genistein also significantly decreased cellular 
uptake while chlorpromazine had negligible effects, indicating that nanoparticles were also taken up through 
lipid raft- and caveolin-mediated endocytosis but not through clathrin-mediated endocytosis. Finally, confocal 
laser scanning microscopy images of cells after 4 h incubation with C5/FITC-BSA nanoparticles revealed 
diffuse FITC-BSA signal throughout the cytosol, indicating that nanoparticles successfully escaped 
degradative endo-lysosomes to enable cytosolic protein delivery (Figures 7-2C and 7-S4). 
 
Endosomal disruption characterization via Gal8-GFP recruitment assay 
We further characterized the endosomal escape capabilities of carboxylated branched PBAE 
nanoparticles using an assay based on the recruitment of galectin 8 (Gal8) to disrupted endosomal 
membranes similar to the method recently innovated by Kilchrist et al.18 Gal8 is a cytosolic protein that binds 
to glycosylation moieties located selectively on the inner leaflets of endosomal membranes. Using a PiggyBac 
transposon, we created a cell line stably expressing a Gal8-GFP fusion protein. Endosomal rupture exposes 
Gal8 binding sites to cytosolic Gal8-GFP, and Gal8-GFP recruitment results in punctate fluorescent spots at 
disrupted endosomes (Figure 7-3A). After staining with Hoechst 33342 nuclear dye to allow for cell 
identification, automated high content imaging analysis can then be used to identify punctate Gal8-GFP spots 
and calculate the number of Gal8-GFP spots per cell as an indicator of the level of nanoparticle-mediated 
endosomal disruption (Figure 7-3B).  
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Figure 7-3. Gal8-GFP recruitment assay to assess nanoparticle-mediated endosomal disruption. (A) 
Gal8 recruitment overview; in cells with intact endosomes, Gal8-GFP is dispersed throughout endosomes 
with no interactions with intra-endosomal glycans. Gal8-GFP binds glycans in disrupted endosomes, resulting 
in punctate fluorescent dots. (B) Gal8–GFP recruitment were quantified by image-based analysis. Individual 
cells were identified through nuclear staining (left); Gal8-GFP recruitment could be visualized in the green 
fluorescence channel (center); punctate GFP+ spots were identified and counted (red dots). (C) 
Representative images of Gal8-GFP+ B16 cells treated with carboxylated PBAE/BSA nanoparticles (125 ng 
BSA per well, 25 w/w; scale bar = 50 µm). (D) Endosomal disruption level quantified by the number of 
Gal8-GFP spots per cell. Data presented as mean±SD; statistical significance determined by one-way 
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ANOVA with Dunnett’s post-hoc tests as compared to the C5 group (n=4). *P<0.05, **P<0.01, 
****P<0.0001. 
 
Our results revealed that among the carboxylate end-capped polymers, polymer C5 enabled the 
highest level of endosomal disruption (Figure 7-3D). This was not due to the buffering capabilities of these 
polymers, as pH titration experiments showed that there was no significant difference in buffering capacity 
among the different carboxylated polymers (Figure 7-S5A). It is also important to note that there was no 
significant difference between the Gal8-GFP recruitment levels of nanoparticles formed with the E1 base 
polymer and those formed with polymer C5. In fact, polymer end-capping with carboxylate ligands of shorter 
chain lengths (e.g. C1 and C3) resulted in a decrease in endosomal disruption levels. This may be explained by 
the fact that the E1 monomer itself interacts with endosomal membranes in a way that causes disruption, as 
was demonstrated in previous reports using this molecule as an end-cap to efficiently deliver plasmid DNA.17 
Further end-capping with carboxylate ligands masked this effect, and endosomal disruption became 
dependent on hydrophobic chain length. PBAEs have also been shown to form polymer-only, micellar 
nanoparticles in the absence of nucleic acid or protein cargo due to their amphiphilic structure.19 Thus, the 
paradoxical low FITC-BSA uptake and high Gal8-GFP recruitment observed in E1 nanoparticles could be 
explained by the fact that E1 base polymers could not adequately form protein-encapsulated nanoparticles 
and mainly formed polymer-only nanoparticles, which caused endosomal disruption after endocytosis. Taken 
together, our data indicate that polymer C5 clearly outperformed all other polymers in the series and was 
chosen for use in all subsequent experiments.  
 
Robustness of C5-PBAE nanoparticles 
We further examined the robustness of C5 end-capped polymers by utilizing them for cytosolic 
delivery of a variety of proteins. C5 polymers successfully encapsulated FITC-labeled human IgG (FITC-IgG) 
and GFP, respectively, and enabled diffuse cytosolic delivery of both (Figure 7-4). To investigate the 
capability for functional protein delivery, C5 polymers were further utilized to encapsulate the ribosome-
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inactivating protein saporin, a potent toxin lacking cellular internalization domains20 (Figure 7-4C). In all three 
cell lines tested, C5/saporin nanoparticles induced high levels of cell death even at very low saporin doses 
(EC50<5 nM). This indicates that C5 nanoparticles enabled functionally intact saporin proteins to reach the 
ribosome, their intracellular sites of action, with high efficiency. In contrast, unencapsulated saporin could not 
be internalized on its own and resulted in negligible cytotoxicity even at high concentrations. Our data 
demonstrate that C5 end-capped branched PBAEs are a versatile and robust protein delivery platform, 
enabling cytosolic, functional protein delivery to a variety of cell lines. More importantly, the polymers are 
largely agnostic to the size and surface charge of the protein cargo that they carry (Figure 7-4E & Table 7-S1), 
unlike traditional PBAEs that depend on electrostatic interactions and can only encapsulate strongly 
negatively charged cargos such as nucleic acids. 
 
Figure 7-4. Carboxylated C5 polymeric nanoparticles for cytosolic delivery of different protein types. 
Confocal images of HEK cells treated with C5 nanoparticles encapsulating FITC-IgG (A) and GFP (B) for 4 
h; 450 ng protein delivered per well at 30 w/w (scale bar = 50 µm). (C) Functional delivery of ribosome-
inactivating protein saporin resulted in significant levels of cell death; the final polymer concentration per well 
was 0.075 µg/µL. Data presented as mean±SD (n=4). (D) Representative images of CT-2A cells treated with 
10 nM naked saporin or C5/saporin nanoparticles. (E) Molecular weight and isoelectric point of proteins 
delivered by C5 nanoparticles. 
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CRISPR gene editing through RNP delivery in vitro 
C5 polymers were also used to encapsulate and deliver Cas9 ribonucleoproteins (RNPs) to enable 
CRISPR gene editing in vitro. In these experiments, Cas9 protein and gene-targeting short guide RNA 
(sgRNA) were first incubated together at room temperature for 10 minutes to allow RNP self-assembly, then 
simply mixed with polymers to form nanoparticles. Delivery of RNPs targeting the GFP gene in cells 
constitutively expressing the GFP reporter resulted in 77% GFP knockout in HEK cells and 47% GFP 
knockout in GL261 murine glioma cells as quantified by flow cytometry (Figure 7-5B). Surveyor® mutation 
detection assay was also performed to verify that loss in GFP fluorescence was indeed due to perturbations in 
genomic DNA (Figure 7-5C). RNPs were membrane impermeable on their own and treatment with RNP 
alone yielded negligible levels of gene editing.  
  
Figure 7-5. C5 nanoparticle delivery of Cas9 RNPs enable robust CRISPR gene editing in vitro. (A) 
Fluorescence microscopy images of HEK-GFPd2 cells treated with RNPs alone or C5+RNPs; C5+RNPs 
enabled knockout of GFP fluorescence. Scale bar = 50 µm. (B) Flow cytometry quantification of GFP 
knockout in HEK and GL261 cells. Data are mean+SD; n=4. Editing level of the C5-RNP group for each 
cell line was compared to that of the corresponding RNP only group using Holm-Sidak corrected multiple t 
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tests. ****P<0.0001. (C) Surveyor® mutation detector assay of GL261-GFPd2 cells treated with C5+RNP 
nanoparticles. (D) Experimental design of HDR assay in the CXCR4 gene; knock-in of a 12-bp insert flanked 
by homology arms (HA) results in the addition of a HindIII restriction enzyme site. (E) Quantification of 
total editing (via Surveyor® assay) and HDR (via HindIII restriction digest) in HEK cells. Data are 
mean+SD; n=3. (F) HindIII restriction enzyme assay (top) and Surveyor® assay (bottom) of HEK cells 
treated with different C5/RNP/donor DNA combinations; orange arrow indicates HDR. (G) Inference of 
CRISPR Edits (ICE) analysis of Sanger sequencing data from C5+RNP+donor DNA treated cells provides a 
breakdown of different edits. Percentages indicate the percentage of the total DNA population with the 
indicated genotype. The targeted sequence is highlighted in grey and PAM sequence in yellow. 
 
Next, we investigated the capability of C5/RNP nanoparticles to edit an endogenous gene through 
homology directed repair (HDR). Cas9 protein was first self-assembled into RNPs with sgRNA targeting the 
human CXCR4 gene, and RNPs were further mixed with a single-stranded DNA (ssDNA) repair template 
before mixing with C5 polymer. The ssDNA repair template included ~80 base homology arms flanking a 12 
base insert containing a HindIII restriction enzyme site (Figure 7-5D). Successful HDR was quantified by 
HindIII restriction digest of PCR amplicons of the genomic CXCR4 site while total amount of editing 
(NHEJ and HDR) was quantified using the Surveyor® mutation detection assay. Our results indicate that C5 
nanoparticles successfully delivered the combination of RNP+ssDNA into HEK-293T cells. Gel 
electrophoresis analysis of cleavage products indicate that 4% HDR was achieved while over 50% total 
editing was achieved (Figure 7-5E&5F). Inclusion of a ssDNA template into the nanoparticle self-assembly 
process did not change the total level of editing achieved. Inference of CRISPR Edits (ICE)21 analysis of 
Sanger sequencing results confirmed the presence of a 12 bp insert in 2.5% of DNA sequences (Figure 7-5G).  
 
Validation of CRISPR-stop reporter system to assess gene deletion 
We engineered a CRISPR-stop reporter construct wherein a 630-bp stop-of-transcription cassette is 
placed upstream of a red-enhanced nanolantern (ReNL) fluorescent reporter (Figure 7-6A). This CRISPR-
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stop construct was integrated into the genomic DNA of GL261 and B16-F10 cells via a PiggyBac transposon, 
and targeting CRISPR RNPs to regions flanking the stop cassette resulted in deletion of the stop cassette and 
turning on of ReNL fluorescence. We chose this system to evaluate in vivo gene editing as gain-of-function 
ReNL expression via dual-cut gene deletion could be easily and clearly detected. 
 
Figure 7-6. C5/RNP nanoparticles enable CRISPR editing in vivo. (A) Schematic of CRISPR-stop gene 
construct; deletion of a 630-bp expression stop cassette turns on downstream ReNL expression. (B) Direct 
intracranial administration of C5/RNP nanoparticles to an orthotopic GL261-stop-ReNL tumor enabled 
CRISPR editing in vivo. Nanoparticles were formulated at 3.5 pmol RNP with 15 w/w C5 polymer. Tumors 
boundary outlined in white. 
 
In vitro assessment of this CRISPR-stop system using C5/RNP nanoparticles indicated that 16% and 
43% editing were achieved in GL261 and B16 cells, respectively (Figure 7-S6A). Compared to commercially-
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available CRISPR delivery agents, C5/RNP nanoparticles enabled significantly higher editing levels than 
LipofectamineTM CRISPRMAXTM at all RNP doses tested and significantly higher editing levels than 
jetCRISPRTM at equimolar RNP doses tested (Figure 7-S6B). jetCRISPRTM enabled significantly higher levels 
of editing than C5/RNP nanoparticles only when twice the RNP dose was used, further demonstrating the 
robustness of our nanoparticle system in delivering CRISPR RNPs.  
This reporter system also allowed us to easily assess the stability of our nanoparticles under 
physiological conditions. C5/RNP nanoparticles were pre-incubated in serum-containing complete cell 
culture media at 37°C for up to 4 h before adding to cells, and their ability to induce gain-of-function 
CRISPR-stop edits was assessed (Figure 7-S7A). Flow cytometry data revealed that no significant loss of 
nanoparticle efficacy was observed until pre-incubation time reached 4 h, at which time delivery efficacy 
dropped by 25%. This is likely due to PBAE hydrolysis and is consistent with previous reports of PBAE half-
life in aqueous conditions of 4-6 hours, a benefit to facilitate fast biodegradation and minimized toxicity in 
vivo.22 To achieve greater long-term stability of nanoparticles, as would be required for storage and supply 
chain management, we demonstrated that C5/RNP nanoparticles retain their efficacy following lyophilization 
with sucrose as a cryoprotectant, which may be the first documented case of a functional lyophilized RNP 
formulation (Figure 7-S7B).23 
 
CRISPR editing in murine glioma tumors in vivo 
Finally, we investigated the ability of C5/RNP nanoparticles to enable CRISPR gene editing in vivo. In 
vivo assessment of gene editing was performed following intracranial implantation of GL261 cells 
constitutively expressing the CRISPR-stop construct into C57BL/6J mice. C5/RNP nanoparticles were 
infused intracranially through convection-enhanced delivery (CED) 10 days post-tumor inoculation, and mice 
were euthanized and brains extracted 6 days after nanoparticle CED. Histological analysis of mouse brains 
treated with C5/RNP nanoparticles (3.5 pmol RNP dose with 15 w/w polymer) revealed bright ReNL 
fluorescence within the tumor bulk, which was not observed in mice that received naked RNP infusion only 
(Figures 7-6B and 7-S8). Although the brightest ReNL signal was localized in closest proximity to the 
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injection site, ReNL expression was detectable several millimeters away from the primary injection site. These 
results demonstrate proof-of-principle that C5/RNP nanoparticles can enable efficient localized CRISPR 
gene editing in vivo. 
Discussion 
Functional cytosolic protein delivery holds great value in biological research as well as therapeutic 
applications by enabling the perturbation of intracellular pathways previously undruggable by small molecule 
drugs. To overcome the intrinsic cell membrane impermeability of many proteins, we synthesized and 
validated a series of carboxylated branched PBAEs for the encapsulation of a variety of different protein 
types into self-assembled nanoparticles. Carboxylate ligand chain length and hydrophobicity played an 
important role in polymer-protein interactions as well as the ability for protein-encapsulated nanoparticles to 
interact with cellular and endosomal membranes. Polymers terminated with C5, a carboxylate ligand of 
moderate hydrophobicity, outperformed other ligands in the series both in the level of cellular internalization 
as well as endosomal disruption. The superior performance of C5 over end-caps of lesser hydrophobicity 
could be explained by the fact that increased hydrophobicity facilitates nanoparticle stabilization through 
hydrophobic effects. Furthermore, the hydrocarbon chains in the polymer end-group could also interact with 
membranes, facilitating cellular internalization as well as endosomal escape through transient membrane 
perturbations. A similar phenomenon has been extensively reported with lipid-like materials and may also be 
applicable here.24 On the other hand, polymer end-groups such as C10 may be too hydrophobic, or else allow 
too long of a linker length, to efficiently interact with proteins. For example, a potential collapse of the 
hydrocarbon tail in aqueous buffer could obstruct interactions between the carboxylic acid functional group 
with proteins and cell membranes. This biphasic response is consistent with that reported by Ayala et al when 
similar amino acid analogs were utilized for hydrogel synthesis.25  
We further demonstrated the robustness of our nanoparticle system by cytosolically delivering a 
variety of proteins of different size and surface charge. The ability to functionally deliver the ribosome-
inactivating protein saporin, which has an isoelectric point of 9.520 and is thus strongly cationic at the pH of 
nanoparticle formation, validates our hypothesis that carboxylated PBAEs can rely on interactions beyond 
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purely electrostatic forces to complex protein cargo into nanoparticles. This is a significant innovation upon 
traditional gene delivery PBAEs engineered to complex only highly anionic nucleic acid cargos through 
charge interactions.26 
Finally, we demonstrated that C5 polymers were capable of functional delivery of Cas9 RNPs to 
enable CRISPR gene editing. In vitro delivery of RNPs targeting a GFP reporter gene resulted in nearly 80% 
GFP knockout following NHEJ. This level of gene knockout is comparable to that achieved by the DNA 
nanoclew system developed by Sun et al.27 and significantly higher than that reported by Alsaiari et al. using 
ZIF-8 metal-organic framework nanoparticles for CRISPR RNP delivery.13 Compared to commercially-
available CRISPR delivery reagents Lipofectamine™ CRISPRMax™ and jetCRISPR, C5/RNP nanoparticles 
enabled significantly higher levels of gene editing at manufacturer-recommended RNP doses. Further, co-
delivery of RNPs targeting the human CXCR4 gene and a ssDNA repair template in the same self-assembled 
nanoparticle enabled 4% HDR in HEK-293T cells, which is significantly higher than that achieved by the 
CRISPR-Gold system developed by Lee et al.28 in the same cell line when scaled by the RNP dose delivered. 
For translation considerations, the C5/RNP+ssDNA encapsulated nanoparticles can be formulated by simple 
mixing with polymers while the aforementioned CRISPR-Gold requires a multistep synthesis scheme 
including covalent conjugation of DNA sequences.  
C5/RNP nanoparticles induced CRISPR gene editing in vivo as well using a challenging reporter 
model requiring a 631 bp deletion for gain-of-function fluorescence. In a proof-of-principle study, we 
demonstrated that deletion of an expression stop cassette resulted in gain of function ReNL reporter 
fluorescence upon intracranial injection of C5/RNP nanoparticles in a mouse glioma model. The highest 
levels of editing occurred near the primary nanoparticle infusion site, covering a region in the brain 
approximately 0.4 mm2 in area, which is comparable to that reported by Wang et al.,9 who used bio-reducible 
lipids to deliver 5 pmol supercharged GFP-Cre to mouse brains containing a CRISPR-stop reporter system in 
which the stop cassette is flanked by LoxP sites. In another study, Staahl et al. utilized a protein engineering 
approach to enable cellular internalization by adding 4×NLS residues to the N-terminus of the Cas9 protein 
but required an order of magnitude higher RNP dose to achieve wide-spread editing.29 Intracranial injection 
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of 4 pmol modified RNPs enabled gain-of-function tdTomato fluorescence in mouse brain regions similar in 
area to that observed by Wang et al.9 In comparing in vivo editing efficiency, it is important to note that gene 
editing occurred in primary mouse neurons in the two abovementioned studies while our study investigated 
gene editing in orthotopic mouse brain tumors. However, the bright ReNL signal induced by the C5/RNP 
nanoparticles highlight their robust in vivo delivery capabilities.  
A further advantage of our polymeric nanoparticle-based protein delivery system is its ability to 
potentially evade immune responses. It has been demonstrated that PBAE nanoparticles optimized for 
nucleic acid delivery could be administered repeatedly to immune-competent animals without a reduction in 
transfection efficacy,30 indicating that neutralizing antibodies were not formed against the nanoparticles. We 
hypothesize that our protein delivery system would have similarly low levels of vector-mediated immune 
responses, which is a significant advantage over traditional viral delivery vectors for which immunogenicity is 
a serious concern. Immunogenicity to Cas9 protein cargo may be a concern for direct in vivo CRISPR editing 
in human patients as Charlesworth et al. recently reported that pre-existing immunity against spCas9 is likely 
to limit the editing efficacy of CRISPR RNPs delivered to human patients.31 Polymeric nanoparticle 
encapsulation may attenuate immune responses against the protein cargo itself by protecting against 
circulating neutralizing antibodies, enabling CRISPR gene editing in patients with pre-existing immunity. This 
effect was not studied in this work but would be an interesting future direction to explore. 
In summary, we have reported herein a polymeric nanoparticle system that can encapsulate and 
enable robust cytosolic delivery of a variety of different protein types, including potent cytotoxic agents as 
well as CRISPR/Cas9 RNPs. RNP delivery in vitro and in vivo induced high levels of gene editing at relatively 
low RNP doses. Biodegradable nanoparticles were formulated via a facile, highly scalable self-assembly 
process that is also amenable to lyophilization and storage. This versatile protein delivery platform provides a 
powerful tool for biological research as well as potential therapeutic applications for neurological disorders 
and beyond.  
Materials and Methods 
Materials 
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Acryloyl chloride (CAS 814686), glycine (CAS 56-40-6), 4-aminobutanoic acid (CAS 56-12-2), 6-
aminocaproic acid (CAS 60-32-2), 8-aminooctanoic acid (CAS 1002-57-9), 11-aminoundecanoic acid (CAS 
2432-99-7), bisphenol A glycerolate (1 glycerol/phenol) diacrylate (B7; CAS 4687949), trimethylolpropane 
triacrylate (B8; CAS 15625895), 1,3-diaminopropane (E1; CAS 109-76-2), FITC-BSA, saporin from S. 
officinalis seeds, FITC-IgG from human serum, and Cas9-NLS were purchased from Sigma-Aldrich (St. Louis, 
MO). 4-Amino-1-butanol (S4; CAS 133251005) was purchased from Alfa Aesar (Tewksbury, MA). 
 
Carboxylate Ligand Synthesis 
Carboxylate ligands were synthesized according to the method by Ayala et al.25 Briefly, 0.1 mol 
carboxylate precursor molecule (listed in Figure 7-S2B) was added at a 1:1.1 molar ratio with NaOH and 
dissolved in 80 mL DI water with vigorous stirring in an ice bath. 0.11 mol acryloyl chloride in 15 mL THF 
was added drop-wise, and the pH of the reaction was maintained at 7.5-7.8 with 1M NaOH solution. The 
reaction was allowed to proceed overnight before being acidified to the pH listed in Figure 7- S2B with 1M 
HCl solution and extracted 3 times with ethyl acetate. The organic layer was collected, dried with sodium 
sulfate, and the solvent was removed with rotary evaporation to yield a white powder. 
 
Polymer Synthesis 
Monomers B7 and B8 were dissolved in anhydrous DMSO at 0.8:0.2 molar ratio, and   
monomer S4 was added at an overall vinyl: amine ratio of 2.2:1 to a final monomer concentration of 150 
mg/mL. The reaction was allowed to proceed at 90qC with stirring overnight, at which point polymers were 
end-capped by reacting with monomer E1 (0.2 M final concentration in DMSO) at room temperature for 2 
hr. The resulting E1 polymers were purified by 2 diethyl ether washes, after which polymers were dissolved at 
200 mg/mL in DMSO and end-capped with carboxylate ligands (0.2 M final concentration in DMSO) at 
room temperature for 2 hr. The resulting carboxylated polymers were further purified by ether precipitation 
and remaining solvent was removed in a vacuum chamber. Polymers were dissolved in DMSO at 100 mg/mL 
and stored in single-use aliquots at -20qC with desiccant.  
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Polymer Characterization: NMR, GPC, and pH Titration 
Polymer structure was characterized by nuclear magnetic resonance spectroscopy (NMR) via 1H 
NMR in CDCl3 (Bruker 500 MHz) and analyzed using TopSpin 3.5 software. Polymer molecular weight was 
characterized by gel permeation chromatography (GPC); polymers were dissolved in BHT-stabilized THF 
with 5% DMSO and 1% piperidine, filtered through a 0.2 μm PTFE filter, and characterized using GPC 
against linear polystyrene standards (Waters, Milford, MA). pH titrations were performed using a SevenEasy 
pH meter (Mettler Toledo) with 10 mg of polymer dissolved in 10 mL of 100 mM NaCl acidified with HCl as 
previously described.15 Polymer was titrated from pH 3.0 to pH 11.0 using 100 mM NaOH added stepwise, 
and pH was recorded after each addition. 
 
Nanoparticle Characterization 
Nanoparticles were prepared by dissolving polymer and protein separately in 25 mM sodium acetate 
(NaAc, pH 5), mixing the two solutions at a 1:1 volume ratio, and allowing for nanoparticle self-assembly at 
room temperature for 10 minutes. To prepare nanoparticles encapsulating CRISPR ribonucleoproteins 
(RNPs), sgRNA and Cas9 protein were first mixed together at a 2:1 molar ratio to allow RNP assembly at 
room temperature for 10 minutes; RNPs were then mixed with polymers at a 1:1 volume ratio. Nanoparticles 
were diluted 1:5 in 150 mM PBS to determine particle size and zeta potential in neutral, isotonic buffer. 
Hydrodynamic diameter was measured via dynamic light scattering (DLS) on a Malvern Zetasizer Pro 
(Malvern Panalytical); zeta potential was measured via electrophoretic light scattering on the same instrument. 
Transmission electron microscopy (TEM) images were acquired with a Philips CM120 (Philips Research). 
Nanoparticles encapsulating BSA (30 w/w) were prepared at a polymer concentration of 1.8 mg/mL in 25 
mM NaAc. 30 PL nanoparticles were added to 400-square mesh carbon coated TEM grids and allowed to 
adhere for 20 minutes. Grids were then rinsed with ultrapure water and allowed to fully dry before imaging. 
 
sgRNA In Vitro Transcription 
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In vitro transcription was performed using a MEGAshortscript T7 Transcription kit (Invitrogen) and 
purified using a MEGAclear Transcription Clean-up kit (Invitrogen) following manufacturer’s instructions. 
The DNA templates used for in vitro transcription were synthesized as gBlocks from IDT (sequences listed in 
Table 7-S2). 
 
Cell Culture and Cell Line Preparation 
HEK-293T human embryonic kidney cells, GL261 murine glioma cells, CT-2A murine glioma cells, 
B16-F10 murine melanoma cells, and MSC-083 human primary adipose-derived mesenchymal stem cells 
(hAMSCs) were cultured in Dulbecco’s Modified Eagle Medium (DMEM; ThermoFisher) supplemented with 
10% FBS and 1% penicillin/streptomycin. To generate reporter cell lines for CRISPR editing experiments, 
HEK-293T and GL261 cells were induced to constitutively express a destabilized form of GFP (GFPd2) via 
a PiggyBac transposon/transposase system as detailed previously.16 Similarly, GL261 and B16-F10 cells were 
induced to constitutively express a construct where transcription of a red-enhanced nanolantern (ReNL) 
reporter gene is prevented by a dual-SV40 transcription stop cassette (CRISPR-stop). The PiggyBac 
transposon plasmids used to generate GFPd2+ and CRISPR-stop+ cell lines are available on Addgene as 
plasmids #115665 and #113965, respectively. 
 
Transfection 
Cells were plated at a density of 15,000 cells per well in 96 well tissue culture plates and allowed to 
adhere overnight. Protein-encapsulated nanoparticles were prepared as described above, and optimal 
nanoparticle formulations for each protein are listed in Table 7-S1. 20 PL nanoparticles were added per well 
into serum-containing complete cell culture media and incubated with cells for 4 hours. For FITC-BSA 
uptake experiments, the nanoparticle/media mixture was removed at 4 hours, and cells were washed 3 times 
with PBS and uptake was assessed via flow cytometry using a BD Accuri C6 flow cytometer (BD 
Biosciences). Nanoparticle uptake was quantified by normalizing the geometric mean fluorescence of treated 
wells to that of untransfected controls.  
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For all other transfection experiments, fresh complete medium was replenished after 4 hours 
incubation with nanoparticles. For saporin transfection experiments, cell killing was assessed 2 days post-
transfection. Cells were stained with Hoechst 33342 nuclear stain (1:5000 dilution) and propidium iodide 
(1:500 dilution) for 20 minutes and imaged and analyzed using Cellomics Arrayscan VTI with live cell imaging 
module (ThermoFisher). Cell killing was calculated by normalizing live cell numbers in wells treated with 
C5/saporin nanoparticles to those in wells treated with matching nanoparticle formulations delivering non-
toxic BSA. For CRISPR RNP transfection experiments, gene editing was assessed 3 days post-transfection. 
GFPd2 knockout and turning on of ReNL were assessed via flow cytometry. GFPd2 knockout was 
quantified by normalizing the GFP geometric mean fluorescence of C5/RNP treated wells to that of 
untransfected control wells; gain of ReNL fluorescence was quantified as the percentage of cells positively 
expressing ReNL when gated against untreated control.  
For CRISPR HDR experiments, Cas9 and sgRNA targeting the CXCR4 gene were first mixed at a 
1:2 molar ratio and allowed to self-assemble into RNPs. The ssDNA repair template was then added at a 1:1 
volume ratio to the RNPs, and the combined solution was mixed with C5 polymer to allow for nanoparticle 
self-assembly. Each well received a final dose of 300 ng sgRNA, 690 ng Cas9 protein, and 400 ng ssDNA 
repair template. 
 
Commercial Reagent RNP Delivery 
 For CRISPR RNP delivery experiments using commercial reagents, B16-F10 cells expressing the 
PiggyBac CRISPR-stop+ cassette were plated in 96 well plates 24 hours prior. Lipofectamine™ CRISPRMax 
and jetCRISPR™ commercial reagents designed for RNP delivery were formulated with SpCas9 RNP 
nanoparticles according to manufacturer instructions and added to cells at the specified doses. Specifically, 
RNPs were formulated as recommended at 1:1 molar ratio of SpCas9 to sgRNA using the single guide 
CRISPR-stop sgRNA and complexed with commercial reagents prior to adding to cells and incubating 48 
hours. Editing efficacy was assessed two days following RNP delivery using flow cytometry to assess 
percentage of cells expressing ReNL from the 630 bp deletion of the CRISPR-stop+ cassette. 
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Endocytosis Pathway Inhibition 
HEK-293T cells were plated for transfection as described above and incubated for 1 hr with 
endocytosis inhibitors32 in complete cell culture media immediately prior to transfection. Chlorpromazine 
(CPZ; 3 Pg/mL) was used to inhibit clathrin-mediated endocytosis; methyl-E-cyclodextrin (MCD; 7.5 
mg/mL) was used to inhibit lipid raft-mediated endocytosis; genistein (GEN; 10 Pg/mL) was used to inhibit 
caveolin-mediated endocytosis; cytochalasin-D (CYD; 0.5 Pg/mL) was used to inhibit actin polymerization 
and macropinocytosis. C5/FITC-BSA nanoparticles were formulated at 300 ng protein per well and 30 w/w. 
Nanoparticles were incubated with cells for 2 hr, at which time they were washed with PBS and analyzed via 
flow cytometry to assess nanoparticle uptake. Endocytosis inhibition was quantified by normalizing the 
geometric mean fluorescence of wells treated with inhibitor to that of untransfected control wells.   
 
Gal8-GFP Recruitment Assay  
The Gal8-GFP recruitment assay to assess endosomal disruption was based on methods previously 
reported by Kilchrist et al.18 Briefly, B16-F10 cells were made to constitutively express a Gal8-GFP fusion 
protein using a PiggyBac transposon plasmid (Addgene 127191). Nanoparticles encapsulating BSA (125 ng 
BSA per well, 25 w/w) were incubated with cells for 4 hours, at which point cells were replenished with 
complete media and stained with Hoechst 33342 nuclear stain (1:5000 dilution). Gal8-GFP recruitment was 
imaged and analyzed with Cellomics Arrayscan VTI with live cell imaging module; cell count was generated 
using an algorithm to extrapolate area surrounding Hoechst-stained cell nuclei and endosomal disruption was 
reported as the average number of punctate Gal8-GFP spots per cell. 
 
Cellular Viability 
Cell viability was assessed 24 hours post-transfection using MTS CellTiter 96 Aqueous One cell 
proliferation assay (Promega) following manufacturer’s instructions. Cell viability of treated cells were 




HEK-293T or MSC-083 cells were plated on Nunc Lab-Tek 8 chambered borosilicate coverglass 
well plates (155411; ThermoFisher) at 30,000 cells/well in 250 µL phenol red free DMEM supplemented with 
10% FBS and 1% penicillin/streptomycin one day prior to transfection. C5 nanoparticles were prepared at 30 
w/w with the indicated proteins and 50 µL nanoparticles were administered per well for a total dose of 300 
ng protein. Nanoparticles were incubated with cells for 4 hours, at which time cells were replenished with 
fresh complete medium and stained with Hoechst 33342 nuclear stain at a 1:5000 dilution and Cell Navigator 
Lysosome Staining dye (AAT Bioquest). Excess stain was washed away and cells were imaged in live cell 
imaging solution at 37°C in 5% CO
2. Images were acquired at Nyquist limit resolution using a Zeiss LSM 780 
microscope with Zen Blue software and 63x oil immersion lens. Specific laser channels used were 405 nm 
diode, 488 nm argon, 561 nm solid-state, and 639 nm diode lasers. Laser intensity and detector gain settings 
were maintained across all image acquisition for each experiment.   
 
Indel Quantification via Surveyor® Assay 
Genomic DNA from cells treated with C5/RNP nanoparticles and untransfected controls were 
isolated using a GeneJET genomic DNA purification kit (ThermoFisher). A 660 bp region flanking the 
predicted cut site was PCR amplified (primers listed in Table 7-S2), and PCR products were purified using a 
QIAquick PCR purification kit (Qiagen). 400 ng of PCR amplicons were hybridized in the presence of 50 
mM KCl, and the Surveyor® mutation detection assay (IDT) was performed following manufacturer’s 
instructions. The DNA products were then run on a 2% agarose gel stained with ethidium bromide in TBE 
buffer (80 V for 50 minutes) and imaged under UV light. DNA band intensity was quantified using ImageJ 
image analysis software and indel rate was calculated based on the method by Schumann et al.33  
HDR Quantification via Restriction Enzyme Digest 
A restriction enzyme-based assay to quantify HDR rates was adapted from methods reported by Lee 
et al.28 Briefly, a HDR repair template was designed to insert a 12-bp region that includes the HindIII 
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restriction site into the CXCR4 gene, with 78 base homology arm upstream and 90 base homology arm 
downstream of the insert site. The repair template was synthesized as a single-stranded DNA oligo from IDT 
(sequence listed in Table 7-S2). Genomic DNA of cells treated with C5/RNP+ssDNA nanoparticles or 
control nanoparticles was harvested 5 days post-transfection. A 770 bp region surrounding the edit site was 
PCR amplified, and the PCR amplicon was digested with HindIII (0.01 enzyme units/ng DNA) for 1 hr at 
37°C prior to standard gel electrophoresis as described above. Percent HDR was calculated by dividing the 
band intensity of the digested fragment (approximately 400 bp) by the band intensity of all bands in the lane.  
 
GL261-CRISPR-stop Tumor Implantation 
All animal work was done in strict adherence of the policies and guidelines of the Johns Hopkins 
University Animal Care and Use Committee. For intracranial tumor implantations, 6-8 week old female 
C57BL/6J mice (Jackson Laboratory) were anesthetized using a 10 mg/kg ketamine (100 mg/kg)/Xylazine 
(10 mg/kg) cocktail and mounted on a stereotaxic frame. A rostro-caudal incision was made with a scalpel, 
the surface of the skull was exposed and cleaned with 100% ethanol, and a small burr hole was made in the 
skull 4 mm posterior to the coronal suture and 2 mm lateral to the sagittal suture using an electric drill. 
130,000 GL261 murine glioma cells engineered to constitutively express the CRISPR-stop construct were 
implanted into mouse brain parenchyma through the burr hole using a 10 µL Hamilton syringe (Hamilton 
Company); the injection volume was 2 µL. 
 
Intratumoral C5/RNP Nanoparticle Injection  
Tumors were allowed to form for 10 days, at which time C5/RNP nanoparticle administration 
began. Nanoparticles were formed in PBS buffer at a final polymer concentration of 0.86 mg/mL and 3.5 
pmol RNPs (15 w/w) immediately prior to injection. Mice were anesthetized with a 10 mg/kg ketamine 
cocktail as described earlier, and the original incision was opened. Convection-enhanced delivery (CED) was 
performed using a 26 gauge Hamilton needle stereotaxically placed at a depth of 3 mm and an 
UltraMicroPump (UMP3) with SYS-Micro4 Controller (World Precision Instruments, Sarasota, FL) was used 
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to infuse nanoparticles at a rate of 0.5 µL/min.34 10 µL of nanoparticles were injected per animal, after which 
the needle was left at the injection site for 5 min to mitigate backflow. Following needle removal, the incision 
was closed with 4-0 silk sutures and the animal was allowed to awaken and recover.  
 
In Vivo Visualization of ReNL Reporter 
For ReNL reporter analysis, 6-d post-injection mice were anesthetized and perfused with 4% 
paraformaldehyde. Brains were extracted, post-fixed overnight, and soaked in 30% sucrose for 24 h. Brains 
were frozen on dry ice and mounted onto a cryostat sample holder using Optimal Cutting Temperature 
compound (OCT), cryosectioned (coronal plane sections) using a Leica CM 3050 S cryostat (Leica 
Biosystem), and the prepared 40 µm sections were mounted onto glass slides with Hoechst nuclear stain 
(1:4000 dilution) and SlowFade® Gold Antifade Reagent (ThermoFisher). Mounted sections were stored at -
80°C and protected from light until use. Sections were imaged by fluorescence microscopy using a Zeiss 




To characterize nanoparticle stability over time in physiological conditions, C5/RNP nanoparticles 
were incubated in serum-containing complete cell culture medium at 37°C and added to GL261-CRISPR-
stop cells at designated time points up to 4 h. C5/RNP nanoparticles were also lyophilized with 30 mg/mL 
sucrose as cryoprotectant following previously-reported protocols35 and stored at -20°C for 4 days before 
adding to cells. Cells were incubated with nanoparticles for 3 h and the level of gene editing was analyzed via 
flow cytometry 3 days post-transfection. 
 
Statistics 
Prism 6 (Graphpad, La Jolla, CA) was used for all statistical analyses and curve plotting. Statistical tests were 
performed with a global alpha value of 0.05. Unless otherwise stated, absence of statistical significance 
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markings where a test was stated to have been performed signified no statistical significance. The statistical 
test used and the number of experimental replicates were listed in the captions for each figure. Statistical 
significance was denoted as follows: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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Figure 7-S1. Synthesis and characterization of carboxylated branched PBAE polymers. (A) Monomer 
structures. (B) Reaction scheme for branched polymers.  (1) Acrylate-terminated branched PBAE is 
synthesized via Michael addition of B and S monomers; (2) polymer end-capping with monomer E1 results in 
amine-terminated polymers; (3) further end-capping with carboxylate ligands yields final polymer products. 
(C) 1H NMR spectrum of polymer C5; distinctive peaks from each monomer are labeled according to 
chemical structures shown in (A). (D) Molecular weight data of polymer C5 obtained via GPC. 
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Figure 7-S2. Synthesis and characterization of carboxylate ligands. (A) Reaction route schematic. (B) 
Acidification pH for extraction of each ligand. (C) 1H NMR spectrum of each ligand; peaks labeled according 
to the chemical structure shown in (A). 
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Figure 7-S3. Cell viability after treatment with carboxylated branched PBAE protein nanoparticles. 
(A) Cell viability of CT-2A murine glioma cells treated with E1-C10 nanoparticles encapsulating BSA. (B) 
Cell viability of other cell types treated with C5/BSA nanoparticles. Nanoparticle formulation used in both 
















Figure 7-S4. Confocal images of cells treated with C5/FITC-BSA nanoparticles. (A) Human adipose-
derived mesenchymal stem cells and (B) HEK-293T cells were treated with C5/FITC-BSA nanoparticles 
(300 ng protein dose, 30 w/w) and imaged at 5 and 24 hours post-transfection. Untreated cells (UT) were also 
imaged as controls. Scale bar = 10 µm. 
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Figure 7-S5. Characterization of polymer pH buffering and endosomal disruption capabilities. (A) 
pH titration curve of several polymers in the series. Sigmoidal curve fit of the titration curves and comparison 
via sum-of-squares F-test statistically demonstrated that there was no significant difference between buffering 
in the range of pH 4.5-8 for carboxylate ligands (P = 0.062). (B) Representative images from high content 
imaging of B16-F10/Gal8-GFP cells treated with nanoparticles encapsulating BSA (125 ng BSA per well, 25 





Figure 7-S6. C5/RNP nanoparticles enable in vitro gene deletion. (A) C5/RNP deletion of stop 
cassette in vitro in 2 murine cancer cell lines resulted in turning on of ReNL fluorescence as detected by flow 
cytometry. Data are mean+SD; n=4. (B) Comparison in gene editing performance with commercially-
available CRISPR transfection reagents in B16-F10 cells. C5/RNP nanoparticles were administered at an 
RNP dose of 35 nM per well; RNP dose for commercial reagents are indicated. For each commercial reagent, 
the manufacturer recommended RNP dose is indicated by checkerboard pattern. Turning on of ReNL 
fluorescence was quantified by flow cytometry. Data are mean+SD; n=4. Statistical analysis performed using 
one-way ANOVA with Dunnett’s post-hoc tests compared against the C5/RNP group; **P<0.01, 
****P<0.0001. 
  
Figure 7-S7. C5/RNP nanoparticles are stable in serum-containing media and in lyophilized form. 
(A) % Editing observed in GL261-CRISPR-stop cells after treatment with nanoparticles pre-incubated in 
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serum-containing complete medium at 37°C for the designated times. Statistical significance determined by 
one-way ANOVA with Dunnett’s post-hoc tests as compared to time = 0 . Data presented as mean+SD; 
(n=4). *P<0.05. (B) Nanoparticles lyophilized with or without 30 mg/mL sucrose and stored at -20°C prior 
to being added to cells. Percent editing normalized to fresh nanoparticles. Data presented as mean+SD; n=4. 
Statistical significance determined by one-way ANOVA with Dunnett’s post-hoc tests as compared to fresh 
nanoparticles; (n=4). *P<0.05, ****P<0.0001. 
 
 
Figure 7-S8. C5/RNP nanoparticle-enabled in vivo CRISPR editing is reproducible. Red ReNL 
fluorescent signal can be detected in 3 additional mice treated with C5/RNP nanoparticles while untreated 
and RNP only groups showed no signal. Nanoparticles were formulated at 3.5 pmol RNP with 15 w/w C5 





Table 7-S1. Characteristics of proteins and encapsulated C5 nanoparticles and optimal nanoparticle 
formulations used in this study. 
Protein 
Characteristics Nanoparticle Characteristics












GFP 27 kD 5.8 150±50 9.9±0.7 300 ng 0.075 30
Saporin 29 kD 9.5 120±30 8.7±0.4 2.5-15 nM 0.075 2600-175
BSA 66.5 kD 4.7 160±60 5±1 300 ng 0.075 30
IgG 150 kD 6.6-7.2 120±20 -1±1 300 ng 0.075 30
Cas9 163 kD 9 180±10 12.3±0.2 690 ng 0.1 22
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GFP GGAGCGCACCATCTTCTTCAAGG PAM; Positive strand
CRISPR-stop GTATAGCATACATTATACGAGG PAM; Negative strand



























Amplicon size: 630 bp
GFP_REV CACGAACTCCAGCAGGACCATG
CXCR4_FWD TTAATTCTCTTGTGCCCTTAGCCCACTACTTCAG
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Abstract 
Nanoparticle-based mRNA therapeutics hold great promise for the treatment of a variety of diseases. 
However, cellular internalization and endosomal escape remain key barriers in functional, cytosolic mRNA 
delivery. To facilitate in vitro identification of potent mRNA nanoparticle formulations, we developed a dual 
nanoparticle uptake and endosomal disruption assay using high throughput and high content image-based 
screening. Using a genetically encoded Galectin 8 fluorescent fusion protein sensor (Gal8-mRuby), 
endosomal disruption could be detected 6 hours after nanoparticle treatment via Gal8-mRuby clustering on 
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damaged endosomal membranes. Simultaneously, nucleic acid endocytosis was quantified using fluorescently-
tagged mRNA. We used a series of biodegradable poly(beta-amino ester)s as well as Lipofectamine and PEI 
to demonstrate that this assay has higher predictive capacity for in vitro mRNA delivery compared to 
conventional polymer and nanoparticle physiochemical characteristics. Top nanoparticle formulations 
enabled safe and efficacious mRNA expression following intravenous injection, demonstrating that this in 
vitro screening method is also predictive of in vivo performance. Efficacious non-viral systemic delivery of 
mRNA with biodegradable particles opens up new avenues for genetic medicine and human health.  
 
Introduction 
Recent advances in the synthesis of in vitro transcribed (IVT) mRNA1, 2 has spurred a vast amount of 
research into mRNA-based gene therapies including the development of next generation vaccines.3 
Compared to their plasmid DNA counterparts, mRNA offers safer and more controlled gene expression by 
virtually eliminating the risk for integration into the host genome.4 mRNA delivery could also lead to more 
potent expression in cell populations that are largely refractory to DNA transfection, such as T cells, which 
have been shown to mount immune responses against foreign cytosolic DNA.5, 6 However, due to their size 
and hydrophilicity, mRNA molecules are membrane-impermeable, making safe and efficient cytosolic mRNA 
delivery a major obstacle to their clinical utility.  
Non-viral nanoparticle (NP) formulations have emerged as promising mRNA delivery vehicles. Many 
lipid-based7 and several polymeric8 mRNA NP systems have recently been reported for protein replacement,9, 
10 immune modulation,11, 12 and gene editing applications.13, 14 To fully realize the promise of mRNA 
therapeutics, NP systems must be engineered to overcome intracellular barriers, such as cellular 
internalization and escape from endosomal sequestration.15 A study of lipid NPs encapsulating siRNA 
showed that only an estimated 1-2%16 of internalized siRNA reaches the cytosol, highlighting the need for 
improved nanomaterials as well as quantitative high-throughput in vitro assays that can measure NP 
performance at key delivery bottlenecks and improve NP design.  
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Several image-based methods for quantifying the ability of NPs to overcome endosomal entrapment 
have been reported. The most common method is assessing the lack of co-localization of fluorescently 
labeled NPs with the pH-sensitive Lysotracker dye,17, 18 which selectively accumulates in the acidic 
environment of endosomes. This approach is easy to use and applicable to a wide variety of materials, but 
only provides an indirect assessment, as it does not indicate effective endosomal escape or disruption. 
Transmission electron microscopy (TEM) imaging is another widely accepted method for confirming 
endosomal disruption and escape.16, 19 However, this method is not amenable to high-throughput analysis, 
cannot be done on living cells, and requires electron-dense labels such as gold NPs, which could alter the 
properties of the native NP system. More recently, several groups have reported the use of advanced imaging 
approaches such as high-dynamic-range confocal microscopy20 or super-resolution stochastic optical 
reconstruction microscopy (STORM),21 which have yielded important mechanistic data for the intracellular 
fate of the materials being studied, but lack the high-throughput screening capacity required to evaluate arrays 
of nanomaterials.  
In this study, we used Galectin 8 (Gal8) tracking for high-throughput image-based quantification of 
endosomal disruption. Gal8 is a -galactoside carbohydrate-binding protein that selectively binds to glycans 
found on the inner leaflet of endosomal membranes.22, 23 Using cells genetically engineered to constitutively 
express a Gal8-mRuby fusion protein, we characterized the endosomal disruption capabilities of nanocarriers 
by quantifying the fluorescent puncta that formed following Gal8-mRuby clustering on damaged endosomal 
membranes, building upon the Gal8 recruitment assay using PEG-(DMAEMA-co-BMA) siRNA NPs by 
Kilchrist et al.24 We adapted this approach to a high-throughput, widefield imaging assay to simultaneously 
study how cellular internalization and endosomal disruption correlated with nucleic acid delivery efficacy of 
biodegradable poly(beta-amino ester)s (PBAEs) and other common materials for nucleic acid delivery. For 
PBAEs specifically, we systematically varied polymer backbone hydrophobicity as well as polymer end-cap 
structure to probe structure-function relationships. The predictive capacity of this dual cellular uptake and 
endosomal disruption assay was compared to that of several polymer and NP physiochemical properties such 
as polymer nucleic acid binding strength, pH buffering capacity, predicted LogP value, NP hydrodynamic 
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diameter, and zeta potential. The effects of nucleic acid cargo type as well as cell type for in vitro transfection 
were investigated. In total, a library of 22 PBAEs with unique chemical structures were screened as well as 
widely used commercially available transfection reagents such as Lipofectamine™ 3000, polyethyleneimine 
(PEI), and poly-L-lysine (PLL). Finally, we examined whether our new in vitro screening assays correlated with 
systemic in vivo delivery efficacy of polymeric NPs encapsulating mRNA upon tail-vein injection in mice. The 
data presented here demonstrate the robustness of this image-based dual NP uptake and endosomal 
disruption NP screening system across a broad range of materials for mRNA delivery efficacy in vitro as well 
as in vivo. Such a quantitative, high-throughput screening platform with high predictive capacity for delivery 
efficacy has important implications for the standardization of the optimization and testing of novel materials 
for non-viral gene delivery and genetic medicine.   
 
Results 
High-Content Imaging of NP Uptake and Endosomal Disruption  
 We engineered B16-F10 murine melanoma cells to genetically encode a Gal8-mRuby endosomal 
disruption sensor to facilitate simultaneous characterization of NP uptake and endosomal disruption. NP 
uptake was measured by quantifying Cy5 puncta resulting from intracellular delivery of NPs carrying Cy5-
labeled nucleic acids; endosomal disruption was measured by quantifying mRuby puncta resulting from Gal8-
mRuby clustering at damaged endosomal membranes (Figure 8-1A). This dual NP uptake and endosomal 
disruption assay was performed in a high-throughput manner using a CellInsight CX7 LZR high content 
imager capturing 20 fields of view per well of a 96-well plate at 20X magnification. An image analysis 
algorithm was then optimized and used to identify cells by extrapolating the cell body surrounding Hoechst 
33342-stained cell nuclei and provide puncta counts per cell (Figure 8-1B). On average, intracellular puncta 
count was collected for over 15,000 cells per NP formulation. 
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Figure 8-1. Image-based analysis of NP uptake and Gal8 endosomal disruption assay. (A) Assay 
overview: cells genetically encoding a Gal8-mRuby fusion fluorescence protein exhibited diffuse cytosolic 
mRuby signal in the absence of endosomal disruption. Endosomal disruption caused by NPs carrying Cy5-
labeled nucleic acid NPs allow Gal8-mRuby to bind to intra-endosomal glycans, resulting in punctate 
fluorescent spots. (B) A typical field-of-view (taken from 80 per NP formulation) imaged by high-throughput 
fluorescence microscopy of B16-F10 murine melanoma cells after 6 h exposure to PBAE NPs carrying Cy5-
mRNA. Cell identification was done using Hoechst 33342 staining of cell nuclei. Identification of Gal8-
mRuby puncta and Cy5 puncta were used to quantify endosomal disruption and NP uptake, respectively. 
Scale bars = 50 m. (C) Representative distributions of the Gal8 puncta or Cy5 puncta count per cell 
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 To identify the optimal time point to conduct the assay, we performed a time course experiment in 
which B16-mRuby-Gal8 cells were incubated with PBAE NPs for up to 30 h and imaged at select time 
points. We found that the Cy5 and Gal8 puncta counts both peaked at 6 h post-transfection for most nucleic 
acid cargo types and generally decreased thereafter (Figure 8-S1), guiding us to perform this assay at 6 h for 
all remaining experiments. The decreases in Gal8 and Cy5 puncta over time are consistent with expected 
autophagy timelines for damaged endocytic vesicles.25  
 
Effects of PBAE Backbone Hydrophobicity  
 We synthesized two series of PBAE polymers with varying hydrophobic monomer content to 
investigate the effects of polymer backbone hydrophobicity on NP uptake, endosomal disruption, and 
transfection capabilities. These were first synthesized as lipophilic PBAE terpolymers consisting of a linear 
diacrylate (B7) copolymerized with a hydrophilic amine (S90) and a hydrophobic amine (ScX) synthesized via 
Michael Addition reactions (Figure 8-2). Polymer hydrophobicity was varied in one series by incorporating 
hydrophobic amines of varying lipid tail length at 30 mol % and in a second series by varying the molar 
content of the Sc12 monomer. Polymers in both series were then end-capped with monomer E63 to create 
PBAE quadpolymers and molecular weight was found to be in the range of 4-10 kDa. All polymers were 
found to rapidly self-assemble into NPs with plasmid DNA, mRNA, and siRNA after simple pipette-mixing 
in aqueous buffer. NPs encapsulating nucleic acid cargo were 100-400 nm in diameter with positive zeta 
potential in the range of 30-60 mV (Figure 8-S2).  
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Figure 8-2. Chemical structure and characterization of PBAE NPs. (A) PBAE synthesis via 2-step 
Michael Addition reactions for linear, end-capped polymers (B) Structures of diacrylate (B), hydrophilic side 
chain (S), hydrophobic side chain (Sc), and endcap (E) monomers used in the synthesis of backbone 
hydrophobicity variation polymer series. (C) Representative TEM image of 7-90,c12-63, 50%-Sc12, mRNA 
NPs formulated at 60 w/w with 10% DMG-PEG2k and dialyzed into PBS. Scale bar = 100 nm. (D) DLS 
measurements of z-average NP hydrodynamic diameter and zeta potential of 7-90,c12-63, 50%-Sc12 NPs 
formed at 60 w/w and diluted into PBS. Data shown as mean + SD; n = 3.  
 
 We next assessed NP uptake, endosomal disruption, and gene delivery efficacy. In both PBAE 
polymer series, increasing polymer backbone hydrophobicity generally increased nucleic acid uptake and 
transfection in all three nucleic acid modalities (Figure 8-3A). The opposite was true for Gal8 endosomal 
disruption, where the polymer containing 100% Sc12 (most hydrophobic) resulted in half of the Gal8-mRuby 
puncta count compared to the polymer containing 0% Sc12 (least hydrophobic). Commercially available gene 
delivery materials were used to provide a benchmark for the bioassays. Of the five commercially available 
materials tested, Lipofectamine™ 3000 enabled the highest transfection across all nucleic acid types, followed 
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cells engineered to be GFP+, while transfection by DNA and mRNA NPs was assessed by GFP expression 
resulting from functional delivery of DNA or mRNA encoding the GFP gene in non-GFP+ cells. 
Transfection with these commercially available materials correlated positively with endosomal disruption 
(Spearman’s coefficient of 0.68), and no significant correlation with NP uptake was observed. The Gal8 
puncta counts for these materials were much lower than those achieved by PBAE NPs even when 
transfection efficacy was similar, suggesting that the two classes of materials utilize different mechanisms to 




Figure 8-3. Validation of dual nanoparticle uptake/Gal8 endosomal disruption assay in PBAE 
nanoparticles and commercial reagents delivering different nucleic acid cargos to B16-F10 cells. (A) 
Heatmaps summarizing nanoparticle uptake, Gal8 endosomal disruption, and transfection efficacy data. 
Uptake and Gal8 data were obtained from high-throughput imaging analysis. Transfection efficacy was 





































50 ng nucleice acid/well; 
Lipo3k - 1.2 uL reagent
bPEI - 15 w/w
lPEI - 60 w/w
PLL - 30 w/w










50 ng nucleice acid/well; 
Lipo3k - 1.2 uL reagent
bPEI - 15 w/w
lPEI - 60 w/w
PLL - 30 w/w
Fixed and stained 6 hr post-TF








































Increasing alkyl chain length
30% Alkyl: 7-90,cX-63
UT   0    8    10  12   14  16   18 UT   0   15  30  50 65  80 100
Hydrophobicity
















































Polymer Characteristics NP Properties NP-Cell Interactions
A
B C D




























r = -0.73  p = 0.004
r = -0.27   p = 0.35 (n.s.)
































r = 0.02     p = 0.94 (n.s.)
r = -0.38   p = 0.25 (n.s.)
r = -0.52   p = 0.06 (n.s.)siRNA
pDNA
mRNA




























r = 0.28     p = 0.33 (n.s.)
r = 0.57   p = 0.04 
r = 0.41   p = 0.14 (n.s.)siRNA
pDNA
mRNA




























r = 0.69    p = 0.008
r = 0.22   p = 0.44 (n.s.)
































r = 0.04    p = 0.88 (n.s.)
r = -0.77  p < 0.005 




































r = 0.03  p = 0.93 (n.s.)
r = -0.43  p = 0.13 (n.s.)
Combined r = -0.37 p = 0.01 Backbone HydrophobicityVariation
 262 
was normalized to the max fluorescence intensity across all treatment conditions. siRNA-mediated GFP 
knockdown was quantified by normalizing the percent GFP+ cells for siGFP treated wells to the 
corresponding formulation delivering scRNA control. Data presented as the mean of 4 replicate wells. 
Transfection efficacy of nanoparticles formed with PBAE polymers encapsulating all nucleic acid types was 
plotted against common predictor readouts such as (B) various polymer characteristics, (C) nanoparticle 
properties, and (D) nanoparticle-cell interactions. Correlation significance was assessed for PBAE 
nanoparticles using Spearman’s method, and data sets with statistically significant correlations were indicated 
with fitted lines. Data presented as mean ± SD, N=4. 
 
 We further assessed the predictive capacity of various polymer and NP properties on transfection 
efficacy. The polymer IC50 of nucleic acid binding, with larger values indicating weaker nucleic acid binding 
affinity, correlated negatively with DNA transfection but positively with siRNA knockdown. This may be due 
to the different intracellular sites of action for each nucleic acid. Plasmid DNA needs to reach the nucleus 
and strong initial binding could facilitate nuclear trafficking and maximize likelihood of transfection in each 
cell.  On the other hand, siRNA needs to only be released to the cytosol to be active, and thus weaker 
polymer-nucleic acid binding could enable quicker and more effective cargo release and activity. mRNA 
transfection was not observed to correlate significantly with nucleic acid binding affinity in these experiments 
(Figures 8-3B and 8-S4). Standard biophysical characterization measurements of NP size and zeta potential 
showed no significant correlations with transfection efficiency (Figure 8-3C). The NP-cell interactions 
quantified by our new high-throughput and high-content imaging-based assay showed that PBAE 
transfection generally correlated positively with NP uptake and negatively with Gal8 endosomal disruption 
(Figure 8-3D). The negative correlation between transfection and endosomal disruption levels in this series 
of PBAE NPs was surprising, although, even at their lowest, the endosomal disruption levels achieved with 
the PBAE NPs were significantly higher than those induced by the commercial gene delivery materials. Thus, 
all PBAE NPs evaluated may be above a critical threshold of endosomal disruption capacity necessary to 
enable functional nucleic acid delivery that is at least equal to or greater than the endosomal disruption 
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capacity achieved by commercial gene delivery materials. The data indicated that in these experiments 
endosomal disruption was not a major transfection bottleneck for PBAEs. Interestingly, empty PBAE 
polymeric NPs in the absence of nucleic acids resulted in equivalent levels of endosomal disruption as NPs 
loaded with nucleic acids (Figure 8-3A). This may explain why certain PBAE NP formulations less effective 
at transfection nonetheless exhibited high levels of endosomal disruption as these polymers may have formed 
a larger fraction of empty NPs. Such empty PBAE NPs could lead to a high Gal8 puncta count, indicating 
endosomal disruption, but would do so in a non-productive manner as no nucleic acids would be delivered to 
the cytosol. Interestingly, PBAE transfection with this series of polymers also did not correlate significantly 
with the polymers’ effective pKa, as quantified in the physiologically relevant pH range (Figures 8-3B, 8-S3, 
and 8-S5A), which also reinforces that endosomal disruption is not a rate-limiting step for these PBAE NPs 
to achieve intracellular delivery under these conditions. Other polymer properties such as the predicted LogP 
value, which is a measure of polymer hydrophobicity, showed strong positive correlations with transfection 
for all three cargo types (Figure 8-S5B), further confirming our hypothesis that increased backbone 
hydrophobicity improves polymeric gene delivery efficacy.  
 
Effects of Polymer End-groups 
 We next investigated the effects of polymer end-group structure on NP uptake and endosomal 
disruption by synthesizing an end-group variation polymer series by utilizing a moderately hydrophobic 
PBAE terpolymer backbone (7-90,c12-X, 50%-Sc12) and then independently conjugating 11 different end 
group monomers to it (Figure 8-4A). Previous work by our lab has shown that polymer end-group structure 
can play an important role in imparting biomaterial-mediated, selective transfection in certain cell types over 
others26, 27 and that these effects may be due to changes in NP uptake pathways.28 We hypothesized that our 
dual NP uptake/endosomal escape assay could be useful in further ascertaining how polymer end-group 
structure affect NP function in different cell types.  To test this hypothesis, and to further evaluate the 
robustness of our new high-throughput and high-content bioassay, we evaluated these polymers on 3 
different cell types induced to express the Gal8-mRuby construct: B16-F10 murine melanoma cells, RAW 
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264.7 murine macrophages, and NIH/3T3 murine fibroblasts. Our results showed highest mRNA 
transfection levels in B16-F10 cells, medium transfection in RAW 264.7 macrophages, and lowest 
transfection levels in  NIH/3T3 fibroblasts (Figure 8-4A). Endosomal disruption showed positive 
correlations with mRNA transfection levels in RAW and 3T3 cells but not B16 cells, with a significant 
positive correlation when all three cell lines were evaluated together (Figure 8-4B). This effect is particularly 
striking for more difficult-to-transfect cell types such as RAW 264.7 and NIH/3T3 cells (Spearman’s 
coefficient of 0.92 and 0.67, respectively), which suggests that mRNA transfection efficacy in difficult-to-
transfect cells may largely be attributable to barriers in endosomal escape. Interestingly, the highest NP uptake 
levels were observed in NIH/3T3 cells, which demonstrated the lowest levels of mRNA transfection, and in 
general mRNA transfection did not show significant correlations with PBAE NP uptake among these cell 
types  (Figure 8-4C). Collectively, these results suggest that for PBAEs with the same polymer backbone 
(and similar hydrophobicity), end-group structure plays an important role in endosomal disruption. These 
results also indicate that for these PBAEs, endosomal disruption, rather than NP uptake, is acting as a greater 
bottleneck for effective mRNA delivery. Differing levels of resistance to endosomal disruption among 





Figure 8-4. Effects of polymer end-group structure on mRNA transfection efficacy in multiple cell 
lines. (A) NP uptake, Gal8 puncta count, and mRNA delivery efficacy of polymer end-group variation 
PBAE library on three different cell lines. Transfection efficacy was plotted against (B) Gal8 puncta count 
indicating endosomal disruption or (C) Cy5 puncta count indicating NP uptake. Data presented as mean ± 
SD, n = 4. Correlation significance in (B)-(C) were calculated using Spearman’s method; a hyperbolic curve 
was fitted in (B) to indicate a statistically significant correlation.  
 
In Vivo mRNA Delivery: Whole-Body and Organ Level Expression 
 We next characterized the in vivo mRNA delivery capabilities of PBAE NPs after intravenous 
administration of NPs encapsulating mRNA encoding firefly luciferase (fLuc) to mice. For these experiments, 
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PEG-lipids into related PBAE NPs has been shown to enhance serum stability and in vivo mRNA 
expression.29, 30 Incorporation of DMG-PEG2k into the PBAE quadpolymers was observed to decrease NP 
size and neutralize surface charge (Figure 8-S8).  Dialysis and PEG-lipid coating did not significantly change 
transfection efficacy or endosomal disruption in vitro, though NP uptake was reduced. Upon in vivo 
administration, PEG-coated and dialyzed NPs enabled significantly higher mRNA expression compared to 
NPs without PEG coating, and this increased expression was predominately due to increased expression in 
the liver (Figure 8-S8F-G).  
Four polymers with 0-80% Sc12 content in the polymer backbone and five polymers with different 
polymer end-groups were chosen to assess the effects of polymer backbone and end-group structure on in 
vivo expression. On the whole-body level, increased backbone hydrophobicity generally resulted in increased 
mRNA expression (Figures 8-5B-C and 8-S6) while polymer end-group variation resulted in differential in 
vivo expression levels (Figures 8-5D and 8-S7). Interestingly, overall in vivo expression correlated positively 
with in vitro transfection of B16-F10 cells (Figure 8-5E), indicating that in vitro screening had predictive 
capacity for in vivo performance with these nanomaterials. At the level of individual organs, increasing 
backbone hydrophobicity increased expression in all of the organs evaluated (Figure 8-5F), while polymer 
end-group played a major role in targeting NP expression to specific organs (Figure 8-5G). Indeed, when 
expression in the lungs and spleen was normalized to that in the liver, polymer E1 showed preferential 
expression in the spleen, polymer E63 in the liver, polymer E58 in the lungs, and polymer E39 was almost 
equally split between the lungs and spleen (Figure 8-5H).  
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Figure 8-5. In vivo validation of PEG-coated PBAE NPs delivering mRNA. (A) Schematic depicting 
the experimental workflow. PBAE polymers were dialyzed with fLuc mRNA and the PEG-lipid DMG-
PEG2k in PBS to form PEG-coated mRNA NPs, which were administered intravenously. fLuc expression 
was assessed 24 h after NP injection. (B) Whole body bioluminescence was assessed for NPs formulated with 
PBAEs with differential backbone hydrophobicity and (C) representative IVIS images (N = 3). (D) Whole 
body bioluminescence quantification for NPs formulated with 50%-Sc12 PBAEs with different end-groups 
(N = 4). (E) In vivo transfection efficacy (from (B) and (D)) was plotted against in vitro transfection in B16 
cells. Spearman’s correlation was used to measure the strength of association between the two variables. 
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hydrophobicity (blue triangles below organ labels indicate increasing backbone hydrophobicity) and (G) 
polymer end-group structure. Statistical significance was determined using one-way ANOVA with Dunnett’s 
post-hoc analysis comparing against the least hydrophobic polymer (0% Sc12) in (B) and (F) and against end-
group E63 in (D) and (G). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. ns, not significant. (H) 
The organ targeting index as calculated by normalizing bioluminescent flux in each non-liver organ against 
that of the liver was calculated for the lungs and spleen in high-expressing polymers of the polymer end-
group variation series (E7 was excluded due to minimal expression observed). Dotted black line indicates 
liver expression level. N = 4. Data presented as mean ± SD in all bar graphs. 
 
In Vivo mRNA Delivery: Expression in Different Cell Types 
 We further probed the cell populations that were transfected in each organ using the Ai9 mouse 
model, which contains a floxed expression stop cassette upstream of a tdTomato reporter gene. NPs 
encapsulating Cre mRNA were administered via tail vein injection into Ai9 mice, and transfected cells 
underwent Cre-Lox recombination, resulting in tdTomato expression that was measured by flow cytometry 3 
d post-injection (Figure 8-6A). For this study, we used 7-90,c12-63, 80%-Sc12 NPs as they were found to 
enable high in vivo mRNA expression levels from fLuc mRNA experiments. We found that 7-90,c12-63, 80%-
Sc12 NPs systemically administered transfected nearly 0.2% of the cells in the spleen, 2% of the cells in the 
liver, and 4% of the cells in the lungs, with minimal transfection levels seen in any of the other organs 
evaluated (Figure 8-6B). Over 20% of endothelial cells in the lungs were transfected following systemic 
injection, which is consistent with previous reports for related PBAE structures,29 in addition to significant 
populations of macrophages and dendritic cells in the lungs (Figure 8-6C). Endothelial cells also made up a 




Figure 8-6. Assessment of in vivo mRNA transfection in different cell types. (A) Experimental 
workflow: Ai9 mice were injected with PEG-coated 7-90,c12-63, 80%-Sc12 NPs encapsulating Cre mRNA 
and single cell level transfection could be detected by tdTomato expression, which was quantified 3 days post-
injection using flow cytometry. (B) tdTomato+ cells as a percentage of the total cell population in each of 
several major organs. (C) tdTomato expression in the lungs in different cell types (tdTomato+ cells as a 
percentage of the overall population of each cell type). (D) Distribution of tdTomato+ cells across different 
cell types in liver, lungs, and spleen. N = 3. Data presented as mean ± SD in bar graphs.  
Discussion 
To realize the full therapeutic potential of mRNA therapeutics, a high-throughput, standardized NP 







































































































































































capacity for transfection efficacy is needed. In this study, we developed a high-throughput, high content, 
imaging-based screening platform designed to simultaneously assess the cellular internalization and 
endosomal disruption capabilities of nucleic acid delivery NPs, requiring only wide-field, epifluorescence 
microscopy to enable full assessment of the cytosolic compartment. This bioassay was developed to be 
implemented in multiwell plates, enabling the evaluation of many intracellular events per cell, in thousands of 
replicate cells per condition, with up to 96 conditions per plate. Endosomal sequestration has long been 
identified as a major bottleneck to functional RNA delivery in multiple NP systems,31, 32 but quantitative 
evaluation of endosomal disruption has been limited to low-throughput imaging methods requiring 
specialized microscopy modalities.16, 21 We utilized a genetically encoded endosomal disruption sensor based 
on the natural clustering of Gal8 molecules at damaged endosomal membranes to detect NP induced 
endosomal disruption quantified at the level of intracellular events within single cells. Simultaneously, cellular 
internalization of NPs could be tracked by delivering nucleic acids labeled with a different fluorophore. We 
hypothesized that this dual NP uptake and endosomal disruption assay could provide useful information on 
structure-function relationships when used to screen several NP gene delivery systems. 
We used two series of PBAE quadpolymers to validate this screening platform. PBAEs are cationic, 
biodegradable polymers that have been shown to be highly effective at in vitro delivery of plasmid DNA,33 
siRNA,34 mRNA,29 and protein cargos.35 The highly modular nature of these polymers facilitate combinatorial 
library synthesis via Michael Addition of small molecule precursors, making it possible to systematically vary 
polymer backbone or end-group characteristics to directly probe the effects of incremental differential 
polymer structural changes on downstream nucleic acid delivery efficacy. The PBAE quadpolymer is the 
majority component of all our NP delivery formulations, including systemically administered in vivo 
formulations, which have 10% PEG-lipid incorporated as a second component, without the presence of 
other lipids or cholesterol. This approach differs significantly from many previously studied lipid-based NP 
systems, in which the NP formulation was changed primarily by varying the ratios of incorporated lipids36 or 
the structure of the ionizable lipid in a NP system consisting of multiple lipid components.11  
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Two polymer series in which polymer backbone hydrophobicity were modulated by varying the 
content of lipophilic side chain monomers were synthesized to probe the effect of polymer backbone 
structure on cellular interactions of polymeric NPs. Traditional metrics of predicting NP function, such as 
polymer nucleic acid binding affinity, endosomal pH buffering potential, NP hydrodynamic diameter, and 
zeta potential, generally correlated poorly with functional delivery efficacy of multiple nucleic acid cargos, 
highlighting the need for new metrics for rapid and meaningful NP screening. The dual NP uptake and 
endosomal disruption assay presented here showed significant correlations with transfection efficacy for all 
nucleic acid cargos tested. NP uptake correlated positively with transfection (global r = 0.55, p < 0.001). 
Endosomal disruption correlated negatively with transfection for these PBAE NPs (that each had greater 
endosomal disruption capacity than that achieved by the commercial gene delivery materials) (r = -0.57, p < 
0.0001). The negative correlation with endosomal disruption is surprising, but may be attributed to the 
formation of polymer-only NPs that do not contain nucleic acid cargo. Amphiphilic PBAEs like the ones 
presented in this study have been reported to form polymer-only micellar NPs without any nucleic acid.37 
Thus, PBAEs that are effective at endosomal disruption, but not efficient at leading to transfection, may be 
forming large populations of polymer-only NPs empty of nucleic acid cargo. When these polymer-only NPs 
are internalized by cells, they could enable endosomal disruption, resulting in high Gal8 counts but low 
transfection. When this dual NP uptake/Gal8 endosomal disruption assay was applied to commercial gene 
delivery materials such as Lipofectamine 3000, branched and linear PEI, and PLL, endosomal disruption as 
indicated by Gal8 puncta count was significantly lower for all of these commercial materials than the PBAE 
NPs, which for the most part also resulted in lower transfection efficacy compared to PBAE NPs. 
Transfection of these positive control materials correlated positively with endosomal disruption for all cargo 
types (global r = 0.68, p = 0.02). Taken together, our data show that a threshold for endosomal disruption, as 
defined by the amount achieved by the most effective commercial transfection reagent Lipofectamine 3000 (  
2 Gal8 puncta per cell in B16-F10 cells), must be reached in order for gene delivery to efficiently occur. 
PBAE NPs generally enabled endosomal disruption levels significantly above this threshold in the B16-F10 
cells evaluated here and resulted in generally high transfection levels, while commercial materials such as 
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linear PEI and PLL enabled endosomal disruption levels below this threshold and consequently showed 
negligible transfection levels. The lack of high transfection of PBAE NPs across the board indicates that 
delivery obstacles further downstream (such as intracellular trafficking or cargo release) may pose significant 
delivery challenges for some of these materials.  
Previous studies have shown that the structure of PBAE polymer end-groups can significantly alter 
the transfection efficacy of the backbone polymer as well as impart biomaterial-mediated selectivity in 
transfection of certain cell types.26-28 We synthesized a polymer series with a common backbone but varying 
end-group structure and evaluated mRNA delivery efficacy on three cell lines. The endosomal disruption 
levels of these polymers had positive correlations with transfection efficacy, which were strongest in more 
difficult-to-transfect cell lines as indicated by Spearman’s coefficients (r) that are closer to 1; r = 0.93 for 
difficult-to-transfect RAW 264.7 cells but r = 0.47 for easier-to-transfect B16-F10 cells. Differences observed 
in transfection efficacy were not attributable to polymers’ pH buffering capabilities, which varied with 
backbone structure but were generally unaffected by end-group structure. Even in the 7-90,c12-63 X% alkyl 
side chain polymer series, in which the effective pKa decreased with increasing hydrophobic Sc12 content in 
the polymer backbone, the correlation between pH buffering and transfection efficacy was poor. This is in 
contrast to an observation recently reported by our group with hyperbranched PBAEs, where increasing 
polymer branching by incorporation of a triacrylate monomer in the backbone increased both effective pKa 
and transfection33 suggesting that different classes of PBAE polymer structures can enable endosomal escape 
via differing mechanisms. In the case of the linear lipophilic PBAE quadpolymers, the endosomal disruption 
mechanism may rely on the lipophilicity of the polymers causing them to associate with and directly interact 
with the endosomal membrane, where the charged polymer end-groups may cause transient pore formation 
that leads to NP leakage out of damaged endosomes, similar to that observed with lipid materials,16, 32 rather 
than acidic buffering-induced complete endosomal rupture as proposed by the proton sponge hypothesis.21 
NP uptake of the end-modified linear PBAEs did not correlate significantly with mRNA transfection efficacy 
(r = 0.22, p = 0.44), although a significant positive correlation was observed when PBAE NPs carrying each 
of the three nucleic acid cargos were analyzed globally (global r = 0.55, p < 0.001). Collectively, our data 
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suggest that endosomal escape is the primary barrier in mRNA delivery to more difficult-to-transfect cells and 
that the differential gene delivery efficacy mediated by polymer end-groups is largely due to their ability to 
facilitate endosomal disruption.  
Finally, we validated these PBAE NPs for in vivo mRNA expression following tail vein injection into 
mice. NPs formulated by simple mixing of mRNA and polymer in aqueous buffer yielded significantly lower 
transfection, particularly in the liver, than similar formulations with 10% PEG-lipid dialyzed into the NPs. 
Using dialyzed PEG-coated formulations, we saw that in vivo mRNA expression levels correlated strongly 
with in vitro transfection efficacy in B16-F10 cells, indicating a predictive capacity that is rare in large library 
screens.38 Increasing polymer backbone hydrophobicity increased whole-body mRNA expression in general, 
following trends that we observed in vitro, and which could also be due in part to improved incorporation of 
PEG-lipid in hydrophobic formulations which could lead to more stable NPs in the blood.30 Similar to 
differential transfection of various cell types in vitro, polymer end-group variation also led to tuning of organ 
tropism in vivo. Unlike most lipid NP formulations which have been demonstrated to predominantly target 
liver hepatocytes,39, 40 the four top performing NP formulations from the in vitro mRNA transfection screens 
in the end-group variation polymer series exhibited alternative patterns of expression in non-liver organs, 
with preferential transfection in the lungs and/or spleen. Particularly high expression was seen in the lungs 
for most formulations, which is consistent with previous reports by Kaczmarek et al. utilizing related PBAE 
lipid-polymer NP formulations for mRNA delivery.29 Within each organ, multiple cell types were transfected, 
including endothelial cells, B cells, and macrophages, all of which have distinct clinical relevance. The 
lipophilic side chains of the polymers enabled the PEG-lipid DMG-PEG2k to be easily incorporated into NP 
formulations via dialysis, which increased in vivo expression by an order of magnitude compared to NPs 
without PEG-lipid coating despite slightly lowering in vitro transfection. Cheng et al. recently reported that 
incorporation of selective organ targeting (SORT) molecules at defined ratios enabled highly targeted mRNA 
expression in select organs and that these molecules maintained their organ targeting capabilities across 
multiple lipid NP platforms.41 This suggests intriguing future directions where an innate organ tropism of 
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PBAE NP formulations could perhaps be combined with other technologies to enhance selective organ 
targeting, and potentially cell-type specific targeting.  
In summary, we have reported a high content high throughput quantitative imaging assay capable of 
simultaneously quantifying NP uptake and endosomal disruption. This assay is robust, has higher predictive 
capacity for in vitro mRNA delivery efficacy compared to conventionally used metrics of polymer or NP 
properties, and can be performed with ~100 nanoparticle formulations in a few hours. Assay validation using 
PBAE NPs elucidated structure-function relationships through incremental changes in both the polymer 
backbone and end-groups for these highly modular polymers. Moreover, we showed that this assay is 
generally applicable across all major nucleic acid types, several different cell lines, and multiple gene delivery 
systems. The NP screening platform presented herein can be a useful tool for high-throughput identification 
of promising candidates for gene delivery and further elucidation of structure/function relationships for the 
delivery of DNA, siRNA, and mRNA. Lead nanomaterials composed of PBAE quadpolymers demonstrated 
safe and effective delivery of mRNA in vivo, including organ-targeted expression based on polymer structure. 
PEGylated PBAE NPs enabled significant exogenous mRNA expression differentially to the liver, lung, and 
spleen. Critically, nanomaterial formulations identified as lead candidates in vitro also performed well for in vivo 
mRNA delivery following systemic intravenous injection.  Such a broadly applicable screening method 
provides a new metric for nanomaterial characterization, which is important for directly comparing and 
contextualizing the myriad NP systems that have been reported in the burgeoning field of intracellular gene 
delivery. With further study, the PBAE-based materials investigated here may be promising for mRNA 
delivery to promote human health.  
 
Materials and Methods 
Materials 
 Bisphenol A glycerolate (1 glycerol/phenol) diacrylate (B7; CAS 4687949), 4-(2-
aminoethyl)morpholine (S90; CAS 2038-031), octylamine (Sc8; CAS 111-86-4), 1-decylamine (Sc10; CAS 
2016-57-1), oleylamine (Sc18; CAS  112-90-3), 1,3-diaminopropane (E1; CAS 109-76-2), 
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tetraethylenepentamine (E31; CAS 1112-57-2),  N,N-diethyldiethylenetriamine (E58; CAS 24426-16-2), tris(2-
aminoethyl)amine (E32; CAS 4097-89-6), 2-(3-Aminopropylamino)ethanol (E6; CAS  4461-39-6), 4,7,10-
trioxa-1,13-tridecanediamine (E27; CAS 4246-51-9), and 1-(2-aminoethyl)piperazine (E39; CAS 140-31-8) 
were purchased from Sigma-Aldrich (St. Louis, MO). 1-Dodecylamine (Sc12; CAS 124-22-1) and 1-(3-
aminopropyl)-4-methylpiperazine (E7; CAS 4572-031) were purchased from Alfa Aesar (Tewksbury, MA). 
Tetradecylamine (Sc14; CAS 2016-42-4) and hexadecylamine (Sc16; CAS 143-27-1) were purchased from 
Acros Organics (Pittsburgh, PA). Diethylentriamine (E63; CAS 111-40-0) was purchased from EMD 
Millipore (Burlington, MA). 3,3′-Iminobis(N,N-dimethylpropylamine) (E56; CAS 6711484) was purchased 
from Sant Cruz Biotechnology (Dallas, TX). 1,4-Bis(3-aminopropyl)piperazine (E65; CAS 7209-38-3) was 
purchased from MP Biomedicals (Solon, OH).  
Plasmid eGFP-N1(Addgene 2491) was purchased from Elim Biopharmaceuticals (Hayward, CA) and 
amplified by Aldevron (Fargo, ND). Cy5-labeled plasmid DNA was synthesized following a method reported 
by Wilson et al.42 5-methoxyuridine-modified CleanCap® eGFP mRNA (L-7201), fLuc mRNA (L-7202), and 
Cy5-labeled mRNA (L-7702) were purchased from TriLink Biotechnologies (San Diego, CA). Negative 
control siRNA (1027281) was purchased from Qiagen (Germantown, MD). GFP siRNA targeting the 
sequence 5’-GCA AGC TGA CCC TGA AGT TC-3’ (P-002048-01) was purchased from Dharmacon 
(Lafayette, CO). Cy5-labeled siRNA (SIC005) was purchased from Sigma Aldrich (St. Louis, MO). Plasmid 
DNA encoding a Gal8 fluorescent fusion protein was a generous gift from the lab of Dr. Craig Duvall and 
cloned into a PiggyBac transposon vector (PB-mRuby3-Gal8, Addgene #150815) for stable integration into 
mammalian chromosomal DNA. 
 
Polymer Synthesis 
 Polymers were synthesized using previously reported protocols.33 Briefly, diacrylate monomer B7 and 
side chain monomers (S90 and combinations of ScX monomers) were dissolved at 600 mg/mL in 
dimethylformamide (DMF) and reacted with stirring for 48 h at 90 C to allow polymerization via step-wise 
Michael Addition reactions. Monomers were reacted at an overall vinyl:amine ratio of 2.3 to allow acrylate-
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terminated polymers to form. Polymers were end-capped by further reaction with primary amine-containing 
E monomers at room temperature for 2 h [200 mg/mL polymer and 0.3 M E monomer in tetrahydrofuran 
(THF)] and purified by 2 diethyl ether washes. Diethyl ether was decanted, dried thoroughly under vacuum, 
and polymers were dissolved in dimethyl sulfoxide (DMSO) at 100 mg/mL and stored at -20 C with 
desiccant in single-use aliquots.  
 
Polymer Characterization 
 Polymer molecular weight was characterized using gel permeation chromatography (GPC) against 
linear polystyrene standards (Waters, Milford, MA). Polymers were dissolved in BHT-stabilized THF and 
filtered through 0.2-μm PTFE filters prior to GPC measurements. Predicted polymer LogP values were 
calculated using the online cheminformatics software molinspiration.com.  
 
Polymer Buffering Capacity and Determination of Effective pKa 
 pH titrations were performed using a SevenEasy pH meter (Mettler Toledo, Columbus, OH) as 
previously described.33 Briefly, 10 mg polymer was dissolved in 10 mL of 100 mM NaCl acidified with HCl 
and titrated from pH 3.0 to pH 11.0 via stepwise addition of 100 mM NaOH. To calculate the effective pKa 
of the polymer in the physiologically relevant pH range (pH 5-8), normalized buffering capacity was 
calculated from titration data as Δ(-OH)/Δ(pH) for each titration point. Effective pKa was defined as the pH 
point corresponding to the maximum normalized buffering capacity.  
 
Nucleic Acid Binding Assays 
Ribogreen nucleic acid binding dye (Invitrogen, Carlsbad, CA) was mixed with nucleic acids in 25 
mM magnesium acetate buffer (MgAc2, pH 5.0) at a final nucleic acid concentration of 5 μg/mL (siRNA), 2.5 
μg/mL (mRNA), or 1 μg/mL (pDNA) and a final 1:2000 RiboGreen dilution. Polymers were dissolved and 
serially diluted to a range of concentrations in MgAc2, and 25 μL polymer solution was mixed with 75 μL 
nucleic acid/RiboGreen solution per well in 96-well black bottom assay plates. The solutions were incubated 
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at 37 C for 20 minutes before fluorescence readings were taken on a Biotek Synergy 2 fluorescence 
multiplate reader (BioTek, Winooski, VT). To characterize nucleic acid binding affinity, the polymer IC50 of 
binding (polymer concentration at which 50% of RiboGreen fluorescence is quenched by RiboGreen 
displacement from polymer binding to nucleic acids) was calculated by plotting % fluorescence quenching as 
a function of polymer concentration and fitting a sigmoidal curve to the data. Polymer IC50 of binding varies 
inversely with binding affinity; lower IC50 values indicate higher binding affinity. 
 
NP Formulation and Characterization 
For in vitro studies, NPs were formulated in 25 mM magnesium acetate buffer (MgAc2, pH 5) and 
added directly to cells without the addition of PEG lipids or dialysis. Polymers and nucleic acids (plasmid 
DNA, mRNA, or siRNA) were dissolved separately in 25 mM MgAc2 at concentrations of 0.83 ng/ L for 
nucleic acids and 50 ng/ L for polymers, and mixed together via pipetting at a 1:1 volume ratio. NPs were 
allowed to self-assemble for 10 minutes at room temperature; the polymer-to-nucleic acid ratio was 60 by 
weight (60 w/w) for all experiments.  
 NP hydrodynamic diameter was measured via dynamic light scattering (DLS) using a Malvern 
Zetasizer Pro with universal dip cell (Malvern Panalytical, Malvern, United Kingdom). Samples were prepared 
in 25 mM MgAc2 and diluted 1:6 in 150 mM PBS to determine NP characteristics in neutral, isotonic buffer. 
Zeta potential was measured by electrophoretic light scattering on the same instrument. Transmission 
electron microscopy (TEM) images were captured using a Philips CM120 transmission electron microscope 
(Philips Research, Cambridge, MA). 30 L NP samples were allowed to coat 400-square mesh carbon coated 
TEM grids for 20 minutes. Grids were then rinsed with ultrapure water and allowed to fully dry before 
imaging.  
  
Cell Culture and Cell Line Preparation 
 B16-F10 murine melanoma and RAW 264.7 murine macrophage cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM; ThermoFisher, Waltham, MA) supplemented with 10% FBS and 1% 
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penicillin/streptomycin. GFPd2+ B16-F10 cells used in siRNA knockdown experiments were established 
previously35 and cultured using the same medium. NIH/3T3 murine fibroblasts were cultured in DMEM 
supplemented with 10% bovine calf serum and 1% penicillin/streptomycin. Cells were induced to 
constitutively express the Gal8-mRuby fusion fluorescent protein construct using the PiggyBac 
transposon/transposase system. The PiggyBac transposon plasmid carrying the Gal8-mRuby gene was 
created using restriction enzyme cloning and is available on Addgene (plasmid #150815). The transposase 
expression plasmid (PB200A-1) was purchased from System Biosciences (Palo Alto, CA). The transposon 
plasmid was co-transfected with the PiggyBac transposase plasmid using PBAE NPs as described below. 
mRuby+ cells were isolated using at least two rounds of fluorescence assisted cell sorting using a Sony SH800 
Cell Sorter (Sony Biotechnology, San Jose, CA) to generate stably expressing cell lines. 
 
Transfection 
 Cells were plated at 10,000 cells per well in 100 L complete medium in CytoOne 96 well plates 
(USA Scientific, Ocala, FL) and allowed to adhere overnight. NPs were formulated following the in vitro 
transfection formulation described above; 20 L NP solution was added to 100 L fresh complete medium, 
and 120 L per well of the NP medium mixture was used to replace the culture medium. For all in vitro 
transfections, NPs were formulated at 60 w/w delivering 50 ng nucleic acids per well. For cellular uptake 
experiments, 20% of the total nucleic acid drugs were replaced with Cy5-labeled nucleic acids prior to mixing 
with polymers. NPs were incubated with cells at 37 C for the appropriate duration, depending on assay 
conditions (6 h for dual uptake/Gal8 assay, 24 h for mRNA and siRNA transfections, and 48 h for DNA 
transfections).  
 For transfections using commercially available reagents, LipofectamineTM 3000 (ThermoFisher) was 
used as instructed by the manufacturer. 25 kD branched polyethylenimine (BPEI), 2.5 kD linear 
polyethylenimine (LPEI), and 15 kD poly-L-lysine (PLL) were used at the highest concentrations that did not 
cause significant cytotoxicity (15 w/w for BPEI, 60 w/w for LPEI, and 30 w/w for PLL). PEI NPs were 
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formulated in 150 mM NaCl solution, and PLL NPs were formulated in 10 M HEPES buffer (pH 7); all 
formulations delivered 50 ng nucleic acids to match the dose delivered by PBAE NPs.  
 Transfection efficacy was evaluated via flow cytometry using a BD Accuri C6 flow cytometer (BD 
Biosciences, East Rutherford, NJ). For plasmid DNA and mRNA transfections, the expression of a GFP 
reporter gene was quantified by normalizing the geometric mean fluorescence intensity of each NP treatment 
to that of the formulation achieving maximum expression. Cells previously engineered to constitutively 
express GFP43 were used siRNA knockdown transfections, and the percentage of cells positively expressing 
GFP when gated against untreated cells in wells treated with siRNA targeting GFP was normalized against 
that of wells treated with non-coding control siRNA.  
 
Dual NP Uptake and Gal8 Endosomal Disruption Assay 
 NPs of matching formulation as those used for transfection experiments were used to deliver nucleic 
acids cargo containing 20% Cy5-labeled nucleic acids to enable visualization of NP uptake. NPs were 
incubated with Gal8-mRuby+ cells for 6 h (assay time point optimized in Figure 8-S2), at which point NPs 
and cell culture medium were removed, cells were washed with PBS, and fixed with 10% formalin for 10 
minutes at room temperature. The formalin was then removed, cells washed with PBS, and Hoechst nuclear 
stain (1:5000 in PBS) was applied for 10 minutes. NP uptake and Gal8-mRuby endosomal escape were then 
quantified by high-content imaging analysis of Cy5 and mRuby puncta per cell, respectively, using a 
CellInsight CX7 LZR high-content imager (ThermoFisher) with HCS Studio analysis software.  
 
NP Formulation for In Vivo Studies 
 NPs for in vivo mRNA delivery were formulated at 30 w/w. mRNA was dissolved in MgAc2, while 
polymer and the PEG-lipid 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2k, 
10% by mass) were dissolved in 100% ethanol. The mRNA and polymer-PEG lipid solutions were mixed via 
pipetting at 1:1 volume ratio, and NPs were allowed to self-assemble at room temperature for 10 minutes. 
NPs were then dialyzed against cold PBS at 4 C for 75 minutes using Spectra/Por Float-A-Lyzer G2 dialysis 
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devices (Repligen, Waltham, MA) with 50 kD molecular weight cut-off. NP volume post-dialysis was adjusted 
with PBS for final mRNA concentration of 0.1 mg/mL. NPs were administered to animals via 100 L tail 
vein injections for a final dose of 10 g mRNA per animal.  
 To investigate the effects of PEGylation and dialysis on in vivo mRNA expression, NPs with no PEG 
lipid and no dialysis were formulated in 25 mM MgAc2 at the same final mRNA concentration and w/w ratio 
as above. 500 mg/mL sucrose solution was used to bring the mixture to isotonicity.  
 
fLuc mRNA In Vivo Bioluminescence  
 NPs encapsulating fLuc mRNA were formulated as described above and administered to 6-7 week 
old male BALB/c mice via lateral tail vein injection. Whole-body bioluminescence was assessed 24 h post-
injection. D-luciferin potassium salt solution (25 mg/mL in PBS; Cayman Chemical Company, Ann Arbor, 
MI) was administered to mice via 150 L intraperitoneal injection, and mice were imaged using an IVIS 
Spectrum Imager (Perkin Elmer, Waltham, MA) 10 minutes later. The same animals were euthanized 
immediately after whole-body imaging via cervical dislocation, and select organs were extracted, submerged in 
250 g/mL D-luciferin solution, and imaged with IVIS.  
 
Cre mRNA Delivery to Ai9 Mice 
 NPs encapsulating Cre mRNA were formulated with DMG-PEG2k and dialyzed in PBS as described 
above. NPs were administered to 6-week old male Ai9 mice via tail vein injection, and tdTomato expression 
following Cre-Lox recombination was allowed to accumulate for 3 days, at which point animals were 
euthanized via cervical dislocation. Select organs were extracted and dissociated by a 1 hr incubation in 2 
mg/mL collagenase at 37 C followed by mechanical pressing through a 70- m cell strainer. Cells were 
pelleted by centrifugation, the supernatant was removed, and red blood cells in the cell pellet were lysed by 
incubating in ACK lysing buffer (Quality Biological, Gaithersburg, MD) for 1 min at room temperature. Cells 
were diluted in PBS, passed through a 100-µm cell strainer, pelleted by centrifugation, and resuspended in 
FACS buffer (2% FBS in PBS with 0.02% sodium azide). Surface staining of cells with fluorescent antibodies 
 281 
was then performed using the antibodies and dilutions listed in Table 8-S1 in FACS buffer for 30 min at 4 C, 
at which time cells were washed twice and resuspended in FACS buffer for further analysis. FACS 
experiments were performed using an Attune NxT flow cytometer (ThermoFisher) and analyzed using 
FlowJo software (FlowJo, Ashland, OR). Gating strategies to identify cell populations are provided in Figure 
8-S9.  
 
Data Analysis and Statistics 
Curve plotting and statistical analysis were performed using Prism 8 (Graphpad, La Jolla, CA). Data 
are shown as mean ± SD for groups of three or more replicates or as individual values with the mean 
indicated. Unless otherwise stated, absence of statistical significance markings where a test was stated to have 
been performed signify no statistical significance. The statistical tests used for each figure are indicated in the 
figure captions. Statistical significance is denoted as follows: *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 
0.0001. ns = not significant.  
 
Graphical Illustrations 
Graphical illustrations were created using BioRender (https://biorender.com/). 
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Figure 8-S1. Time course optimization for dual NP uptake/Gal8 endosomal disruption assay. (A) 
Gal8 puncta count and (B) Cy5 puncta count for 7-90,c12-63, 50%-Sc12 NPs delivering various nucleic acid 
cargos to B16-F10 cells after different incubation times. Black arrow indicates the 6 h time point, which was 
chosen as the NP incubation time for this assay. Data presented as mean ± SD, n = 4. 
  
















































Figure 8-S2. Polymer and nanoparticle characteristics for the polymer backbone hydrophobicity 
variation series. (A) Z-average hydrodynamic diameter and (B) zeta potential for polymers encapsulating 
plasmid DNA, mRNA, siRNA, or polymer only nanoparticles (no nucleic acids). Data shown as mean ± SD, 






























































































Sc0 None 7277 2.20
Sc8 30% Sc8 4358 1.15
Sc10 30% Sc10 9330 3.05
Sc12 30% Sc12 4446 2.66
Sc14 30% Sc14 7578 2.05
Sc16 30% Sc16 8774 3.07













15% 15% Sc12 7473 1.62
50% 50% Sc12 4464 2.66
65% 65% Sc12 5820 2.50







Figure 8-S3. Polymer effective pKa and pH titration curves. (A) Effective pKa in the physiologically 
relevant pH range for polymers in the backbone variation series. (B) Representative pH titration curves. (C) 
Normalized buffering capacity was calculated from pH titration data as ∆(OH)/ ∆(pH) at each titration point 
(pH 5-8). (D) Effective pKa value of each polymer was determined as the pH point of the maximum 
normalized buffering capacity (indicated by red arrows in representative curves).   



























































































































































































































































































































































































































































Capacity = ∆(OH)/ ∆(pH)
C
D












Sc0 6.7 ± 0.1
Sc8 6.6 ± 0.01
Sc10 6.5 ± 0.01
Sc12 6.5 ± 0.01
Sc14 6.5 ± 0.1
Sc16 6.7 ± 0.04













15% Sc12 6.3 ± 0.1
50% Sc12 6.2 ± 0.1
65% Sc12 5.6 ± 0.7
80% Sc12 5.0 ± 0.1
100% Sc12 5.3 ± 0.6
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Figure 8-S4. RiboGreen nucleic acid binding data. (A) Tabulated polymer IC50 of binding for polymers 
in the backbone variation series assessed with plasmid DNA, mRNA, and siRNA. (B) RiboGreen 
fluorescence quenching competitive binding curves for polymers in the alkyl chain length variation series. (C) 
Binding curves for polymers in the alkyl fraction variation series. Red line indicates 50% fluorescence 
quenching. Data shown as mean ± SD, n = 2. 
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3 Sc0 12.2 ± 0.2 4.0 ± 0.7 5.8 ± 0.1
Sc8 10.6 ± 0.9 3.15 ± 0.04 5.9 ± 0.1
Sc10 6.3 ± 0.5 4.3 ± 0.3 6.2 ± 0.4
Sc12 6 ± 2 4.23 ± 0.03 6.3 ± 0.1
Sc14 7 ± 2 4.03 ± 0.01 6.6 ± 0.4
Sc16 6 ± 1 3.99 ± 0.06 10.8 ± 0.1













15% Sc12 6.3 ± 0.2 3.0 ± 0.2 6.5 ± 0.2
50% Sc12 5 ± 1 5.8 ± 0.7 11.4 ± 0.5
65% Sc12 3 ± 2 7.1 ± 0.8 13.1 ± 0.1
80% Sc12 4.5 ± 0.9 1.6 ± 0.4 13.1 ± 0.3
100% Sc12 7 ± 2 1.1 ± 0.5 12.7 ± 0.1


























Figure 8-S5. Correlations in vitro transfection efficacy and polymer buffering capacity and 
hydrophobicity, respectively. Correlations between transfection efficacy and (A) polymer effective pKa in 
the physiological pH range or (B) predicted polymer LogP values of nanoparticles from backbone 
hydrophobicity variation polymers delivering different nucleic acid cargo (left) or end-group variation 
polymers delivering mRNA to different cell lines (right). Spearman’s correlation was calculated to assess the 
strength of association between variable groups, and a line of best fit is shown for data sets with significant 




































r = 0.62  p = 0.02
r = 0.91  p < 10-4
Backbone Hydrophobicity
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Combined r = 0.79 p < 10 -4
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End-group Structure
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Figure 8-S6. IVIS images of BALB/c mice treated with NPs formulated with fLuc mRNA and select 
polymers from the backbone hydrophobicity variation series. (A) Whole-body, live animal 
bioluminescence imaging. (B) Bioluminescence imaging of select organs. Readings taken 24 h after NP 
injection. (n = 3).  
 
0% Sc12 30% Sc12

















































Figure 8-S7. IVIS images of BALB/c mice treated with NPs formulated with fLuc mRNA and select 
polymers from the end-group variation series. (A) Whole-body, live animal bioluminescence imaging. (B) 



































































Figure 8-S8. Effect of PEG-coating and dialysis on mRNA transfection. (A) DLS NP measurements of 
dialyzed, PEG-coated PBAE mRNA NPs with increasing lipid-PEG content. (B) Transfection efficacy and 
(C) Cy5 and Gal8 puncta count for NPs with various combinations of PEG-coating and dialysis (assay 
performed using B16-F10 cells and delivering 50 ng mRNA per 96-well). Data presented as mean ± SD, n = 
3. Statistical significance calculated using one-way ANOVA with Tukey’s post-hoc analysis. *P < 0.05, **P < 
0.01, and ***P < 0.001. ns, not significant. IVIS bioluminescence imaging for (D) whole-body, live animals 
and (E) select organs in animals injected with dialyzed and PEG-coated or non-dialyzed and non-PEG-
coated NPs. Readings taken 24 h after NP injection. Quantification of luminescence from (F) whole-body or 
(G) organ level images. Statistical significance calculated using Student’s t-test with Welch’s correction for (F) 
and 2-way ANOVA with Sidak’s post-hoc analysis for (G). ***P < 0.001. ns, not significant. (n = 4).  
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Figure 8-S9. Flow cytometry gating strategies to identify cell type expression in Ai9 mice. 
Representative flow cytometry histograms to identify (A) various immune cell populations (panel 1) or (B) 
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Antigen Color Supplier Clone Dilution Catalog No. Lot No.
CD45 Brilliant Violet 421 Biolegend 30-F11 1:100 103134 B287242
CD11b Alexa Fluor 488 Biolegend M1/70 1:100 101217 B254608
CD11c Allophycocyanin (APC) Biolegend N418 1:100 117310 B278343
I-A/I-E Alexa Fluor 700 Biolegend M5/114.14.2 1:100 107622 B264454
Ly6G APC/Cyanine7 (Cy7) Biolegend 1A8 1:100 127624 B264760
CD3 Alexa Fluor 488 Biolegend 17A2 1:80 100210 B284975
CD19 APC Biolegend 6D5 1:100 115512 B284257
CD31/PECAM Alexa Fluor 700 Biolegend 390 1:100 102443 B303280
CD326/EpCAM APC/Cy7 Biolegend G8.8 1:80 118218 B266989
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Chapter 9: Future perspectives in the field of non-viral gene delivery 
9.A: Recent advances with high potential to redefine the field 
 In the twenty-five years since polyethylenimine was first reported as a delivery vector for plasmid 
DNA, the field of non-viral gene delivery has moved forward by leaps and bounds, with large numbers of 
papers published on polymeric or lipid-based systems each year. What follows is a brief selection of advances 
during my PhD years (2015-2021) that I found particularly interesting. 
 On the materials chemistry side, I found the work coming out of Dr. Daniel Siegwart’s lab very 
exciting. Their 2016 paper using asymmetrical linkages to synthesize modular degradable polyester 
dendrimers enabled structural variations in core/shell chemical structures as well as dendrimer generation for 
small RNA delivery.1 Their work using zwitterionic amino lipids for co-delivery of Cas9 mRNA and sgRNA 
to enable gene editing was also very informative both on the materials side as well as on gene editing assays,2 
and the Ai9 mouse model for detecting in vivo transfection or gene editing is an assay that the Green lab has 
since started using broadly. Most recently, their work demonstrating that altering the biophysical properties of 
a supplemental component of lipid nanoparticles (NPs) which they termed SORT molecules precisely 
targeted in vivo RNA delivery to highly specific, non-hepatocyte tissues3 touched on the very exciting idea of 
highly controlled, biomaterial-based tissue targeting and could be applied to many different delivery systems.  
 Another rapidly advancing area is non-viral delivery of CRISPR gene editing systems, which has seen 
a veritable explosion of publications during my PhD. One of the first papers to apply non-viral vectors to 
CRISPR delivery and was also a favorite read during my first year came out of Dr. Zhen Gu’s lab, where 
rolling circle amplification was used to synthesize DNA nanoclews which encapsulated and enabled 
intracellular delivery of CRISPR ribonucleoproteins (RNPs).4 Although this system was rather complex and 
the efficacy reported has since been far outstripped by other delivery systems, the idea of non-viral CRISPR 
delivery was so new at the time that this paper provided much of the groundwork for me as I first 
approached this field. Another paper worth mentioning involves the CRISPR-Gold system, which used a 
gold NP core with a DNA and polymer coated shell for CRISPR RNP delivery.5 While this was a rather 
complex hybrid NP system, their demonstration of in vivo homology-directed repair to enable genotypic and 
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functional correction of a mouse model of Duchenne muscular dystrophy was very exciting. Finally, the work 
coming out of Dr. Alexander Marson’s group using electroporation, a process where an electrical field is 
applied to cause transient permeabilization of the cell membrane, to deliver CRISPR RNPs to primary human 
T cells is potentially very close to clinical utilization as it facilitates efficient ex vivo generation of immune cells 
that could be infused into patients. As immune cells are notoriously difficult to transfect using chemical 
delivery systems, the reported gene knock-in efficiency of up to 20% using this method6 is truly astonishing. 
Recent reports using the two-pronged strategy of modified repair templates and polymer coating for CRISPR 
RNPs further enhanced editing efficiencies by upwards of fourfold;7 this has major implications for CRISPR 
editing for adaptive cell therapies.  
 Finally, it’s worth mentioning recent advances in assay development to characterize non-viral delivery 
as these innovations play a major role in standardizing delivery technologies and moving the field forward. As 
described previously, the Ai9 mouse is a valuable tool for determining specific cell types being transfected 
after intravenous administration of gene delivery or gene editing NPs. This transgenic mouse model contains 
a transcription STOP cassette flanked by two LoxP sites that’s situated directly upstream of a tdTomato 
fluorescent reporter.8 Excision of the Lox-STOP-Lox sequence by introducing Cre recombinase or Cas9 
RNPs targeting the LoxP sites result in turning on of the previously silenced tdTomato signal, and the cells 
expressing Cre or Cas9 RNPs could be identified through flow cytometry. This is useful for quantifying the 
percentage of cells transfected in a specific tissue as well as identifying the cell populations transfected after 
IV administration of NP systems carrying nucleic acids coding for Cre9 or CRISPR RNPs.2, 3 Another very 
exciting technology for detecting tissue and cellular level NP transfection in vivo utilizes high-throughput 
DNA barcoding to simultaneously measure the distribution of thousands of NP formulations and was 
pioneered by Dahlman et al.10 In this method, chemically distinct NPs are formulated to carry specific nucleic 
acid barcodes. After the pooled NPs are administered to animals, NP distribution into organs and tissues are 
quantified using deep sequencing. This method of high throughput NP screening in vivo is superior to the 
traditional paradigm of in vivo testing of the handful of top formulations from large library in vitro NP screens 
as it has been shown that the correlation between in vitro and in vivo nucleic acid delivery is often very weak.11 
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It enables identification of NP formulations for delivery to specific tissues and cell types such as endothelial 
cells12 and bone marrow13 and is further advantageous in that it allows rapid testing of very large NP libraries 
with relatively few animals.  
 
9.B: Future perspectives on where the field is heading 
 Although non-viral delivery of gene therapy or gene editing has great potential to treat (and even 
cure) a large variety of diseases, only a few delivery systems have a realistic chance of reaching the clinic in the 
next ten years. Most of the non-viral delivery systems being published are extremely difficult for clinical 
implementation as many are complex, multi-component hybrid systems that would be almost impossible to 
reliably synthesize at scale. Many systems would also not be able to reach efficacy levels necessary to treat 
human patients without the need to use unreasonably high doses that could cause high levels of vector-
mediated toxicity. Nevertheless, recent publications point to a few areas in which bench-to-bedside 
translation could happen reasonably soon.  
 The most exciting recent development in non-viral gene delivery is the rapid development, 
widespread use, and astonishing efficacy of lipid NP-based mRNA vaccines for COVID-19. The fact that it 
took less than a year between the first identification of the disease to producing viable vaccines for shots in 
arms showcases the flexibility in design and ease of manufacturing of nucleic acid vaccines.14 Several issues 
with the Pfizer-BioNTech and Moderna vaccines currently approved by the FDA under emergency use 
authorization such as severe allergic reactions and even cases of anaphylaxis against vaccine components15, 16 
and the need for ultralow storage temperatures17 may limit their ability to gain full regulatory approval or 
achieve widespread use for future non-emergency vaccination campaigns. Nevertheless, mRNA COVID 
vaccines are still a major success story for nucleic acid vaccines and I very much look forward to seeing non-
viral mRNA vaccines in regular rotation for diseases such as the seasonal flu in the near future. 
 Immuno-oncology is another area where I would expect rapid growth and clinical application of non-
viral delivery. Recent work by Dr. Steph Tzeng in the Green lab showed that intratumoral administration of 
polymeric NPs delivering plasmid DNA encoding costimulatory molecule 4-1BBL and immunostimulatory 
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cytokine IL-12 enabled in situ reprogramming of tumor cells into antigen-presenting cells to significantly 
reduce tumor growth in combination with immune checkpoint blockade.18 Similarly, Moderna published a 
study using mRNA NPs encoding OX40L, IL-36 , and IL-23 lead to tumor regression and systemic 
immunity in several mouse models of cancer.19 This strategy is particularly advantageous in that it does not 
require prior knowledge of the patient’s tumor neo-antigen profile and could be an off-the-shelf cancer gene 
therapy for several types of solid tumors.  
 In the area of non-viral delivery of CRISPR gene editing, I would expect the earliest FDA approval 
to occur for disease treated by infusing patients with cells edited ex vivo. This is due to the still widely debated 
issue of off-target editing, which, despite new iterations of higher fidelity Cas9 being published regularly,20-22 
still has a high likelihood of occurring, leading to potentially deleterious edits that limit applications of in vivo 
CRISPR delivery. In contrast, ex vivo editing offers the advantage of quality controlling the edited cells prior to 
administration into patients, and a small clinical study has already been reported using mainly electroporation 
of CRISPR RNPs into hematopoietic stem cells to create cell therapies for diseases such as sickle cell anemia 
and -thalassemia with functionally active edits observed more than a year after treatment.23 A similar strategy 
could be applied to HIV treatment by creating CCR5 knockout hematopoietic stem cells that are resistant to 
HIV cellular entry, and CCR5 targeting with zinc finger nucleases (another gene editing modality) is currently 
in phase II clinical trials for HIV/AIDS treatment.24  
Although I think IV administration of gene editing molecules is still far off due to concerns of off-
target editing mentioned above, diseases related to the liver will likely be the first candidates when this 
application does eventually happen. Lipid NPs, a non-viral delivery system in clinical utilization, 
overwhelmingly target the liver.25 It’s no surprise that Alnylam’s Patisiran (Onpattro), which uses lipid NPs to 
deliver siRNA to treat transthyretin-mediated amyloidosis, is the first non-viral gene therapy approved by the 
FDA.26 Indeed, Intellia Therapeutics reported that a single administration of lipid NPs delivering Cas9 
mRNA and a chemically modified sgRNA enabled >97% reduction in serum protein levels of mouse 
transtheyretin for at least 12 months after gene editing in the liver.27 For these applications, I predict that 
CRISPR gene editing complexes will likely be delivered in mRNA or RNP form to reduce the risk of off-
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target editing due to prolonged RNP persistence.28 Other liver diseases amenable to CRISPR editing and are 
also currently in the Intellia pipeline include transthyretin amyloidosis, hereditary angioedema, and hemophilia 
A and B.29   
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